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71 General introduction
Part of  this chapter has been adapted from:
Natural killer cells: the secret weapon in dendritic cell vaccination strategies
Van Elssen C.H.M.J. 1, Oth T. 1, Germeraad W.T.V. 1, Bos G.M.J. 1, Vanderlocht J. 2
1 Division of  Haematology, Department of  Internal Medicine, MUMC+, Maastricht
2 Tissue Typing Laboratory, Department of  Transplantation Immunology, MUMC+, Maastricht 
Clin Cancer Res. 2014 Mar 1;20(5):1095-103. Review.

9General introduction 1
INNATE IMMUNITY & PATHOGEN RECOGNITION
During their lifespan, humans are continuously exposed to a variety of  pathogens including 
viruses, bacteria, fungi, and parasites. The immune system is equipped with various 
sophisticated innate and adaptive strategies to counteract these pathogenic insults. 
The innate immunity is the first line of  host defence, and this non-specific response is 
initiated within hours upon exposure to an infectious agent. The innate immunity consists of  
anatomic (e.g. skin), physiologic (e.g. pH), phagocytic (e.g. macrophages) and inflammatory 
barriers. Pattern recognition plays a crucial role in inducing an innate immune response. 
Highly conserved and unique microbial structures of  pathogens (pathogen-associated 
molecular patterns; PAMPs) are detected by so-called pattern recognition receptors (PRR), 
which are germ-line encoded receptors and are either secreted, membrane-bound or 
located in the cytoplasm 1, 2. A variety of  innate immune cells, such as dendritic cells (DC) 
and macrophages, are equipped with various PRR, which enable the cells to discriminate 
between different classes of  microorganisms, and to tailor appropriate immune responses 
against the nature of  the pathogen 3, 4. In addition, necrotic and apoptotic cells, as well as 
stressed cells are able to trigger these PRR via the release of  damage-associated molecular 
patterns (DAMPs)5. PRR expression is, however, not limited to innate immune cells; also 
cells of  the adaptive immune systems (e.g. T cells) and non-immune cells (e.g. stromal 
cells) are equipped with diverse PRR 6. Triggering of  PRR leads to the production of  
pro-inflammatory cytokines and type I interferons (IFNs) and the induction of  innate host 
defence. Moreover, the sensing of  pathogens via PRR is indispensable for the orchestration 
of  proper and coordinated pathogen-tailored adaptive immune responses including the 
activation of  antigen-specific B (induction of  humoral immune responses) and/or T cells 
(induction of  cell-mediated responses). This cellular interplay of  innate and adaptive immune 
cells is required for the successful elimination of  a pathogenic threat and the generation of  
immunological memory 4, 7. 
PRR recognize distinct classes of  PAMPs, initiate different signalling pathways and 
responses, and display different expression patterns among (immune) cell (sub)types. They 
can be divided into different families according to their function, localisation and ligand 
specificity: Toll-like receptors (TLR) 8, 9, nucleotide oligomerisation receptors (NOD)-
like receptors (NLR) 10, C-type lectin receptors (CLR) 11, 12, retinoic acid-inducible gene 
(RIG)-I-like receptors (RLR) 13, 14, and AIM2-like receptors (ALRs) 15. Depending on the 
nature of  the pathogen different members of  PRR classes get triggered as listed in Table 1. 
In general, the TLR family recognizes bacteria, viruses, fungi, and parasites, whereas NLR 
sense bacteria, CLR detect fungi and bacteria, RLR the presence of  viral RNA, and ALR 
sense DNA viruses. The particular combination of  PRR being triggered during a pathogenic 
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insult determines the type, quality, magnitude, and duration of  the initiated immune 
response 4. Additionally, the cell type-specific expression of  PRR affects the induction of  
immune responses. Figure 1 exemplifies the TLR expression pattern of  different immune 
cells and in particular of  different DC subsets. This expression pattern is linked to their 
respective function.
Table 1 | PRR classes and properties.
PRR 
family
members localization structure ligand sources ligands
TLR1 cell membrane TM bacterial lipids triacylated lipopeptides
TLR2 cell membrane TM bacterial lipids,          fungal cell wall diacylated lipopeptides
TLR3 endosome TM viral RNA dsRNA
TLR4 cell membrane/ endosome TM bacterial lipids lipopoly-saccharides
TLR TLR5 cell membrane TM bacterium, parasite flagellin
TLR6 cell membrane TM bacterial lipids lipopeptides
TLR7 endosome TM viral RNA ssRNA
TLR8 endosome TM viral RNA ssRNA
TLR9 endosome TM bacterial/ viral RNA CpG DNA
TLR10 endosome TM bacterium, parasite profiling-like proteins
RLR
RIG-I
MDA-5
LGP2
cytoplasm soluble viral RNA ssRNA, dsRNA
CLR
Dectin-1
Dectin-2
cell membrane TM fungal cell wall
b-glucan
mannan
NLR
NOD1
NOD2
NALP1
NALP3
cytoplasm soluble bacterium, virus, host
peptidoglycan
peptidoglycan
peptidoglycan
ATP, RNA, DNA
ALR
AIM-2
IFI16
cytoplasm soluble DNA viruses
dsDNA
ssDNA, dsDNA
CLR and NLR: not all family members are listed. ALR: AIM-2-like receptors; CLR: C-type-lectin receptors; 
NLR: nucleotide-binding oligomerisation domain (NOD)-like receptors; RLR: RIG-I-like receptors; TLR: 
Toll-like receptors; TM: transmembrane.
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The best characterized class of  PRR is the TLR family. Up-to-date 10 human TLR members 
have been identified. Extracellular TLR (TLR1, 2, 4, 5, 6, 10) are specialized in the recognition 
of  unique bacterial products allowing a good self-non-self-discrimination. The intracellular 
TLR (TLR3, 7, 8, 9) are mainly responsible for viral detection. TLR signalling occurs via 
two main adaptor molecules: MyD88 (TLR1, 2, 4, 5, 6, 7, 8, 9) and TRIF (TLR3 and 4). 
Further recruitment of  different kinases initiates the signalling cascade which includes MAP 
kinase pathway, NFkB pathway or IRF pathway and leads to the production of  pro- (e.g. 
Interleukin [IL]-6, TNF-α, IL-12) and anti-inflammatory cytokines (e.g. IL-10), chemokines 
or type I IFNs.
NLR constitute a group of  at least 22 identified human proteins, sensing microbial 
components as well as metabolic stress. NLR can be divided into different functional 
subgroups. Receptors like NOD1 and NOD2 homo-oligomerize, recognize peptidoglycan 
components of  bacterial cell walls, and their activation leads to the production of  type I 
IFNs. The second subgroup oligomerizes to form a multi-protein signalling complex 
including adaptor proteins and caspase-1, the inflammasome. Via their caspase activity these 
inflammasomes activate the pro-inflammatory cytokines IL-1β and IL-18. ALR also form 
these complexes 10. CLR synergize with the fungal TLR sensing system. CLR are located 
TLR1
TLR2 
TLR4-9
TLR1-10
TLR1
TLR2 
TLR4-9
TLR1-3
TLR6
TLR7
TLR9
TLR10
T
B
Mono
NK
MØ
TLR1-3
TLR5-9
pDC
BDCA-1+
BDCA-3+
moDC
TLR1
TLR7
TLR9
TLR10 
TLR1-8
TLR10
TLR1-3
TLR6
TLR8
TLR10
TLR1-8
Figure 1 | TLR expression of  human immune cells. Cells of  the innate and adaptive immune 
system express a diverse repertoire of  TLR. Expression patterns of  blood DC subsets pDC and cDC 
(BDCA-1+ and BDCA-3+) as well as inflammatory moDC are shown. B: B cells; MØ: macrophages; 
Mono: Monocytes; NK: NK cells; T: T cells 16-20. 
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at the cell surface and are involved in several biological processes, including antigen-uptake 
and presentation. Dectin-1 is an example of  CLR, which recognizes the fungal component 
zymosan 11, 12. RLR are cytosolic receptors and like intracellular TLR, these receptors act as 
viral sensors mediating immune responses via the release of  type I IFNs 13, 14. The different 
classes of  PRR cooperate in the recognition of  pathogens 4, 9, 21, 22. For example, poly(I:C) 
can be recognized by TLR3 and RIG-I/MDA-5. This interplay is required for the induction 
of  robust immune responses 23. 
In general, responses induced by PRR-triggering lead to the shaping of  T cell responses 
via release of  cytokines and upregulation of  co-stimulatory molecules on immune cells, 
recruitment of  other immune cells to the site of  infection, upregulation of  chemokine 
receptors allowing migration towards lymph nodes, secretion of  anti-microbial molecules as 
well as enhanced antigen uptake and presentation 4, 7. The importance of  the PRR system, 
which is partly overlapping and redundant, in sensing pathogens and mediating appropriate 
immune responses is illustrated by several reports indicating increased susceptibility to 
human diseases in case of  receptor polymorphisms 24, 25. 
PATHOGEN SENSING BY DENDRITIC CELL SUBSETS
Dendritic cells (DC) constitute a heterogeneous population of  bone marrow-derived cells 
which are equipped with molecular sensors allowing the detection of  pathogens and with 
an antigen-processing machinery. As such, DC are described as the most potent antigen-
presenting cells (APC) of  our body able to survey their environment and instruct the 
immune system to induce appropriate immune responses. DC have a unique role in linking 
the innate and adaptive immunity 26.
Under physiological conditions immature DC (iDC) act as sentinels at infection sites where 
they capture and ingest antigens, which induces phenotypic changes/functional maturation 
and their migration to secondary lymphoid organs. This recognition occurs via the expression 
of  diverse PRR. During the maturation process DC lose their phagocytic and endocytic 
properties, upregulate co-stimulatory molecules and major histocompatibility complex 
(MHC) molecules, and secrete inflammatory cytokines 27, 28. Mature DC (mDC) present the 
processed peptides from the original antigen in the context of  MHC molecules which are 
in turn recognized by T cells. DC are able to initiate, program and regulate antigen-specific 
immune responses by activating different immune effector cells (T cells, B cells, NK cells) 29. 
Depending on the environmental stimuli DC encounter, the transmitted signals to various 
immune effector cells are of  immunogenic or tolerogenic origin 30, 31.
Different DC subsets have been identified which can be divided according to their 
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development, function, and location 19. In general, DC are MHC class II+ and LIN- (CD3-, 
CD56-, CD19-/CD20-) 32 and are divided into myeloid/conventional (myDC/cDC; CD1c+/
BDCA-1+ and CD141+/BDCA-3+), plasmacytoid (pDC; CD303+CD304+CD123+) or 
monocyte-related DC (moDC). DC are either migratory or lymphoid tissue-resident. In 
human peripheral blood, spleen and tonsils three major DC subsets have been identified: 
pDC, CD1c+ cDC and CD141+ cDC 33-36. Blood DC are considered to be more immature 
than their tissue-resident counterparts 32.
CDc1+ cDC (mouse counterpart: CD11b+) 37 constitute the dominant cDC population in 
blood, tissue, and lymphoid organs 33, 38, 39. CDc1+ cDC express various TLR (1-8, 10) and 
recognize LPS, flagellin, R848 and poly(I:C) 40. Furthermore, the expression of  Dectin-1 
and Dectin-2 indicates a role in fungal recognition 41, 42. In general, matured CD1c+ cells are 
good stimulators of  naive CD4+ T cells responses, but less efficient at cross-presentation 43-45. 
Cross-presentation is the capacity to process and present exogenous antigens not only in 
the conventional MHC class II pathway but also in the context of  MHC class I. This is an 
important mechanism for the induction of  cytotoxic CD8+ T cells in case the DC are not 
infected themselves 46. Depending on the encountered stimuli, CDc1+ DC have the potential 
to secrete TNF-α, IL-8, IL-10, IL-12p70, and IL-23. CD141+ cDC (mouse counterpart 
CD8+) are more efficient in cross-presentation 44, 47, 48. They also express a wide range of  
TLR (1-3, 6, 8, and 10) and are efficient in detecting dead and necrotic cells via CLEC9A 45. 
TNF-α, CXCL10, IFN-λ are efficiently produced by these CD141+ DC, however, they are 
less potent producers of  IL-12p70 43, 48, 49.
pDC are specialized in anti-viral defence and express mainly TLR7 and TLR9, but also 
TLR1 and TLR6 19. They are potent producers of  type I IFNs (IFN-α, β, ω, λ) 50, 51. Under 
steady-state conditions pDC have low MHC class II and costimulatory molecule expression 
levels and reside in low numbers in tissues, but constitute 20% of  lymph node HLA-DR+ 
cells 52. Upon inflammation, rapid recruitment and accumulation occurs in lymphoid and 
non-lymphoid tissue. Freshly isolated blood pDC are only able to prime CD4+ T cell 
polarization after activation 53-55. pDC secrete a diverse cytokine and chemokine repertoire 
(IL-12p70, IL-6, TNF-α, CXCL9, CXCL10, CCL3, CCL4, CCL5) enabling them to attract 
among others CD4+ and CD8+ cells to the site of  inflammation. Same as cDC, pDC are able 
to present the processed antigens in the context of  MHC class I or II 56-59. Immunogenic 
pDC play a role in the induction of  CTL, memory T cell induction and survival, and T 
helper (Th)1/Th17 polarization of  CD4+ T cells 56, 57. Moreover, TLR9-activated pDC are 
able to activate NK cells increasing their cytotoxic potential and proliferation 60, 61.
Monocyte-related DC can be divided into three groups: CD14+, CD16+, and inflammatory 
DC. The latter DC subset arises only under pathogenic inflammation from circulating 
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monocytes which have migrated towards the inflamed tissue. Inflammatory DC migrate to 
secondary lymphoid organs where they effectively stimulate naive CD4+ T cell responses and 
cross-present antigens to CD8+ T cells. They are producers of  IL-1, IL6, TNF-α, IL-12p70 
and IL-23 62, 63. Currently under investigation is whether the inflammatory environment 
encountered during differentiation of  monocytes will induce various moDC with specific 
functions 64. In vitro IL-4/GM-CSF-differentiated moDC express all TLR except 9 and 10 18.
Thus, the different DC subsets are equipped with selected combinations of  PRR which are 
partly overlapping (exemplified for the TLR family in Figure 1). Several studies underpinned 
the importance of  PRR-triggering for the functional maturation of  DC 65, 66. Depending on 
the encountered pathogen and the DC subset a specific response is mediated by the DC to 
efficiently counteract the nature of  the invading pathogen 7, 27, 67, 68. Likewise, the sensing of  
intracellular pathogens (e.g. bacteria, virus) initiates a type 1 immune response, including 
induction of  Th1 cells, CTL, NK cells and IFN-γ-producing innate lymphoid cells (ILC) 69. 
The dysregulation of  type 1 immune responses can lead to autoimmune diseases 70.
IMMUNOMODULATORY ROLE OF T HELPER CELLS
Naive CD4+ T cells are characterized by the expression of  CD45RA, CD62L, and CCR7 
allowing their circulation between peripheral blood and lymph nodes 71, 72. These cells still 
lack adhesion molecules and specific chemokine receptors enabling their migration into 
non-lymphoid tissues. The polarization of  naive CD4+ T cells into different specific Th cell 
subsets is induced by pathogen-triggered DC and is of  capital importance in orchestrating 
specific adaptive immune responses against the nature of  the pathogenic insult. This multistep 
process is tightly controlled and regulated. Uncontrolled activation and dysregulation of  
this process is associated with immune-related diseases 73-75. The polarization includes the 
activation of  naive CD4+ cells via a two-signal model in which the first signal consists in 
antigen recognition in the context of  MHC-II-TCR ligation and the second one in the co-
stimulation 27 (Figure 2). Whereas initial studies postulated that different Th cell responses 
would be induced according to the encountered DC subtype 76, it is now clear that the 
environmental instruction of  the DC also plays a critical role in this process 77. The cytokine 
milieu is the third signal which is of  crucial importance for determining the Th cell fate and 
inducing a tailored immune response 77, 78. More recently, the role of  a fourth DC-derived 
signal has been described, instructing T cells with a certain homing potential by inducing 
expression of  particular chemokine receptors and integrins 79, 80. Classically, a Th subset is 
defined by differentiation-inducing cytokines, its transcription factors, cell surface markers 
(e.g. co-stimulatory molecules, cytokine and chemokine receptors), signature cytokines and 
tissue localization. Moreover, each Th subset induces immune responses against a specific 
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class of  pathogens 81-83 (Figure 2). Notably, Th cell subsets specific for one particular 
pathogen may also belong to different subsets. This is depending on the various antigens 
expressed by a pathogen, the timing of  DC encounter (early or late priming), interaction 
with a second stimulating DC, or DC subsets mediating the polarization 84.
1
2
3 IFN-γ
LT-α
IL-4
IL-5
IL-13
IL-17
IL-22
IL-9
IL-10
IL-21
IL-21
Th1
Th2
Th17
Th9
Tfh
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STAT1, STAT4
GATA-3
STAT6
RORγT
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STAT6
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STAT3
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IL-6
IL-1β
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Figure 2 | Polarization of  CD4+ T helper cells. Matured DC interact with naive CD4+ T cells and 
provide antigen-specific signal 1 (MHC-II-TCR interaction), signal 2 (co-stimulation), and signal 3 
(polarizing cytokines), which influence the generation of  a specific Th cell subtype. Lineage-specifying 
transcription factors are indicated for each Th cell subset. Th cell subset-specific cytokines and mediated 
immune responses are displayed next to the various Th cells.
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T helper cell commitment, phenotype stability, and plasticity 
Since the first description of  two different subsets of  activated murine Th cells in 1986 85, our 
understanding on the induction, phenotypic discrimination, and functional consequences 
of  different CD4+ Th subsets has enormously expanded. Almost two decades later, the 
presence of  a third distinct Th subset was described in both human and mice: Th17 cells 86, 87. 
Nowadays, the possible fates of  Th cells are: Th1, Th2, Th9, Th17, Th22, Thf  and diverse 
Treg subsets 88. The three best described effector Th cell subsets are Th1, Th2 and Th17. 
Th1 cells provide help for eliminating intracellular viral and bacterial pathogens and lead to 
cellular immunity. The expression of  T-bet induces IFN-γ production and the upregulation 
of  CXCR3 on the cell surface. IFN-γ activates macrophages and enhances IL-12 production 
by DC and thus represents a positive feedback loop. CXCR3 allows the Th1 cells to migrate 
to peripheral tissues 89. Th2 effector cells are primarily responsible for mediating immune 
responses to eliminate extracellular parasites, such as helminths, and to induce humoral 
immunity. The induction of  GATA-3 is followed by the secretion of  Th2-specific cytokines 
IL-4, IL-5, and IL-13 as well as the upregulation of  CCR4 and CRTh2 90-92. IL-4 blocks the 
differentiation into Th1 and Th17 cells and induces IgE production by B cells. IL-5 leads 
to activation of  eosinophils 92, 93. Th17 cells are required to fight extracellular bacteria and 
fungi. Committed Th17 cells express RORC, produce mainly IL-17 and express CCR6 and 
IL-23R. IL-17 is involved in recruiting neutrophils and CCR6 is required for Th17 cells to 
migrate into inflamed tissues 94-96. Even though the induction of  Th responses is a tightly 
regulated process, dysregulation can lead to cellular-mediated autoimmune disorders (Th1), 
atopy (Th2), and chronic tissue inflammation (Th17) 83, 97, 98. 
The functional differentiation of  Th cells is a complex process including multiple lineages, 
interaction of  signaling pathways, transcription factors, microRNAs, and epigenetic 
regulation. The signals received upon activation such as strength of  TCR stimulation, 
co-stimulation and cytokines determine the state of  a helper T cell. The classical view defines 
the different Th cell subsets as terminally differentiated cells expressing Th-specific master 
regulators, e.g. Tbet (Th1), GATA-3 (Th2), ROR-γT (Th17), and BCL-6 (Tfh) 99. Whereas it 
was believed for a long time that expression of  such a Th-specific master regulators would 
be both required and sufficient to determine the fate of  naive CD4+ T cells and that its 
expression would equal a specific Th phenotype, this concept has been proven to be more 
complex over the last few years. 
The fate of  CD4+ T cells is more flexible and diverse as evidenced by recent research. For 
example, the so-called master regulators can be co-expressed (transiently or permanently) in 
one Th cell subtype. This co-expression can be either cooperative or antagonistic depending 
on the regulators and the Th subtype. As such the co-expression of  T-bet and Bcl-6 is needed 
17
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to establish Th1 cells, as Bcl-6 is repressing other Th cell fates 100. In addition, also other 
factors are crucial for the initiation of  Th cell polarization, such as the cytokine-regulated 
environmental response factors (ERF). Among these, the signal transducer and activator of  
transcription (STAT) proteins, interferon regulatory factors (IRF), and activator protein 1 
(AP-1) specifically regulate lineage-specific enhancers and induce the transcription of  master 
regulator transcription factors 101, 102. Due to their evidenced restricted function as master 
regulators, they are currently called lineage-specifying transcription factors. Even though 
they are not solely responsible for inducing the CD4+ T cell differentiation process and 
have a minimal role in the de novo activation of  enhancers, these transcription factors still 
play a crucial role on regulatory DNA elements and enhancers 102, by binding to previously 
activated regulatory elements to augment or tune the activity of  the CD4+ T cell. In this 
way, the lineage-specifying transcription factors are able to inhibit the expression of  genes 
instructing other Th lineages and to stimulate their own Th fate via a positive feedback loop.
Furthermore, it has been shown that polarized Th cells are not terminally differentiated 
and committed cells, but that they retain a certain degree of  flexibility (e.g. cytokine gene 
expression) and plasticity and are able to respond and adapt their phenotype to changing 
environmental cues 103. When cultured in Th2-favoring conditions, human memory Th1 
were shown to upregulate secretion of  Th2 cytokines 104. Another example are the Th1/
Th17 cells; under certain environmental conditions, such as chronic inflammation, Th17 
cells can acquire properties of  Th1 cells and secrete IFN-γ 105, 106. These IL-17/IFN-γ 
double producing cells are increased in patients with autoimmune diseases 94, 107. In this 
line, the classification of  the more recently discovered Th9 and Th22 cells is still ongoing; 
whether they can be considered as separate subsets or represent different states of  Th2 
respectively Th17 cells is still debatable 108-110.
Besides their helper function, CD4+ T cells can also acquire cytolytic capacities under certain 
environmental circumstances, such as chronic activation and the associated persistent 
antigen exposure. During the development of  CD4+ Th cells, the transcriptional regulator 
ThPOK plays an important role in repressing the cytolytic gene expression programme and 
thus repressing the CD8+ T cell fate. In mature CD4+ T cells, the expression of  ThPOK can 
be downregulated allowing the induction of  the cytolytic gene expression programme and 
the generation of  CD4+ CTL 111, 112. These CD4+ CTL cells gradually appear with persistent 
viral infections and seem to be of  importance in controlling these chronic infections 113. 
Differences between mice and men
Up-to-date the majority of  our current knowledge on T cell polarization has been generated 
by using murine models. These models are great tools to study e.g. the importance of  
18
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specific transcription factors or other proteins involved in the differentiation process 
of  naive CD4+ T cells 114. Nevertheless, a pivotal limitation of  using these models is the 
discrepancy of  some crucial aspects between murine and human immune systems 115. This 
makes it challenging to use and to extrapolate knowledge generated from murine models in 
the context of  human CD4+ T cell polarization. 
Murine and human DC subsets differ in terms of  cytokine profiles 116, their PRR expression 
patterns 117-122, and ligand recognition 123. In mice, LPS triggers TLR3, whereas in humans 
the only ligand for TLR3 is dsRNA. Moreover, divergences occur in transcription factors 
involved in the skewing towards different Th subsets 124-126. Whereas in humans STAT4 is 
activated by IFN-α and is required for Th1 polarization, in mice INF-α does not lead to 
Th1 polarization 127. Additionally, Th subtypes are responsible for clearance of  the different 
pathogenic classes; the clearance of  schistosomiasis caused by parasitic worms occurs by 
Th2 induction in humans, whereas in mice the activation of  Th1 cells is crucial 128,129. Thus, 
murine models are suboptimal to study all aspects of  human CD4+ T cell polarization and 
there is need for valorisation of  therapeutic interventions identified in murine models. This 
is strengthened by findings revealing that a cure identified in murine models was ineffective 
in humans 130-132. 
Considering the emerging complexity of  the regulation of  Th responses reveals the necessity 
for good, consistent tools and methods to study the CD4+ T cell regulation in more depth. 
Currently available human in vitro assays to study APC-dependent initiation of  naive CD4+ 
T cell responses are limited. Despite the progress in understanding the processes involved 
in CD4+ T cell polarization, the currently available methodologies limit the study of  certain 
aspects of  human CD4+ T cell immunity. 
IMMUNOMODULATORY ROLE OF NK CELLS 
NK cells were first described in the early seventies 133-135 and are large granular lymphocytes 
arising from the same lymphoid progenitors as T and B lymphocytes. Different from B and 
T lymphocytes, NK cells are part of  the innate immunity. More recently, they have been 
classified as being part of  innate lymphoid cells (ILC), which are considered to be the innate 
counterpart of  the adaptive Th cells. Conventional IFN-γ-producing NK cells are part of  
group I ILC 136. Initially, NK cells were described as ′killers′ having capacity to eliminate 
malignant cells without the need for priming. Up-to-date the functions ascribed to NK cells 
are extended: cytotoxicity and secretion of  antimicrobial products, cytokine and chemokine 
secretion, contact-dependent co-stimulation and regulation of  other immune cells 137. 
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Cellular cytotoxicity is mediated by a tight balance of  NK cell inhibitory (several killer 
immunoglobulin receptors [KIRs], NKG2A/CD94) versus activating receptors (natural 
cytotoxicity receptors [NCR], NKG2D, DNAM-1) and their interaction with the respective 
ligands on the target cells. Ligands for inhibitory receptors are classical and non-classical 
MHC class I molecules. Abnormal cells are recognized by NK cells due to lack of  MHC 
class I ligation to inhibitory NK cells receptors (known as missing self-recognition) or by the 
upregulation of  stress ligands ligating activating receptors expressed on NK cells (known as 
stress-induced self-recognition) 138 (Figure 3A). Additionally, NK cell licensing (also called 
NK cell education) prevents autoreactivity of  NK cells. During functional maturation of  
NK cells, the cells need to engage self-MHC via their KIRs to acquire full effector function. 
NK cells that fail to engage the corresponding MHC class I molecules for the expressed 
KIR repertoire are hyporesponsive 139. Upon contact of  licensed NK cells with target cells 
triggering their activation (activating signals > inhibitory signals), lysosomes, containing 
perforin and granzymes, are transported to the membrane of  NK cells and secreted into 
the immunological synapse inducing the lysis of  target cells (granule exocytosis) 140. Another 
mechanism of  eliminating target cells is via death receptor pathway involving FasL, TRAIL 
and TNF-α 141. NK cells can recognize antibody-coated target cells via their FcγRIII 
(CD16) which can bind to the Fc portion of  the antibody and mediate activation of  NK 
cells and lysis of  the target cell. This process is called antibody-dependent cell-mediated 
cytotoxicity (ADCC) 142. Additionally, NK cells are potent cytokine producers; depending 
on their activation, NK cells secrete IFN-γ, TNF-α, GM-CSF, IL-5, IL-13, CCL3, CCL4 
and CCL5 143-145.
In peripheral blood two major NK cell subsets can be distinguished: CD56dimCD16+ (90%) 
and CD56brightCD16- (10%). In lymph nodes (LN) this ratio is inversed. CD56dimCD16+ are 
commonly referred to as the cytotoxic subset, expressing KIRs and containing cytotoxic 
granules, whereas CD56brightCD16- NK cells are considered to be the major cytokine 
producers 146. Nonetheless, reports on the IFNγ-secreting NK cell subpopulation are 
still controversial and both CD56bright and CD56dim subsets have been shown to produce 
IFN-γ 147-149. Moreover, LN CD56brightCD16- NK cells upregulate CD16, KIR and NCR 
(NKp46 and NKp30) after encounter of  T cells and IL-2, enabling them to kill their 
targets 150,151. After acquisition of  KIR expression and perforin, the expression of  CD56 
and CD16 is reported to be stable 152. Possibly, CD56dim NK cells represent a subsequent 
stage of  CD56bright cells and are more mature 153. Furthermore, the classification of  NK 
cell subsets can be refined by CD57 and CD27 expression pattern 154-156. These two subsets 
express divergent chemokine receptor profiles. Resting CD56dimCD16+ express a variety 
of  chemokine receptors, mainly CXCR1 and CX3CR1, and migrate upon CXCL12 and 
CXC3L1 towards peripheral sites of  inflammation. In contrast, CD56brightCD16- express 
CCR5 and CCR7 allowing their migration to secondary lymphoid organs upon CCL19, 
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CCL21, CXCL10, CXCL11, and CXCL12 145, 153. 
DC-induced NK cell responses
DC have the capacity to activate NK cells by soluble as well as contact-dependent factors 
and thereby enhancing cytokine production, proliferation, survival, and cytotoxicity of  NK 
cells as illustrated in Figure 4.
DC activate NK cells to produce cytokines (mainly TNF-α and IFN-γ), which is dependent 
on a two-signal activation by soluble or contact-dependent factors or a combination 
of  both 157-159. Depending on the encountered maturation stimuli, DC produce specific 
cytokines and upregulate NK-cell activating surface molecules. DC-derived soluble factors, 
such as IL-12, IL-15, IL-18, IL-2, and IFN-α/β are highly efficient in activating NK cell 
responses 160-167. The NK cell-activating capacity is confined to PRR-triggered DC 160,168. 
In addition to soluble factors, the activation of  NK cells is enhanced by direct interaction 
with DC, suggesting that contact-dependent factors also play a role 160. These factors include 
surface molecules expressed on DC that ligate with NK cell-activating receptors. One of  
these receptors is NKG2D, which is a C-type lectin co-activation receptor that binds to 
stress-inducible members of  the polymorphic MHC class-I related chain A/B (MICA/B) 
family and ULBP 169, 170. Moreover, the activating NCR NKp30 and NKp46 are expressed 
by all NK cells and activate NK cells in the absence of  additional stimuli 171, 172. They bind to 
currently unknown ligands expressed by DC 173-175. The expression of  a third NCR, NKp44, 
is restricted to activated NK cells 176. A high expression of  NCR on NK cells is correlated 
with high cytotoxic capacities 171, 172. Another contact-dependent interaction, ligation of  
CD48 by 2B4 receptor expressed on NK cells, is still promiscuous as the 2B4-pathway can 
be either activating or inhibitory 177, 178, depending on the maturation status and localization 
of  the NK cell itself  179. These stress-dependent factors can be upregulated during DC 
maturation and mediate danger signals to the surrounding tissue. The resulting cytokine 
release by NK cells can further amplify DC maturation or enhance Th1 responses in an 
IFN-γ-dependent manner (Figure 3B).
Besides enhanced NK cell cytokine production also NK cell cytotoxicity can be enhanced 
by DC-dependent mechanisms 158, 180. DC-derived cytokines IL-12, IL-2, and IL-15 or 
combination of  diverse cytokines (e.g. IL-12, IL-15, and IL-18) as well as interaction with 
contact-dependent factors (e.g. NKp30, NKp46, NKG2D) have been shown to influence 
NK cell-mediated cytotoxicity 174, 181-183. These DC-induced cytolytic mechanisms include 
both perforin and granzyme B-pathways and FasL/Fas-based pathways 184.
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NK cell-induced DC responses
NK cells hold the capacity to control and enhance DC-induced immune responses, mainly 
by influencing the maturation of  Th1-polarizing DC, providing antigenic material for 
presentation by DC, and killing of  inappropriately matured or immature DC (DC editing) 
(Figure 3B-D).
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Figure 3 | Functions of  NK cells. (A) Concept of  tolerance, missing-self  and induced-self  regulating 
the cytolytic activity of  NK cells. (B) Activated NK cells provide cytokines and contact-dependent 
activation factors for DC maturation. Moreover, NK cells provide IFN-γ and co-stimulatory factors to 
enhance Th1 polarization. (C) Cytolytic activity of  NK cells provides antigenic material for DC (cross-)
presentation (D) NK cell-mediated editing of  immature DC.
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As NK cells have the natural capacity to kill virally infected or malignantly transformed 
cells 138, they are not only involved in the direct elimination of  these cells, but also 
provide (tumour-related) antigenic material facilitating the uptake, processing, and (cross-) 
presentation by DC 185, 186. 
NK cells mediate immunoregulatory ′helper′ functions. These helper cells are characterized as 
CD83+CCR7+CD56dim NK cells that possess DC-activating capacities 148, which is mediated 
by both NK cell-derived soluble factors, mainly IFN-γ and TNF-α 187, 188, as well as ligation 
of  surface receptors (e.g. CD40 ligation) 189. NK-DC interaction results in the development 
of  stable, type-1-polarized DC that produce high amounts of  pro-inflammatory cytokines 
and, thereby, are able to enhance Th1 and CTL-mediated immunity against intracellular 
pathogens and cancer 159, 187, 190, 191. In the absence of  NK cells, Th polarization is biased 
towards Th2 polarization, without induction of  CTL 192, 193. NK cell-derived IFN-γ induces 
upregulation of  the Th1 lineage-specifying transcription factor T-bet and inhibition of  the 
Th2 lineage-specifying transcription factor GATA-3 194. These ′helper′ NK cells gained 
their function after activation by IL-12 or IL-18 148. Other pro-inflammatory cytokines 
(IL-2, IL-15, type-I IFNs: IFN-α/β), NK cell-sensitive tumour cell lines and opsonizing 
tumour-specific antibodies can synergize in a two-signal mechanism 159, 190, 195. 
NK cells also have the capacity to eliminate autologous and allogeneic iDC 187, 196. NKp30 
has been shown to play a major role in iDC lysis and cooperates with DNAM-1. Because 
both mature as well as iDC express ligands for NKp30 and DNAM-1 197, an additional 
mechanism must be involved. Analysis of  NK cell clones has revealed that killing of  iDC 
was confined to NK cells that lack expression of  inhibitory KIRs specific for self-HLA 
class I alleles, but do express the HLA-E-specific CD94/NKG2A inhibitory receptor 198. 
iDC become susceptible to NK cell-mediated cytotoxicity due to low HLA-E expression 
irrespective of  expression of  other HLA molecules. In contrast, mDC upregulate HLA-E 
and are, therefore, kept untouched 198, 199. iDC have been implicated in tolerance and 
induction of  regulatory T cells 200. Thus, it can be hypothesized that by eliminating iDC, NK 
cells ensure activation of  adaptive immune responses by preventing inadequately matured 
DC to interact with T cells 196, 201, 202. Although in apparent paradox, NK cells can induce DC 
maturation as well lysis of  iDC, which depends on the relative numbers of  each cell type 187.
The crosstalk of  NK cells and DC can occur at multiple locations; NK-DC interaction takes 
place at the site of  inflammation as well as in the lymph nodes 203. During an inflammatory 
response, a burst of  immunoactive molecules is secreted, including chemokines, resulting in 
immune cell recruitment. We and others have shown that upon maturation, TLR-triggered 
DC produce large amounts of  many different chemokines 204, 205. Among these, NK 
cell-recruiting chemokines are produced, like CCL5, CXCL10, and CCL19. Different 
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chemokines and chemokine receptors have been shown to be involved in DC-mediated 
NK cell recruitment 147, 194. Because maturing DC migrate into the draining lymph nodes, 
chemokine production by mature DC is possibly also responsible for the recruitment of  
NK cells into the lymph node. In CXCR3−/− mice, it has been shown that Th1 polarization 
was inhibited, due to impaired recruitment of  NK cells into the lymph nodes 194. In humans, 
however, additional NK cell-recruiting mechanisms have been proposed. NK cells are 
able to upregulate their CCR7 expression and subsequently their responsiveness to the 
lymph node-homing chemokine CCL19 upon activation with IL-18 and after NK-DC 
crosstalk 147,148. This would represent an additional mechanism by which DC induce NK cell 
mDC
maturation
iDC
PRR
PAMPs
NK
soluble factors
(IL-12, IL-15, IL-18, and IL-2, IFN-α/β)
contact-dependent factors
(NKp30, NKp46, NKG2D, 2B4, CD27)
NK
1
2
3
4
granzymes
perforins
TNF-α
IFN-γ
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Figure 4 | DC-induced NK cell responses. (1) PAMP-matured DC activate NK cells via contact-
independent and/or via contact-dependent factors by a two-signal activation. This leads to enhanced 
NK cell proliferation and survival (2), increased cytotoxic capacity of  NK cells via granule exocytosis 
and death receptor pathway (3). Additionally, the NK-DC crosstalk enhances helper activity of  NK cells 
by inducing the release of  pro-inflammatory cytokines (mainly TNF-α and IFN-γ). These soluble factors 
enhance maturation of  surrounding DC, Th1 polarization, and CTL activation (4).
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migration into the draining lymph nodes. Given the heterogeneity of  DC subsets and the 
location of  NK cells at different sites of  the body 206, NK-DC crosstalk may have different 
functional consequences on the induced immune responses depending on the site of  
interaction. Likewise, BDCA-1+ DC, described as potent IL-12 producers 207, could provide 
this cytokine in the secondary lymphoid organs to enhance the helper function mediated by 
NK cells via the release of  IFN-γ and stimulate the induction of  potent T cell responses. On 
the other hand, BDCA-3+ cells located in inflamed tissue could be a source of  IFN-α, which 
enhances the cytolytic function of  NK cells at the site of  infection 208. This bi-directional 
crosstalk between different human DC subsets and NK cells needs further investigation.
NK cells and T cell responses
Another feature of  NK-DC crosstalk is the CD4+ T cell-independent induction of  CTL 
responses. Different studies established the need for proper NK cell function for the 
induction of  CTL responses. Moreover, CTL induction was abolished after removal of  NK 
cells. Thus, NK cells are important players of  CTL initiation and persistence 209-213. This 
function of  NK cells is attributed to NK cell-secreted cytokines which are partly dependent 
on NK-DC crosstalk 214. For example, IL-2 and IL-15-stimulated NK cells upregulate CD137 
and via CD137 ligation NK cells produce IFN-γ and proliferate, which is accompanied by 
expansion of  activated CD8+ T cells in vitro 215.
Besides providing IFN-γ to enhance DC-induced Th1 polarization, NK cells may also 
directly interact with CD4+ T cells. Activated NK cells can upregulate MHC class II and 
co-stimulatory molecules (e.g. CD80, CD86, CD70 OX40L) 216,217 displaying APC-like 
properties with unique pathways for antigen uptake, presentation, and direct activation of  
CD4+ T cells 217-219. This process may be locally limited to secondary lymphoid organs. 
Interestingly, NK cells present in human inflamed tonsils displayed higher MHC class II 
and co-stimulatory molecules expression 217. The upregulating of  co-stimulatory molecules 
is probably influenced by the local environment. Likewise, innate cytokines or crosslinking 
of  various activating receptors were sufficient to upregulate CD86 expression on NK cells. 
However, the ligation of  activating receptors (e.g. CD16, NKG2D) in combination with 
innate cytokines were required to induce OX40L. Crosstalk between activated NK cells and 
autologous CD4+ T cells induced proliferation and cytokines secretion of  Th cells 217, 219, 220.
Direct recognition of  pathogens
The importance of  NK cells in human host defence and control of  infections is supported 
by several patients with NK cell deficiencies displaying an increased susceptibility to 
recurrent viral infections (mainly herpes- and papillomavirus) 221-224. Besides the activation 
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of  NK cells via PAMP-sensing accessory cells (e.g. DC), NK cells have also been identified 
to express a repertoire of  innate PRR, allowing a potential direct recognition of  PAMPs. 
Until now the expression of  TLR1-10 as well as RIG-I, NOD2, NRLP3, and MDA5 225-227 
has been confirmed. Engagement of  various TLR (TLR2, 3, 7, 8, and 9) has been shown 
to activate NK cells and enhance their proliferation, cytotoxicity against various tumour 
cell lines 228-231 as well as increase their DC editing capacity 231. Moreover, the activation 
of  NK cells via MDP (NOD2 receptor ligand) enhanced cytokine production, but not 
cytotoxicity 225. Whereas NK cells could recognize certain PAMPs directly, for others the 
presence of  accessory cytokines was required for efficient sensing 229, 232. Further research 
is needed to reveal the exact role of  triggering other PRR expressed by NK cells on their 
function as well as the role of  PRR-triggering in the induction of  their ′helper′ properties.
Regulatory functions of  NK cells
Besides all the immune stimulatory capacities assigned to NK cells, they can also act as 
immune regulators to keep immune homeostasis. This attributes an important function to 
NK cells in autoimmunity, pregnancy, tolerance, and organ transplantation. Several animal 
models revealed a progress of  autoimmune disorders when NK cell were depleted. In 
this line, patients with diabetes, multiple sclerosis, or rheumatoid arthritis display reduced 
numbers and activity of  NK cells 233-235. The NK cell rheostat function can be mediated by 
direct elimination of  overstimulated immune cells (e.g. activated T cells) or by secretion of  
inhibitory cytokines (e.g. IL-10 and TGF-β) blocking the activation and proliferation of  
T cells 236-241. The precise functions and mechanisms of  action of  regulatory NK cells are 
currently being explored; definition of  NK cell regulatory subsets and their induction as 
well as the influence of  viral load on the mediated outcome are subject of  investigation 242. 
CANCER IMMUNOTHERAPY & DC VACCINATION
Besides the conventional cancer treatments such as surgery, radiation-, and chemotherapy, 
immunotherapy has been implemented into standard treatment regimens for certain types 
of  cancer. The main goal of  cancer immunotherapy is to stimulate and/or restore the 
patient’s immune system to specifically attack and to reject the tumour. Different types of  
cancer immunotherapy exist, which can be divided into passive and active approaches as 
well as specific and non-specific mechanisms of  action. Immunomodulatory agents (e.g. 
cytokines, adjuvants), monoclonal antibodies (mAb; e.g. rituximab), adoptive cell transfer or 
therapeutic vaccines are examples of  cancer immunotherapy. In 1891, W. Coley applied the 
first form of  cancer immunotherapy by treating cancer patients with bacterial injections 243. 
In the mid 1980’s, the first cytokine, IFN-α, was approved by the FDA as cancer treatment. 
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This was followed by approvals of  other cytokines as well as the use of  mAb, the first one 
being rituximab in 1997 targeted against CD20 to treat B cell lymphomas. A breakthrough 
for active cancer immunotherapy occurred in 2010, with the FDA-approval of  the first 
therapeutic cancer vaccine, sipuleucel-T (Provenge®) 244 for the treatment of  advanced 
prostate cancer resulting in a prolonged survival of  patients by 4.1 months. This success was 
followed by the FDA-approval of  the cytotoxic T-lymphocyte-associated protein 4 (CTLA-
4; ilipimumab), a checkpoint-inhibitor extending the survival of  patients with metastatic 
melanoma. In 2014, mAb targeting another checkpoint, PD-1, have been approved, 
nivolumab and pembrolizumab, designated for the treatment metastatic melanoma and 
squamous non-small cell lung cancer. In the meanwhile, promising clinical trials with 
optimized or novel as well as combinatorial approaches of  cancer immunotherapy are 
ongoing. One of  these approaches is the chimeric antigen receptor (CAR) T cell therapy. 
This approach applies genetically modified T cells from patient’s body to target and 
specifically eliminate the cancer cells. Promising results have been shown in several clinical 
trials reaching 89-100% response rates 245-247.
The approval of  Provenge® by the FDA illustrates the potential of  cell-based vaccines for 
anti-cancer immunotherapeutic treatments. DC are of  particular interest in vaccination 
strategies since they are sentinel cells of  the innate immune system and are the key regulators 
in linking the innate and adaptive immune system 248. In patients with cancer DC display an 
increased immature phenotype, reduced stimulatory capacities, and an impaired induction 
of  type-1 immune responses 249, 250, which are important to induce effective anti-tumour 
responses. Thus, one of  the strategies to overcome the problem of  dysfunctional DC in 
cancer patients is the injection of  ex vivo-matured DC, which are capable of  restoring the 
immunosuppressive balance. In contrast to endogenously developing DC, they are partially 
resistant to tumour-related suppressive factors 77, 251. The generation of  new methods to isolate 
monocytes in large numbers from peripheral blood and culture them ex vivo into iDC 252,253, 
opened new possibilities to apply these cells in vaccination strategies. The most commonly 
applied strategy to generate ex vivo DC is illustrated in Figure 5. In 1996, the results of  the 
first clinical trial using antigen-pulsed iDC were published 254. Initial studies applied iDC or 
partly matured DC, which only displayed limited T cell-stimulating activity and turned out 
to induce tolerogenic instead of  immunogenic responses. The next generation of  DC-based 
vaccines, which is by far the most common approach 255, applied long-term IL-4/GM-
CSF-differentiated monocytes (5-7 days), which have been matured with a PGE2/TNF-
α-cocktail (± IL-6/IL-1-β; often referred to as golden standard) 256. These DC displayed a 
fully mature phenotype (high expression of  MHC and costimulatory molecules), as well as 
enhanced in vitro migration and immune stimulation. However, the resulting mDC were 
lacking an immunostimulatory cytokine profile, mainly the production of  IL-12p70, which 
turned out to be crucial for the efficacy of  DC to induce type 1 immune responses 257-260. 
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Subsequent studies explored the addition of  various cytokines and/or PRR-triggers as well 
as ′fast′ differentiation/maturation protocols to enhance the immunostimulatory cytokine 
production. Defining an optimal combination of  different factors to be included in the 
maturation cocktails is of  relevance as it impacts the resulting DC phenotype, the amount, 
timing and duration of  cytokine production and their trafficking properties 261. Clinical trials 
applying this third generation of  DC-based vaccines are still ongoing. Besides identifying 
the appropriate differentiation and maturation protocols for the use of  moDC, current 
studies also investigate the effectiveness of  using endogenous blood-circulating subsets in 
DC vaccination 262, 263. Moreover, crucial advances have been made in identifying optimal 
injection routes and regimens, and antigen-loading strategies. The combination of  DC-
based vaccines with other approaches, such as adjuvants or checkpoint inhibitors, are also 
currently explored. 
In general, many aspects need to be considered to design an optimal DC-based vaccine such as 
isolation methods of  monocytes (or other DC subsets), differentiation pathways, maturation, 
choice and source of  Ag and Ag-loading, injection route and regimen, combination with 
TNF-α
IFN-γ
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DC subset usage
in vivo targeting of  DC
combination therapies
isolation
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differentiation pathway
duration of  differentiation 
DC maturation
selection of  Ag
Ag-loading
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monocytesiDC
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Figure 5 | DC-based vaccination. One of  the most common methods to generate ex vivo-matured 
DC is shown. Monocytes are isolated from the patient’s blood via leukapheresis, followed by elutriation. 
Monocytes are differentiated into iDC, which are matured and loaded with tumour-associated antigens. 
The obtained mature DC are re-injected into the patient where they possibly induce a type 1 immune 
response against the tumour including interaction of  at least NK cells, CTL, and Th1 cells. Different 
intervention points to boost DC-based vaccines are indicated.                                        © T.H.P.M Habets
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adjuvants, and patient characteristics (e.g. host immunological competence, tumour size). 
DC used in clinical trials should ideally not be exhausted (still able to produce cytokines 
upon CD40 ligation), express high levels of  costimulatory molecules (especially CD83), 
MHC class I and II molecules, and CCR7 (migration towards secondary lymphoid organs) 
and produce IL-12p70.
Besides the use of  ex vivo-generated DC other approaches exist to manipulate and boost 
anti-cancer activities of  DC, such as: endogenous vaccination (e.g. checkpoint blockade), 
reprogramming inflammation (e.g. blocking of  cytokines), and the targeting antigens to 
DC subsets in vivo 264, 265.
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SCOPE OF THE THESIS
During a pathogenic insult, the efficient cooperation of  innate and adaptive immunity 
is needed to eradicate the invader. PRR, expressed on various types of  immune cells, 
are important components of  the innate immunity and are responsible for sensing and 
instructing appropriate and coordinated immune responses. The main cell type expressing 
PRR and thus linking innate and adaptive immunity are APC, such as DC. Because of  their 
importance and unique properties of  instructing various immune effector cells, DC have 
been considered as promising targets in immunotherapeutic strategies against cancer. 
Cancer immunotherapy aims to stimulate the patient’s immune responses to eliminate the 
tumour cells. One approach of  cellular immunotherapy are DC-based vaccines, which have 
been proven to be safe and non-toxic, however, overall clinical outcome is still limited. In 
2010, the first DC-based vaccine against advanced prostate cancer, Provenge®, has been 
approved by the FDA 266. This vaccine prolonging the patient’s life-time for several months 
(without eradicating the tumour) in combination with different ongoing clinical trials testing 
DC-based vaccination, exemplifies the potential role of  DC-based vaccines in future standard 
anti-cancer treatments. Nonetheless, the limited overall positive clinical outcome monitored 
is indicative for the need of  further optimizations. Initial studies focused on generating DC 
having the potential to efficiently induce anti-tumour CTL responses. However, increasing 
evidence indicates that the induction of  more complete type 1 immune responses, including 
also Th1 and NK cells, is crucial for the induction of  efficient anti-tumour responses.
The main aim of  this thesis was to study the cellular interplay of  DC, NK cells and T helper 
cells after PAMP encounter with main focus on type 1-induced helper responses (Figure 6). 
Identifying which signals induce and enhance the interaction of  DC with different immune 
effector cells is important to increase the efficacy of  DC vaccination strategies. 
To study the crosstalk between DC, NK cells, and naive CD4+ T cells and the influence of  
PAMPs on this cellular interplay, we started with setting up an assay allowing the study of  
naive CD4+ T cell polarization by autologous DC subsets in a human setting as described 
in chapter 2. Moreover, we applied the assay to evaluate the capacity of  DC matured with 
various cocktails currently used in clinical trials to polarize naive CD4+ T cells. In chapter 3, 
we studied the capacity of  specific PAMP-matured DC to induce both NK helper cell 
activation and Th1 polarization. Additionally, we aimed to identify common soluble factors 
regulating this interaction. Moreover, in chapter 4, we aimed to study whether NK cells 
could be directly activated by different viral and bacterial PAMPs. We investigated whether 
these PAMP-activated NK cells could enhance the maturation of  DC via the release of  
soluble factors. In the context of  cancer, these cellular interactions are influenced by the 
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presence of  inhibitory factors released by tumor cells. In chapter 5, we studied the direct 
effect of  such an immune suppressor, PGE2, on PAMP-induced DC maturation, NK 
cell activation, and on NK-DC crosstalk. This thesis concludes with a general discussion 
presented in chapter 6, reflecting the most important findings in the context of  adjuvants 
for vaccination and the impact of  helper cells in future DC vaccination strategies as well as 
the impact of  tumour-derived suppressive factors on the efficacy of  immunotherapy.
PAMPs & cellular interplay
chapter 2 chapter 3
chapter 4 chapter 5
 Th1
 NK
Tumour
NK
DC  Th1
 Th0
 Th2
Figure 6 | Outline of  the dissertation. The aim of  the studies presented in this dissertation was to 
investigate how the cellular interplay between DC, NK cells and T helper cells could be influenced by 
various PAMPs. Chapter 2 describes the setting up of  a human autologous naive CD4+ T cell polarization 
assay allowing to study the capacity of  differently matured DC to polarize Th0 cells. In chapter 3, we 
investigated the potential of  PAMP-matured DC to activate both NK helper cell responses and Th1 cells. 
Chapter 4 describes the direct sensing of  PAMPs by NK cells and how these cells can contribute to the 
activation of  DC. In chapter 5, the influence of  tumour-derived suppressive PGE2 on NK-DC crosstalk 
was investigated.
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ABSTRACT
A crucial step in generating de novo immune responses is the polarization of  naive cognate 
CD4+ T cells by pathogen-triggered dendritic cells (DC). In the human setting, standardized 
DC-dependent systems are lacking to study molecular events during the initiation of  a 
naive CD4+ T cell response. 
We developed a TCR-restricted assay to compare different pathogen-triggered human DC 
for their capacities to instruct functional differentiation of  autologous, naive CD4+ T cells. 
We demonstrated that this methodology can be applied to compare differently matured 
DC in terms of  kinetics, direction, and magnitude of  the naive CD4+ T cell response. 
Furthermore, we showed the applicability of  this assay to study the T cell-polarizing 
capacity of  low-frequency blood-derived DC populations directly isolated ex vivo.
This methodology for addressing APC-dependent instruction of  naive CD4+ T cells in a 
human autologous setting will provide researchers with a valuable tool to gain more insight 
into molecular mechanisms occurring in the early phase of  T cell polarization. In addition, 
it may also allow the study of  pharmacological agents on DC-dependent T cell polarization 
in the human system.
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INTRODUCTION
Since the first description of  two different subsets of  activated murine T helper (Th) cells 1, 
the understanding on induction, phenotypic discrimination, and functional consequences of  
the different Th lineages has enormously expanded. The polarization of  naive CD4+ T cells 
into different Th subtypes is a tightly controlled and regulated process, which is induced 
by the interaction of  CD4+ T cells with pathogen-triggered antigen-presenting cells (APC), 
such as dendritic cells (DC). This interaction consists of  antigen-specific, co-stimulatory, 
and polarizing signals 2, 3. Th lineage specialization is induced according to the nature of  
the pathogenic insult 2, 4-6 and the different Th lineages are defined by the expression of  
various transcription factors and cytokines. Uncontrolled activation and dysregulation of  
this process is associated with immune-related diseases 7-9. It is of  crucial importance to get 
more insight into initiating pathways and regulating networks involved in human CD4+ T cell 
polarization to identify potential intervention points for therapy and to improve diagnostics.
Over the last decade, it has become clear that the functional differentiation of  Th cells is 
a complex process in terms of  lineages, involvement of  transcription factors, plasticity, 
and epigenetic imprinting. Whereas lineage-specifying factors, e.g. T-bet for Th1 10, were 
initially considered as being both required and sufficient to determine the Th phenotype, 
recent research revealed their possible co-expression and interplay in one particular Th 
subtype 11,12. Moreover, the transcriptional programming during the initiation of  CD4+ T 
cell responses has been shown to be imprinted only to a limited extend by these Th lineage-
specifying factors and instead by cytokine-regulated environmental response factors, such 
as signal transducers and activators of  transcription (STATs) 3, 14. Furthermore, it has been 
shown that polarized Th subsets are not terminally differentiated and retain a certain degree 
of  flexibility and plasticity; they are able to respond and adapt their phenotype to changing 
environmental cues 15. These environmental changes, e.g. invasion of  pathogens causing 
cell damage or inflammation, are sensed by DC and translated into an appropriate immune 
response 6. The concentration as well as the nature of  these ′danger′ signals influence the 
expression of  co-stimulatory molecules and the cytokine profile of  DC 16-22 and thereby 
indirectly the T cell priming. It is important to study naive CD4+ T cell polarization in an 
APC-dependent manner to better understand how different pathogens induce specific Th 
responses and to take into account the complex network of  soluble and membrane-bound 
factors presented by DC. 
Up-to-date the majority of  knowledge on Th cell differentiation was generated using murine 
models, such as the OT-II system or knockout models lacking specific genes involved in T 
cell skewing. However, murine and human immune systems display some crucial differences. 
This makes the extrapolation of  data generated from these models in the context of  human 
48
Chapter 2
2
Th cell polarization challenging. Murine and human DC subsets display divergences in terms 
of  cytokine profiles 23, pattern recognition receptor (PRR) expression patterns 24-29, and 
ligand recognition 30. In addition, CD4+ T cells show interspecies heterogeneity in terms of  
cytokine secretion by the different Th subtypes 31, 32 and the involvement of  lineage-specifying 
transcription factors 33-35. These divergences illustrate that the mechanisms and therapeutic 
interventions identified in murine models require confirmation in human in vitro systems 
before their translation into clinical trials. This need of  valorisation is underscored by 
studies revealing the possibility to cure mice but not humans with a similar treatment 36-38. 
However, human in vitro assays to study the APC-dependent initiation of  naive CD4+ T cell 
polarization are still limited.
Importantly, efforts were undertaken to study the kinetics of  the in vitro programming 
of  human naive CD4+ T cells using high-throughput genome-wide microarrays 39, 40. The 
advantage of  this approach is gaining insight into the kinetics of  the individual molecular 
events and pathways during the differentiation of  naive T cells into specific lineages, which 
may result in the identification of  therapeutic targets; the limitation is the APC-independent 
setup. Even though this approach can be used as complementary method to study the 
involvement of  single or multiple soluble factors in the initiation of  a T cell response, 
the contribution of  DC-derived contact-dependent factors is ignored. Their importance 
for the induction of  a proper Th response has been shown 4 and thus it is important to 
study the early molecular events during the differentiation of  naive CD4+ T cells in an 
APC-dependent manner. In current APC-dependent assays many confounders exist: 
medium usage, source and purity of  cells, restimulation, ratio of  effector:target cells, time 
point of  measurement, culture density and the use of  superantigens 4, 6, 41-46. Most importantly, 
these current approaches do not address the initiation phase of  naive DC-induced CD4+ 
T cell responses without adding supplemental environmental or blocking factors to the 
co-cultures. Furthermore, the monitoring of  a broader range of  the induced responses is 
limited. 
We set up a system to study the initiation phase of  autologous naive CD4+ T cell polarization 
in an APC-dependent and TCR-restricted manner. This system allows studying the effect 
of  different PRR stimuli on DC-mediated direction, potency, and kinetics of  Th cell 
differentiation. It takes into account how DC-derived soluble factors interact together with 
co-stimulatory molecules during priming of  naive CD4+ T cell responses without additional 
artificial stimulation of  the co-culture, e.g. addition of  Th cell-polarizing cytokines. It allows 
the comparison of  differently matured DC as well as different DC subsets and has the 
possibility to monitor the kinetics and magnitude of  the lineage-specifying transcription 
factors of  the different Th lineages and their cytokine profiles in parallel in a small-scale, 
serum-free setup.
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MATERIALS AND METHODS
Generation of  dendritic cells
Monocyte-derived DC       
Leukapheresis products obtained from healthy volunteers were used to isolate the 
monocytes; this study was approved by the local Medical Ethics Committee of  Maastricht 
University Medical Center, the Netherlands (MEC azM/UM; MEC 08-2-120) and written 
informed consent was obtained from all participating healthy volunteers. Enrichment of  
monocytes from leukapheresis products was achieved by counterflow centrifugal elutriation 
using the Elutra® Cell Separation System monocyte enrichment application (Elutra, Terumo 
BCT Inc., Lakewood, CO, USA). Purity of  enriched monocyte fractions was 87.9%±5.2 
as assessed by flow cytometry with an average yield of  1.74x109 monocytes ± 0.96 per 
leukapheresis. Characterization of  contaminating cells revealed presence of  B cells, NK 
cells, granulocytes, and T cells. The latter counted up for 0.77% ± 0.22. Monocytes were 
frozen at 50x106 cells per vial in 1ml freeze medium: 86% autologous plasma + 10% 
DMSO (WAK Chemie, Steinbach/Ts. Germany) + 4% Glucose (50% Glucose; B. Braun 
Melsungen AG, Melsungen, Germany). Upon thawing, monocytes were differentiated in 
serum-free AIM-V® medium (Invitrogen, Carlsbad, CA, USA) supplemented with GM-CSF 
(400 U/ml; Berlex Laboratories Inc., Montville, NJ, USA) and IL-4 (2000U/ml; Strathmann 
Biotech AG, Hamburg, Germany) at a density of  2x106 cells/ml. After 7 days, iDC were 
harvested and processed in the DC-T cell co-culture experiments. Unless differently stated, 
monocyte-derived (moDC) were used.
Plasmacytoid DC        
For the isolation of  plasmacytoid DC (pDC), 500ml of  fresh heparin-anticoagulated 
peripheral blood was used as starting material, because of  the low frequency of  CD304+ 
cells in the blood, allowing the separation of  up to 2.5x106 cells. Blood was obtained from 
Sanquin blood bank Maastricht, the Netherlands (project 2000-03AZM) from healthy 
donors who agreed to donate their blood for research purposes and signed an informed 
consent. Peripheral blood mononuclear cells (PBMC) of  healthy donors were isolated by 
density gradient centrifugation using lymphoprepTM (Axis-Shield PoC AS, Oslo, Norway). 
pDC were isolated by positive immunomagnetic cell separation using a CD304 enrichment 
kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to manufacturer’s 
instructions. Purity of  enriched pDC fractions exceeded 85% as assessed by flow 
cytometry, with contaminating CD4+CD45RO+ cells <0.5% of  all living cells. pDC were 
further processed in the DC-T cell co-culture experiments. The remaining PBMC fraction 
(flow-through) was resuspended in serum-free AIM-V® medium at a concentration of  
15x106 cells/ml and incubated overnight at 37°C and 5% CO2. This suspension was used as 
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a starting material to isolate naive CD4+CD45RA+ T cells.
T helper cell isolation
Autologous total CD4+ T cells, CD4+CD45RA+, CD4+CD45RO+ were isolated from 500ml 
of  fresh heparin-anticoagulated peripheral blood. PBMC were obtained by density gradient 
centrifugation and further processed by negative immunomagnetic separation using a 
total CD4+ or CD4+CD45RO+ isolation kit (Miltenyi Biotec) following the manufacturer’s 
instructions. Purities of  the different T cell subsets exceeded 95%. The isolation of  
untouched CD4+CD45RA+ T cells was optimized as illustrated in Figure S1. The negative 
immunomagnetic separation procedure was performed twice as the isolation of  these highly 
pure naive CD4+ T cells required two consecutive rounds of  separation. The highest purity 
(≥99.8% with ≤0.1% CD4+CD45RO+) was achieved by incubating the flow-through of  the 
first separation round a second time with the combination of  antibody-mix and beads. A 
limitation of  this second isolation procedure is the accompanied cell loss of  30-60%. The 
yield of  isolated naive CD4+ T cells was donor-dependent. Autologous CD4+CD45RA+ T 
cells for the pDC-T cell co-cultures were isolated from the remaining fraction obtained 
after positive pDC selection, which has been incubated overnight at 37°C, 5%CO2 at 
15x106 cells/ml in serum-free AIM-V® medium. 
T cell polarization assays
APC-dependent assay         
iDC were matured in round-bottom 96-well plates (0.2x105 moDC/well or 0.1x105 
pDC/well) with different maturation cocktails: PGE2 (18µg/ml; Sigma-Aldrich, St. Louis, 
MO, USA) and TNF-α (1000U/ml; Biosource International, Camarillo, CA, USA); FMKp 
(10µg/ml; Pierre Fabre Laboratories, Boulogne-Billancourt, France) and IFN-γ 
(500U/ml; R&D systems, Minneapolis, MN, USA); LPS (200U/ml; USP, Rockville, MD, 
USA) and IFN-γ (1000U/ml); HKLM (109cells/ml; InvivoGen, Toulouse, France) and IFN-γ 
(500U/ml); or ODN2216 (10µM/ml; InvivoGen). For moDC all cocktails were 
supplemented with IL-4 (500U/ml) and GM-CSF (500U/ml) and for pDC with IL-3 
(100ng/ml; Miltenyi Biotec). The optimal moDC-T cell co-culture ratios were determined 
by culturing increasing numbers of  24h-matured FMKp/IFN-γ-moDC (0.1, 0.2, 0.5x105) 
with 0.5x105 autologous naive CD4+ T cells (Figure S2). To this end, 24h-matured DC 
were harvested, washed and transferred at different ratios into round-bottom 96-well plates 
together with an equal amount of  pooled supernatant of  24h-matured DC. Because of  their 
higher T cell stimulatory capacity in a pilot experiment (data not shown), we co-cultured 
pDC and naive T cells at a ratio of  1:5. In the condition with ′washed FMKp/IFN-γ-DC′, 
the maturation stimuli were removed 6h after the induction of  maturation by washing the 
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DC three times with medium and adding 50µl of  fresh serum-free medium. After 24h of  
maturation, DC were loaded with 50µg/ml of  a pan HLA-DR binding peptide (PADRE; 
AGVAAWTLKAAA) that binds all groups of  HLA-DR variants and leads to a polyclonal 
TCR-restricted T cell stimulation 47. After 1h of  incubation, 0.5x105 autologous T cells were 
added in 25µl to the different wells. As a negative control, T cells were cultured in serum-free 
medium in the absence of  DC. During the 7-day co-culture, samples were collected by 
harvesting each day individual wells of  the different conditions. Supernatant was harvested 
and frozen for cytokine determination, whereas the cell pellets were lysed in RLT buffer 
(Qiagen, Alameda, CA, USA) containing 1% 2-mercaptoethanol (Sigma-Aldrich) and stored 
at -80°C for gene expression analyses. Furthermore, supplementary wells were cultured to 
study surface activation markers, as well as to determine the presence of  intracellular IFN-γ 
on day 7 of  the co-culture. GolgiStop™ and GolgiPlug™ (both BD Biosciences, Franklin 
Lakes, NJ, USA) were added to the latter wells and cells were incubated overnight in absence 
or presence of  PMA (0.25µg/ml) and ionomycin (0.5µg/ml; both Sigma-Aldrich).
APC-independent assay        
Round-bottom 96-well plates were coated overnight with 0.25 µg/ml anti-CD3 (clone 2G3, 
kind gift from Prof. Dr. N. Hellings, Biomedical Research Institute, Diepenbeek, Belgium). 
After extensive washing of  the plates, 0.5x105 pure CD4+CD45RA+ T cells were cultured 
in serum-free medium in absence or presence of  DC supernatant. This supernatant was 
generated by maturing iDC at a density of  5x105/ml for 6h in the presence of  IL-4 (500U/
ml), GM-CSF (400U/ml), IFN-γ (500U/ml) and FMKp (10µg/ml). After the induction of  
maturation, adherent cells were washed three times to remove the maturation stimuli and 
fresh medium was added. After a total of  48h, DC supernatants were collected. During the 
5-day co-culture, each day the culture supernatant was harvested and frozen at -20°C for 
cytokine determination. Cells were harvested and lysed in RLT buffer supplemented with 
1% 2-mercaptoethanol and frozen at -80°C for gene expression analyses.
Flow cytometry
All flow cytometry antibodies used to determine DC and T cell purities as well as 
Th cell surface marker expression were purchased from BD Biosciences, except for 
BDCA-2 (Miltenyi Biotec). Antibodies were used at the proper concentrations either as 
fluorescein isothiocyanate, phycoerythrin, peridinin chlorophyll protein, allophyocyanin, 
allophyocyanin-H7, Horizon 450, Horizon 500, Alexa Fluor 488 or Pe-Cy7. Intracellular 
IFN-γ staining was performed as described previously 48. Analyses were performed with BD 
FACS Canto II and analysed by BD FACSDiva Software v6.1.2 (BD Biosciences).
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qPCR
Total cellular RNA was isolated from lysed T cells using RNeasy Mini kit (Qiagen) 
according to manufacturer’s instructions. Genomic DNA was removed by DNase I 
(Invitrogen) treatment followed by reverse transcription using random hexamer primers 
(Invitrogen) and Superscript III Reverse Transcriptase (Invitrogen) according to the 
standard procedures. Primers for quantitative PCR analysis were generated using primer-
BLAST software (NCBI). All primers were selected to span exon-exon boundaries with 
a maximal amplification length of  300 bp. Primer specificity was tested by melting curve 
analyses, product size confirmation by gel-based PCR analyses and bidirectional sequencing 
of  amplified products after subcloning in plasmids (Topo TA cloning, Invitrogen). Relative 
quantification was done by generating a standard curve of  a reference sample (cDNA of  
total T cell fraction). Real-time PCR was done with SYBR green detection (SensiMix SYBR 
& Fluorescein Kit, both from Bioline Reagents Ltd., London, United Kingdom) using an 
iCycler iQ (Biorad Laboratories Inc., Hercules, CA, USA) and primers (10pmol) specific for 
the different Th lineages (listed in Table S1). The PCR program consisted of  10min initial 
heating at 95°C (hot start polymerase), followed by 35 cycles amplification (30s at 95°C, 
20s at the optimized annealing temperature and 20s at 72°C) and a final heating up to 92°C 
(increasing 0.5°C/7s) for the generation of  a melting curve. Each data point of  the graphs 
was generated by determining expression of  the gene of  interest on the different days in 
duplicate and normalizing these data to the corresponding expression of  CD3ε used as 
housekeeping gene in our assay. 
T helper cell cytokine detection
Quantification of  Th-specific cytokines (IFN-γ, IL-4, IL-5, IL-13, IL-17, IL-10) in the 
supernatant of  the DC-T cell co-cultures on day 1, 3, 5 and 7 (day 1, 3 and 5 for the anti-
CD3 culture) was performed by CBA flex set assay (BD Biosciences) according to the 
manufacturer’s instructions. Measurements were performed with BD FACS Canto II and 
analysed by BD FACSDiva Software v6.1.2 and FCAP array analysis software (version 1.0.1; 
Soft Flow Inc., St. Louis Park, Minnesota, USA).
Statistical analyses
Statistical analyses were performed by Wilcoxon matched pairs test and the correlation was 
tested by nonparametric Spearman correlation; P values <0.05 were regarded as significant. 
Data was analysed using Prism Software (version 6; GraphPad Software, San Diego, CA, 
USA).
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qPCR
Total cellular RNA was isolated from lysed T cells using RNeasy Mini kit (Qiagen) 
according to manufacturer’s instructions. Genomic DNA was removed by DNase I 
(Invitrogen) treatment followed by reverse transcription using random hexamer primers 
(Invitrogen) and Superscript III Reverse Transcriptase (Invitrogen) according to the 
standard procedures. Primers for quantitative PCR analysis were generated using primer-
BLAST software (NCBI). All primers were selected to span exon-exon boundaries with 
a maximal amplification length of  300 bp. Primer specificity was tested by melting curve 
analyses, product size confirmation by gel-based PCR analyses and bidirectional sequencing 
of  amplified products after subcloning in plasmids (Topo TA cloning, Invitrogen). Relative 
quantification was done by generating a standard curve of  a reference sample (cDNA of  
total T cell fraction). Real-time PCR was done with SYBR green detection (SensiMix SYBR 
& Fluorescein Kit, both from Bioline Reagents Ltd., London, United Kingdom) using an 
iCycler iQ (Biorad Laboratories Inc., Hercules, CA, USA) and primers (10pmol) specific for 
the different Th lineages (listed in Table S1). The PCR program consisted of  10min initial 
heating at 95°C (hot start polymerase), followed by 35 cycles amplification (30s at 95°C, 
20s at the optimized annealing temperature and 20s at 72°C) and a final heating up to 92°C 
(increasing 0.5°C/7s) for the generation of  a melting curve. Each data point of  the graphs 
was generated by determining expression of  the gene of  interest on the different days in 
duplicate and normalizing these data to the corresponding expression of  CD3ε used as 
housekeeping gene in our assay. 
T helper cell cytokine detection
Quantification of  Th-specific cytokines (IFN-γ, IL-4, IL-5, IL-13, IL-17, IL-10) in the 
supernatant of  the DC-T cell co-cultures on day 1, 3, 5 and 7 (day 1, 3 and 5 for the anti-
CD3 culture) was performed by CBA flex set assay (BD Biosciences) according to the 
manufacturer’s instructions. Measurements were performed with BD FACS Canto II and 
analysed by BD FACSDiva Software v6.1.2 and FCAP array analysis software (version 1.0.1; 
Soft Flow Inc., St. Louis Park, Minnesota, USA).
Statistical analyses
Statistical analyses were performed by Wilcoxon matched pairs test and the correlation was 
tested by nonparametric Spearman correlation; P values <0.05 were regarded as significant. 
Data was analysed using Prism Software (version 6; GraphPad Software, San Diego, CA, 
USA).
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RESULTS 
Development and setup of  an APC-dependent, TCR-restricted naive CD4+ T cell 
polarization assay
We set out to develop a TCR-restricted, human autologous assay which allows the 
comparison of  the CD4+ T cell polarizing capacity of  differently matured DC using primary 
cells. In order to develop such an APC-dependent system a number of  prerequisites need 
to be considered. These include e.g. the selection of  an appropriate polyclonal antigen, 
isolation of  pure cells, and determining appropriate cell ratios. A schematic overview of  the 
optimized assay is represented in Figure 1. In the following sections more details about the 
assay development will be provided.
Antigen selection        
The human precursor frequencies of  epitope-specific naive CD4+ T cells, counting up to at 
most 100 cells/106 naive T cells 49, limited the development of  small-scale 96-well format 
assay for the comparison of  human naive cognate CD4+ T cell responses. To circumvent 
this, we used a pan HLA-DR-restricted peptide, named PADRE, which polyclonaly 
activates a subset of  T cells 47. PADRE differs from superantigens as it binds inside the 
peptide-binding groove of  HLA-DR. PADRE has the advantage of  binding to all major 
groups of  HLA-DR-restricted variants, which makes it a TCR-restricted peptide for the 
study of  CD4+ T cell responses in the majority of  individuals.
Co-culture ratios        
To determine the optimal DC:T cell ratio, we co-cultured different concentrations of  DC 
with a constant number of  CD4+CD45RA+ T cells (5 x 104/well). To exclude the influence of  
different concentrations of  DC-derived factors on the initiation of  the T cell response, DC 
were washed after 24h of  maturation prior to their addition to the co-culture. Additionally, 
all the co-cultures were supplemented with the same amount of  pooled 24h-matured 
DC-derived supernatant. Based on these experiments (Figure S2), we selected a DC:T cell 
ratio of  2:5 to perform the co-culture experiments, as the amount of  T cell-derived IFN-γ 
in these Th1-polarizing conditions was shown to be the highest.
Setup of  the co-culture        
Summarizing, the ultimate setup of  the assay is as follows (Figure 1): to maximize 
the priming efficiency of  DC 43, iDC were matured in a round-bottom 96-well plate in 
serum-free AIM-V®-medium supplemented with different maturation stimuli. The next 
day, naive CD4+CD45RA+ T cells were isolated from fresh PBMC and added to the 
24h-matured DC preceding a 1h-incubation with PADRE. During a 7-day co-culture, each 
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day supernatant and cells were harvested from a single well to determine Th cytokines and 
Th lineage-specifying transcription factors by CBA and qPCR, respectively. 
Monitoring the initiation of  Th1 responses
In our search for a DC maturation stimulus capable of  polarizing naive CD4+ T cells towards 
a Th1 phenotype, we used a combination of  FMKp and IFN-γ as maturation cocktail. This 
selection was based on previous demonstrations that FMKp/IFN-γ-matured DC were able 
to produce high IL-12 levels 48, 50, 51, a cytokine which is crucial for Th1 responses 52, 53. 
Furthermore, these DC were shown to be potent inducers of  CTL responses 50. 
To study the initiation of  a Th1 response, we compared the polarizing capacities of  
iDC and FMKp/IFN-γ-matured DC (Figure 2). FMKp/IFN-γ-matured DC induced 
the lineage-specifying transcription factor T-bet (gene name TBX21) and IFN-γ mRNA 
levels already after 24h and were peaking on day 3 (30 resp. 90-fold increase in mRNA 
levels compared with T cells on day 0). IFN-γ mRNA induction was associated with 
Figure 2 | FMKp/IFN-γ-matured DC polarize a subpopulation of  naive T cells into the Th1 
lineage. iDC or FMKp/IFN-γ-matured DC were pulsed with PADRE for 1h before the addition of  
autologous CD4+CD45RA+ T cells to the 7-day co-culture. (A) Expression of  T-bet and IFN-γ and 
IFN-γ production of  naive CD4+ T cells co-cultured with iDC (▲) or FMKp/IFN-γ-matured DC (■) 
are compared. CD3ε was used as housekeeping gene and the expression data were normalized to the 
relative mRNA content of  naive T cells on day 0. IFN-γ production by naive T cells co-cultured with 
differently matured DC was determined in the supernatant of  the co-culture on day 1, 3, 5 and 7 by 
CBA. Graphs are representative of  11 independent experiments. (B) On day 7, T cells were stained 
for expression of  CD45RO and CD25 and analysed by flow cytometry. Cells are gated in FSC/SSC on 
lymphocyte gate, excluding dead cells and doublets (light grey dots), and selected for CD4+ cells (dark 
grey and black dots). Percentages of  CD45RO and CD25 positive populations are indicated in the plots. 
Dot plots are representative of  5 independent experiments. (C) On day 6 of  the co-culture, GolgiPlug™ 
and GolgiStop™ were added to T cells with or without PMA/ionomycin restimulation. The next day, 
intracellular IFN-γ staining was performed and cells were analysed by flow cytometry. Representative dot 
plots of  CD45RO and IFN-γ expression of  CD4+ T cells co-cultured with FMKp/IFN-γ-matured DC 
are shown.Data are representative of  5 independent experiments.
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IFN-γ cytokine production as evidenced by CBA. T cells co-cultured with iDC only 
showed minor upregulation of  T-bet levels (up to 5-fold) and no upregulation of  IFN-γ 
levels (Figure 2A). Additionally, T cells of  the two co-cultures were stained on day 7 for 
different activation markers and analysed by flow cytometry. Of  the T cells co-cultured with 
FMKp/IFN-γ-matured DC, 11.4% were double positive for CD25 and CD45RO 
(Figure 2B) compared with 0.3% in the co-culture with iDC. In addition, these double 
positive cells were enlarged in the FSC/SSC compared with the double negative ones.
We performed an intracellular IFN-γ staining to identify whether or not the amount of  
IFN-γ secreted on day 7 of  the co-culture was derived from a few high-producing cells. 
Protein transport inhibitors were added on day 6 of  the co-culture and the cells were 
incubated overnight. To enhance the cytokine secretion of  all Th1-committed cells, we 
performed an additional intracellular cytokine staining on restimulated cells. The percentage 
of  IFN-γ+-T cells was higher in the co-culture of  FMKp/IFN-γ-matured DC compared 
with iDC (data not shown). This corresponds to the higher total IFN-γ levels detected 
in the supernatant of  this condition. Even though restimulation of  the cells for 16h with 
PMA/ionomycin was not required to detect the accumulation of  intracellular IFN-γ in 
CD4+ T cells, more Th1-committed CD4+ T cells were detected in the restimulated condition 
on day 7 of  the co-culture (Figure 2C). This indicates that restimulation is required for 
estimating the total size of  the Th1-committed subpopulation.
Taken together, these data indicate that PADRE-loaded FMKp/IFN-γ-matured moDC are 
capable of  polarizing a subset of  naive CD4+ T cells into the Th1 lineage as evidenced 
by their upregulation of  T-bet and IFN-γ mRNA levels, their expression of  CD25 and 
CD45RO, and the secretion of  IFN-γ.
Th1 polarization is not a direct effect of  the maturation stimuli on T cells  
We performed washing experiments to exclude that T cells are polarized in response to 
the DC maturation stimuli instead of  their interaction with matured DC and their released 
cytokines. Previously, we and others 6, 48, 54 have shown that an imprinting of  the DC 
maturation of  6h is sufficient to trigger the DC maturation programme. We compared 
CD4+ T cell polarizing capacity of  FMKp/IFN-γ-matured DC incubated for 24h with 
maturation stimuli with those of  6h after induction of  maturation extensively washed 
FMKp/ IFN-γ-matured DC. Both washed and non-washed FMKp/IFN-γ-matured 
DC induced the expression of  T-bet and IFN-γ following the same pattern, as well as 
comparable levels of  IFN-γ after 7 days of  co-culture (Figure 3A). These data confirm that 
the Th1 polarization seen by co-culturing FMKp/IFN-γ-matured DC with naive CD4+ T 
cells is APC-dependent and is not a consequence of  direct influence of  the DC maturation 
stimuli on the T cells.
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Effect of  FMKp/IFNγ-derived cytokines on Th1 polarization   
To further investigate the contribution and importance of  the DC-derived soluble factors 
on T cell polarization, an APC-independent approach can be used as complementary tool 
to study their influence independently of  the co-stimulatory and other membrane-bound 
Figure 3 | Dependency of  DC-induced Th1 polarization on DC-derived soluble factors. 
(A) FMKp/IFN-γ-matured DC were either extensively washed (▲) or not (■) 6h after induction of  
maturation and co-cultured for 7 days with autologous CD4+CD45RA+ T cells. Expression of  T-bet and 
IFN-γ and total IFN-γ production are shown. Graphs are representative of  5 independent experiments. 
(B) APC-independent assay using immobilized anti-CD3 allows studying the influence of  DC-derived 
soluble factors on T cell polarization. 5x104 cells CD4+CD45RA+ T cells were cultured for 5 days without 
(▲) or with (■) washed FMKp/IFN-γ-matured DC-derived supernatant in presence of  plate-bound 
anti-CD3 (0.25µg/ml) in a round-bottom 96-well plate. Transcriptional induction of  T-bet and IFN-γ and 
secretion of  IFN-γ were determined. Data shown are representative data of  3 independent experiments. 
(C) FMKp/IFN-γ- and HKLM/IFN-γ-matured DC induce Th1 polarization. iDC were matured with 
HKLM/IFN-γ (▲) or FMKp/IFN-γ (■) and co-cultured with CD4+CD45RA+ T cells. Expression 
of  T-bet and IFN-γ and total IFN-γ production are shown. Data are representative of  4 independent 
experiments.
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factors. To this end, we cultured naive CD4+ T cells for 5 days on immobilized anti-CD3 
in the absence or presence of  FMKp/IFN-γ-DC-derived supernatant. To compare results 
obtained by this assay with our APC-dependent assay and to avoid the direct polarizing 
effect of  the immobilized anti-CD3, we titrated down anti-CD3 to such an extent that 
it gave a similar proliferative response as observed in the APC-dependent assay (data 
not shown). The influence of  DC-derived soluble factors on naive T cells was tested 
with supernatant derived from 24h-matured FMKp/IFN-γ-DC, which were extensively 
washed 6h after induction of  maturation. As shown in Figure 3B, in the presence of  
FMKp/IFN-γ-DC-derived supernatant the expression of  both T-bet and IFN-γ was 
induced and IFN-γ was detected in the culture supernatant as evidenced by CBA. These 
data illustrate that APC-independent systems are complementary to our APC-dependent 
system allowing the discovery of  the causative factors without interference of  contact-
dependent stimuli (e.g. co-stimulatory molecules).
Commercially available DC maturation stimuli inducing Th1 polarization
To investigate whether or not a commercially available DC maturation stimulus 
shows similar effects on the T cell polarization as FMKp, we screened different PRR-
triggers in combination with IFN-γ (data not shown). Among all the triggers we tested, 
HKLM/IFN-γ-matured DC had the most potent capacity to induce Th1 polarization. As 
shown in Figure 3C, a similar expression pattern of  T-bet and IFN-γ was observed, with 
FMKp/IFN-γ-DC leading to faster induction of  these factors in the T cells. The level of  
IFN-γ secretion over time of  the co-culture was not significantly different.
Influence of  memory CD4  T cell contamination     
A disadvantage of  using an HLA-DR-restricted polyclonal peptide in this assay is the 
activation of  memory CD4+ T cells. They do not require a differentiation phase and thereby 
readily produce cytokines upon TCR-triggering. To evaluate to what extent the purity of  
naive CD4+ T cells influences our read-out parameters, we first compared Th1-inducing 
potential of  different CD4+ T cell fractions. The different CD4+ T cell fractions - total 
CD4+, CD4+CD45RA+ and CD4+CD45RO+ T cells - were co-cultured for 5 days with 
FMKp/IFN-γ-matured, PADRE-pulsed DC and supernatants were harvested each day. 
The purities of  the different CD4+ T cell fractions were analysed with flow cytometry 
(Figure S3). On day 5 of  the co-culture, memory CD4+CD45RO+ T cells produced as much 
IFN-γ as the total CD4+ T cell fraction; whereas naive CD4+CD45RA+ T cells produced 
10 times less IFN-γ after 5 days of  co-culture (Figure 4A). 
Compared with a naive response, the magnitude of  the cytokine response is 10-fold 
increased for the memory CD4+ T cells and they are the main contributors of  IFN-γ 
secretion after 5 days of  co-culture with moDC. We performed a spiking experiment to 
+
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evaluate to what extent a contamination with memory T cells during the co-culture with 
CD4+CD45RA+ will influence the read-out parameters of  our PADRE-peptide-based 
assay. Increasing numbers of  CD4+CD45RO+ cells were added to a DC-CD4+CD45RA+ 
co-culture (up to 10% memory spike) and IFN-γ secretion on day 3 and day 5 of  the co-
culture was determined. On day 3, no differences between pure CD4+CD45RA+ co-culture 
and up to 5% spiking with CD4+CD45RO+ were observed, whereas the IFN-γ production 
of  the condition with 10% CD4+CD45RO+ cells was twice as high compared with the other 
conditions (Figure 4B). On day 5, a 2-fold difference in IFN-γ production was detectable 
with 5% spiking and even 3-fold with 10% spiking compared with the pure CD4+CD45RA+ 
fraction. Taking into account that with our procedure it is possible to isolate highly pure 
CD4+CD45RA+ T cells (Figure S1) and that the contamination with CD4+CD45RO+ cells 
is below 0.1 %, the read-out parameters of  our assay are only to a minute extent biased by 
memory CD4+ T cell contamination.
Differential Th cell-polarizing capacity of  DC
Induction of  Th1 and Th2 polarization by moDC     
The current system allows the comparison of  the T cell polarizing capacity of  differently 
matured DC in terms of  kinetics and magnitude of  Th1 responses. We show the example 
of  the capacity of  3 different (pre-) clinical DC maturation cocktails - PGE2/TNF-α, 
LPS/IFN-γ or FMKp/IFN-γ - used for the generation of  ex vivo matured DC for DC-
based vaccines and their capacity to polarize naive CD4+ T cells into Th1 cells (Figure 5). 
Both, in T cells co-cultured with LPS/IFN-γ and FMKp/IFN-γ-matured DC, the mRNA 
levels of  T-bet were induced over time, being higher in the FMKp/IFN-γ-DC co-culture. 
Figure 4 | Presence of  CD4+CD45RO+ T cells in the DC-CD4+CD45RA+ T cell co-culture 
influences Th1 read-out parameters. (A) CD4+, CD4+CD45RO+, CD4+CD45RA+ populations were 
isolated by negative immunomagnetic separation from freshly isolated PBMC. IFN-γ production of  total 
CD4+ (■), CD4+CD45RA+ (●), and CD4+CD45RO+ (▲) T cells co-cultured with FMKp/IFN-γ-matured 
DC for 7 days as measured by CBA. (B) Contribution of  contaminating CD4+CD45RO+ T cells (2.5, 5 
or 10%) to CD4+CD45RA+-derived IFN-γ-production compared with pure (>99.9%) CD4+CD45RA+ T 
cell populations. Data shown are representative of  2 independent experiments.
60
Chapter 2
2
Figure 5 | Differential Th1-polarizing capacity of  differently matured DC. Naive CD4+ T cells 
were co-cultured for 7 days with PGE2/TNF-α (▲), LPS/IFN-γ (●) or FMKp/IFN-γ-(■) matured DC. 
(A) Expression of  T-bet and IFN-γ and production of  IFN-γ were monitored. Graphs are representative 
of  11 independent experiments. (B) Comparison of  the expression of  T-bet and IFN-γ on day 5 and 
IFN-γ production on day 7 of  differently matured DC cultured with naive CD4+ T cells. 11 independent 
experiments and their median levels are shown. Wilcoxon signed-rank test significance, ** P≤0.01, 
*** P<0.001 (C) Correlation between T-bet and IFN-γ expression on day 5 and IFN-γ secretion on day 7 of  
FMKp/IFN-γ-matured DC in co-culture with naive CD4+ T cells. Nonparametric Spearman correlation 
test significance indicated in the graphs. (D) Expression of  CD45RO, CD25, and intracellular IFN-γ of  
naive CD4+ T cells cultured for 7 days with differently matured DC as indicated above the graphs. On 
day 6, GolgiPlugTM and GolgiStopTM were added to the co-culture and the staining was performed on day 
7. Cells shown in the plots represent living singlet cells gated on CD3+CD4+ (dark grey population). T cells 
positive for IFN-γ are shown in black. Dot plots are representative graphs of  3 independent experiments.
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mRNA levels and secretion of  IFN-γ could only be detected in the co-cultures of  T cells 
with FMKp/IFN-γ-matured DC (Figure 5A). In Figure 5B the average expression of  
T-bet and IFN-γ on day 5 of  the co-cultures of  these three different conditions as well 
as the total IFN-γ production detected in the supernatant of  the co-cultures on day 7 are 
combined. In line with the graphs of  Figure 5A, both T cells cultured with LPS/IFN-γ and 
FMKp/IFN-γ-matured DC showed increased levels of  T-bet (up-regulated median 
levels of  5.6 vs. 79.5 compared with T cells alone), but the mRNA levels and secretion 
of  IFN-γ was limited to naive T cells cultured with FMKp/IFN-γ-matured DC. There 
was a significant correlation of  both T-bet and IFN-γ mRNA levels on day 5 of  the 
FMKp/IFN-γ-mDC co-cultured T cells with the accumulated IFN-γ secretion on day 7 
(Figure 5C). Additionally, T cells of  the different conditions were stained for CD45RO 
and CD25 as well as for intracellular IFN-γ. In all three conditions T cells up-regulated the 
expression of  CD25 and CD45RO upon the ′antigen′-encounter. Only in the FMKp/IFN-γ 
conditions, part of  these cells was also positive for IFN-γ, which corresponds to data shown 
in Figure 5A, B.
In parallel, we studied the capacity of  these differently matured DC to induce Th2 
polarization, as illustrated in Figure 6. In all the DC-T cell co-cultures, a transient 
up-regulation of  GATA3 mRNA levels, the lineage-specifying transcription factor of  Th2 
cells, was observed. Only PGE2/TNF-α-DC led to a constantly increasing expression of  
GATA3 in the T cells. In addition, the expression of  IL-4, IL-5, and IL-13, the signature 
Figure 6 | Differential Th2-polarizing capacities of  differently matured moDC. Naive CD4+ T cells 
were co-cultured for 7 days with PGE2/TNF-α (▲), LPS/IFN-γ (●) or FMKp/IFN-γ-(■) matured DC. 
Expression of  GATA3, IL-4, IL-5, and IL-13 and production of  IL-5 and IL-13 were monitored. IL-5 
and IL-13 protein production by naive T cells co-cultured with differently matured DC was determined in 
the supernatant of  the co-culture. Graphs are representative of  5 independent experiments.
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cytokines of  the Th2 lineage, was monitored. IL-5 and IL-13 expression was only detectable 
in the PGE2/TNF-α condition, which paralleled the cytokine secretion profile; only T cells 
of  the PGE2/TNF-α condition secreted IL-5 and IL-13. This is in line with our previous 
demonstration of  CRTH2+CD4+ T cells in a co-culture of  PGE2/TNF-α-matured DC in 
a total T cell pool 50. IL-4 was not expressed nor secreted in any of  the conditions. Thus, 
PGE2/TNF-α-matured DC can be used as a positive control for IL-5/IL-13-secreting Th2 
cells. Unexpectedly, the Th1-inducing FMKp/IFN-γ-DC induced a transient expression 
of  GATA3, but did not lead to any secretion of  Th2 cytokines, supporting the recently 
published studies about co-expression of  different transcription factors 11, 12.
Induction of  Th1 polarization by pDC      
To investigate whether or not the small-scale setup of  the assay allows the study of  a more 
infrequent blood DC subset, we studied the applicability of  this system to pDC, which is 
illustrated in Figure 7. Unstimulated and ODN2216-triggered pDC, a microbial stimulus 
known to trigger pDC via TLR9 55, were co-cultured with naive T cells during 7 days in 
absence or presence of  IL-3. Naive CD4+ T cells co-cultured with unstimulated pDC 
up-regulated T-bet and IFN-γ mRNA and produced minor levels of  IFN-γ (Figure 7A). 
IL-3 stimulation of  pDC increased the magnitude of  T-bet expression, induced faster 
kinetics and led to substantially higher levels of  IFN-γ secretion (117 vs. 3026pg/ml on 
day 7). T cells cultured with ODN2216-stimulated pDC, showed a delayed but overall 
increased T-bet expression compared with pDC alone or pDC+IL-3. The combination of  
ODN2216 and IL-3-stimulated pDC led to faster T-bet expression and both a faster and a 
higher IFN-γ expression, which was also reflected on the cytokine level. These data illustrate 
that IL-3 is not only an important survival factor for pDC 56, but it also influences the 
kinetics and the magnitude of  pDC-induced T cell differentiation. ODN2216-stimulated 
pDC can be used as a positive control to study the effect of  differently stimulated pDC on 
naive CD4+ T cell polarization. 
To investigate whether or not different DC subsets translate a challenge by a particular 
PRR trigger into similar Th cell responses, we tested in the same experiment the influence 
of  differently matured pDC on naive CD4+ T cell polarization (Figure 7B), comparing 
the maturation cocktails described in Figure 5 in the presence of  IL-3. Naive T cells co-
cultured with these three differently stimulated pDC all expressed T-bet. IFN-γ was mainly 
expressed by T cells in culture with FMKp/IFN-γ-pDC, which was also reflected by the 
highest IFN-γ levels produced over 7 days. Even though LPS/IFN-γ-pDC showed the 
fastest kinetics, FMKp/IFN-γ-pDC showed 3-fold higher IFN-γ levels and even 10-fold 
compared with PGE2/TNF-α-pDC on day 7 of  the co-culture. 
We illustrated that this APC-dependent system allows the comparison of  the T cell-polarizing 
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capacity of  differently matured DC in terms of  kinetics, magnitude and direction. 
Moreover, the system can be applied for functional studies with multiple DC subsets.
DISCUSSION
In terms of  human T cell differentiation, fundamental tools to study the initiation of  
APC-dependent naive CD4+ T cell polarization are lacking. However, a dysregulation in 
human CD4+ T cell polarization is associated with a variety of  diseases, such as cancer, 
autoimmunity, and allergies 7, 9. Due to interspecies discrepancies, data generated from 
murine models on e.g. the positive effect of  medication on T cell-mediated diseases awaits 
confirmation in human in vitro assays. In this paper, we have described a standardized 
methodology to study the priming of  human naive CD4+ T cells by differently matured 
DC. This in vitro system consists of  a multi-faceted read-out tool that allows the monitoring 
of  transcriptional events associated with T cell polarization and matching them to a Th 
cytokine secretion profile using a protein-multiplexing platform. 
Inherent to the aim of  setting up a small-scale (96-well format) assay to study CD4+ T cell 
polarization in the human system is that it does not allow antigen-specificity, because of  
Figure 7 | Differential Th1-polarizing capacity of  differently matured plasmacytoid DC. pDC, 
isolated from fresh blood, were stimulated overnight with different cocktails and 24h later autologous naive 
CD4+ T cells were added and the expression of  T-bet and IFN-γ, and secretion of  IFN-γ were monitored 
during 7 days. (A) pDC were stimulated overnight with IL-3 (full grey line), ODN2216 (dashed black line) 
or with a combination of  both (full black line). (B) Comparison of  the capacity of  differently matured 
pDC to induce Th1 polarization. pDC were incubated with PGE2/TNF-α(▲), LPS/IFN-γ (●) or FMKp/
IFN-γ (■) cocktail in the presence of  IL-3. Representative data from 2 independent experiments are shown.
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the low precursor frequencies of  epitope-specific naive CD4+ T cells in humans 49. As a 
consequence the assay is performed in an antigen-independent but TCR-restricted manner 
using the HLA-DR-restricted peptide PADRE. In initial experiments, we observed that 
memory CD4+ T cells were rapidly activated in this system and that they secreted cytokines 
upon TCR-triggering without the need of  a programming phase. A memory contamination 
of  more than 5% in the DC-T cell co-culture contributed to at least 50% of  the Th1-derived 
IFN-γ secretion after 5 days. In addition, memory contamination induced a faster response 
compared with a co-culture of  highly pure naive CD4+ T cells (data not shown), indicating 
the importance of  using pure naive CD4+ T cells in a polyclonally activated system. We 
have shown that these highly pure CD4+CD45RA+ T cells (>99.9% CD4+CD45RA+ and 
<0.1% CD4+CD45RO+) can be obtained using a simple immunomagnetic bead isolation kit 
without the need of  a high-end flow-sorting methodology confirming previous findings 57.
Most existing assays aim to demonstrate the ultimate fate of  the polarized T cell and not the 
initial priming phase of  a naive CD4+ T cell response. Moser et al. 42 introduced a DC-based 
system to study the in vitro priming of  naive T cell responses aiming to predict vaccine 
efficacies. Even though this assay has the advantage of  monitoring antigen-specific T cell 
responses, the co-culture period over 14 days with restimulation by fresh antigen-pulsed 
DC only detects late stage responses of  the naive CD4+ T cell polarization. However, it is 
possible that differently matured DC do not differ in the magnitude nor in the direction 
of  the induced T cell response but that they lead to a faster induction. This knowledge can 
be of  importance in pharmacological studies and may create valuable insight for designing 
vaccines. With our system, we provide a complementary tool to study the acute phase and 
evaluate the kinetics during the initiation of  a naive CD4+ T cell response.
The vast majority of  in vitro assays studying human CD4+ T cell polarization in an 
APC-dependent manner focus on moDC. An important disadvantage of  this DC 
population is that these cells show more similarity with monocytes than with human subsets 
of  lymphoid-tissue-resident DC: pDC and cDC (BDCA-1+ and BDCA-3+) 23. Nevertheless, 
it is generally accepted that moDC are good surrogates to study inflammatory DC and we 
optimized our assay using moDC as source of  APC. In addition, we demonstrated that 
because of  the small-scale assay setup, our findings can be translated to other in vivo and 
low-frequent blood-derived DC subsets. Out of  500ml fresh blood we could obtain between 
1-2.5 x 106 pDC, which allows studying the capacity of  at least 14 differently stimulated pDC 
to prime CD4+ T cells. This opens new perspectives to study the human counterparts of  the 
mouse pDC, CD8α+ cDC and CD11b+ cDC despite their very low blood frequencies. In 
addition, because of  the low-scale setup of  this assay, we foresee that this co-culture system 
may also be applied to study primary tissue-resident DC subsets.
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Previous studies focusing on the differentiation requirements of  mouse and human Th17 
cells showed serum to be a confounder influencing the outcome of  T cell polarization. 
Initially, it was claimed that the requirements differ between these two species and that for 
human Th17 differentiation TGF-β would be a dispensable factor 58, 59. However, follow-up 
experiments in serum-free medium revealed that TGF-β is also required for human Th17 
polarization and that the serum was probably contaminated with platelets that are a source 
of  TGF-β 60. Since serum is a considerable source of  artefacts due to lot-to-lot variability 
and variable protein contents, we established the assay in serum-free AIM-V® medium.
As a proof  of  concept that our assay can be applied to address biological questions, we 
have shown that DC triggered with various bacterial compounds have different capacities 
to induce Th1 polarization. This illustrates that, indeed, the environmental DC instruction 
influences the fate of  the CD4+ T cells. We demonstrated a profound difference in the 
Th1-polarizing capacity of  different bacterial fragments, with LPS being at least 100-fold less 
potent to induce IFN-γ secretion compared with the bacterial lysates FMKp and HKLM. 
Importantly, we also showed qualitative differences in capacity of  different DC subsets to 
induce Th1 responses upon a particular PRR stimulus. Whereas LPS maturation of  moDC 
did not result in high IFN-γ secretion in naive T cells, LPS-triggered pDC did respond with 
a pronounced transcriptional induction of  T-bet and IFN-γ and the secretion of  IFN-γ 
by T cells after 7 days of  co-culture. Moreover, we showed that PGE2/TNF-α-matured 
moDC did not lead to Th1 induction but instead to Th2 cells. This finding is consistent 
with previous studies 3, 61. In contrast to de Jong et al. 4, we showed that this Th2 induction 
was independent of  IL-4, as we neither detected IL-4 mRNA levels nor the secretion of  
the protein. Findings of  other groups did show the possibility for IL-4 independent Th2 
induction by pDC 62.
Complementary APC-independent tools, mimicking the APC by replacing it e.g. by anti-CD3 
(± anti-CD28) or by feeder cells, represent a good approach to study the involvement of  
soluble DC-derived factors. However, anti-CD3 and anti-CD28 exert polarizing capacities on 
their own; this may vary depending on which clones of  anti-CD3 or anti-CD28 antibodies are 
used. It has been shown that triggering of  murine CD4+ T cells, in vitro and in vivo, by anti-
CD28 led to the induction of  GATA3 and to the secretion of  Th2-specifying cytokines 63. 
Additionally, the presence as well as the strength of  TCR-signaling influences the fate of  a 
naive CD4+ T cells independently of  the cytokine milieu 64-66. Strong TCR-signaling induces 
Th1 cells, whereas weak TCR-stimulation favours Th2 responses 67. We tried to titrate down 
anti-CD3 to such an extent that it resulted in similar proliferative responses as observed in 
the co-culture experiments. We also observed that high concentrations of  immobilized anti-
CD3 induced the polarization of  naive CD4+ T cells in the absence of  polarizing signals. 
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We propose a new combination of  tools to study human DC-induced naive CD4+ T 
cell polarization in a small-scale, autologous setup. The assay combines both analyses on 
transcriptional and protein levels. It allows comparing the magnitude, kinetics, and direction 
of  a naive CD4+ T cell response after interaction with different PRR-experienced DC. 
The combination of  monitoring simultaneously the expression kinetics of  the different 
Th subset-related transcription factors and their cytokine release in one culture condition 
offers new perspectives on studying the priming phase of  CD4+ T cells. The continuous 
monitoring of  transcription factor expression over time allows studying differences in the 
kinetics of  transcriptional induction by different DC and whether or not transient expression 
of  transcription factors is responsible for functional subset specialization. Furthermore, 
this system can be of  great value to investigate the influence of  immunomodulating drugs 
or environmental factors on the initiation of  human T cell responses and Th cell fates. 
The most effective moments of  drug administration can be revealed and factors on which 
they eventually have a direct influence may be identified. In addition, it is possible to study 
epigenetic changes related to the priming phase of  a T cell response, in an APC-dependent 
manner, such as the regulation of  Th-specific enhancers.
Overall, this standardized assay will allow a more straightforward comparison of  results 
obtained by different groups and will help to further extend our knowledge on the initiation 
of  human naive CD4+ T cell responses.
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SUPPORTING INFORMATION
Supplementary Figure S1 | Optimization of  CD4+CD45RA+ T cell isolation using immunomagnetic 
beads. PBMC were isolated from whole blood by density centrifugation. CD4+CD45RA+ T cells were 
isolated by negative immunomagnetic separation according to the manufacturer’s instructions. To achieve 
highly pure naive CD4+ T cells, CD4+CD45RA+ T cells were purified a second time. The purification 
protocol was optimized by using the flow-through from the first separation followed by another round over 
a column, incubation with beads and purification over a second column or incubating with antibody-mix 
and beads and running it over a column. Purity staining of  PBMC, first separation of  CD4+CD45RA+ T 
cells and of  different second separations of  CD4+CD45RA+ cell populations were performed and analysed 
by flow cytometry. Cells were gated on lymphocytes in FSC/SSC and on the living cells (7-AAD-negative) 
and set as 100%. CD4+ T cells were gated on CD3+/CD4+ cells and furthermore discriminated between 
CD45RO+ and CD45RA+. Percentages of  the different populations are indicated in the dot plots. 
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Supplementary Figure S2 | Optimization of  DC:T cell ratios. 24h-matured FMKp/IFN-γ DC were 
washed and added at different concentrations to a round-bottom 96-well plate: 1x104 (●), 2x104 (■) or 5x104 
(♦) and co-cultured with 5x104 naive CD4+ T cells for 7 days in the presence of  24h-FMKp/IFN-γ-matured 
DC-derived supernatant. Transcriptional induction of  T-bet and IFN-γ as well as secretion of  IFN-γ were 
determined. Data shown are representative of  4 independent experiments.
Supplementary Figure S3 | Purities of  differently isolated CD4+ T cell populations. (A) Purity 
staining of  total CD4+, CD4+CD45RA+, and CD4+CD45RO+ T cells after negative immunomagnetic 
isolation from freshly isolated PBMC. Percentage of  CD3+ cells is expressed as percentage of  total living 
singlet cells. Percentages of  CD4+ cells are expressed related to total CD3+ cells and those of  CD45RA+ and 
CD45RO+ cells are related to CD4+ T cell population. (B) Increasing percentages (0 – 10%) of  CD45RO+ 
contamination into pure CD4+CD45RA+ T cell population.
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Potency of  both human Th1 
and NK helper cell activation 
is determined by IL-12p70-
producing PAMP-matured DC
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ABSTRACT
Besides T helper (Th) cells also natural killer (NK) cells have been described to participate 
in the shaping of  dendritic cell (DC)-mediated adaptive immune responses. At present, it 
remains unclear to what extent the induction of  these NK helper cell immune mechanisms 
is coupled with Th cell responses and whether both helper immune responses are induced 
by the same DC upon specific pathogen recognition receptor (PRR) stimulation.
Here we demonstrate that maturation of  DC with a cocktail containing FMKp (membrane 
fragments of  K. pneumoniae) mounts both Th cell and NK cell helper responses in a PRR 
trigger dose-dependent manner as determined by the capacity of  the helper cells to produce 
IFN-γ. Furthermore, by triggering an additional PRR-pathway (FMKp in combination 
with poly(I:C) lyovec) we reveal that both approaches modulate the amount of  DC-derived 
IL-12p70 and that this cytokine is the key determinant of  the DC-induced Th1 and NK 
cell helper responses. Moreover, all PRR triggers able to induce IL-12-producing mature 
DC are sufficient to induce these helper responses.
We propose the existence of  a single programme used by DC to induce potent cellular 
immune responses by stimulating both Th and NK cell helper processes. This knowledge 
can help to select the proper PRR triggers in preventive and therapeutic vaccine design.
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INTRODUCTION
Dendritic cells (DC) are key regulators in shaping and linking innate and adaptive immune 
responses. Depending on the environmental stimuli DC encounter, they transmit signals 
to immune effector cells inducing immunogenic or tolerogenic immune responses 1, 2. 
Therefore, DC represent a crucial target of  vaccine adjuvants, both in preventive 
and therapeutic vaccination. In particular the latter type of  vaccines requires further 
improvement. Elucidating the mechanisms by which danger signals induce and enhance the 
interaction of  DC with different immune effector cells will reveal new insights to increase 
the efficacy of  vaccination strategies. 
One of  the crucial mechanisms by which these DC mount appropriate and potent immune 
responses is by activating helper immune cells. In recent years it has become clear that these 
helper immune cells are not limited to CD4+ T cells, but also include innate lymphoid cells 
(e.g. natural killer (NK) cells). Despite these novel insights, the polarization of  naive CD4+ 
T cells into different T helper (Th) lineages is still considered a decisive event to induce de 
novo immune responses 3. The DC modulate this response by co-stimulatory molecules 
and cytokines, which are controlled by the nature of  the pathogenic insult. The priming of  
Th1 cells is crucial for the generation and expansion of  cytotoxic T lymphocytes (CTL) and 
survival of  CD8+ memory T cells, which are in turn able to kill infected or cancer cells 4.
NK cells also serve an important role in regulating DC-mediated adaptive immune 
responses 5-7. Classically, NK cells are involved in the direct early control of  viral infections 
and tumour immunosurveillance 8-10, but NK cells also indirectly provide help by interacting 
with DC at the site of  inflammation or in the lymph nodes 11. Upon their encounter NK 
cells can become activated via a two-signal requirement provided by soluble factors (such as 
IL-12, IL-18, IL-15, IL-21 and IFN-α) or by cell-contact dependent pathways 12, 13, 14. Once 
activated, NK cells enhance the maturation and antigen presentation of  DC 15-17 and gain 
the capacity to edit the DC repertoire 18. Additionally, activated ′helper′ NK cells secrete 
pro-inflammatory cytokines, mainly IFN-γ and TNF-α, which facilitate Th1 responses, 
and which are further stimulated by the expression of  co-stimulatory molecules on NK 
cells 19-22. Moreover, NK cells were shown to enhance anti-tumour CTL responses without 
the induction of  CD4+ T cells 23, 24.
The recognition of  a pathogenic insult via pattern recognition receptors (PRR) has been 
shown to influence the DC cytokine profile and consequently the fate of  naive CD4+ 
T cells 25-27. Furthermore, NK cell activation is confined to PRR-triggered DC and the 
nature of  the PRR stimulus determines the degree of  activation by influencing the release 
of  NK cell-activating factors and the expression of  surface molecules 28, 29. Even though it is 
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plausible that during the mounting of  an immune response multiple helper subsets including 
NK cells participate in concert, there is limited experimental proof  of  this cellular interplay 
in humans. It remains to be established whether both helper mechanisms get enhanced by 
the same PRR-triggered DC or whether the source of  PRR-triggering directs either Th or 
NK cell helper responses. In the current study, we investigated whether the capacity of  DC 
to enhance both Th1 polarization and to promote NK cell helper responses is triggered by 
the same PRR agonist in a dose-dependent manner or by triggering multiple PRR during 
DC maturation. Furthermore, we examined if  common soluble factors are involved in the 
activation of  both helper responses. 
MATERIALS AND METHODS
Generation of  DC
Monocytes were generated as previously described 30 and differentiated in serum-free 
AIM-V® medium (Life technologies, Carlsbad, CA, USA) supplemented with GM-CSF 
(400U/ml; Berlex Laboratories Inc., Montville, NJ, USA) and IL-4 (2000U/ml; Miltenyi 
Biotec GmbH, Bergisch Gladbach, Germany) at a density of  2 x 106 cells/ml. After 7 days, 
immature DC (iDC) were harvested and frozen or immediately processed in the DC-T cell 
co-cultures or NK cell activation assays.
To study quantitative PRR-triggering, iDC were matured with either IFN-γ (500U/ml; 
R&D systems, Minneapolis, MN, USA) or the combination of  IFN-γ and FMKp (Pierre 
Fabre Laboratories, Boulogne-Billancourt, France) at different concentrations (1 or 10µg/
ml). Cooperative PRR-triggering was performed by maturing iDC with IFN-γ and poly(I:C) 
lyovec (1µg/ml; InvivoGen, Toulouse, France) in the presence or absence of  FMKp 
(1µg/ml). All maturation cocktails were supplemented with IL-4 (500U/ml) and GM-CSF 
(500U/ml). 
Washed DC supernatants used to activate NK cells were generated by maturing iDC 
(0.5x106 cells/ml) in 24-well plates with the different cocktails described previously in this 
section. DC were washed 6h after the induction of  maturation to remove all the maturation 
stimuli and cultured for a total of  48h in serum-free in AIM-V® medium. We and others 
have previously demonstrated that this shortened incubation with the maturation stimuli 
irreversibly triggers DC maturation 31-34. Cell-free supernatants were harvested and stored at 
-20°C until further use.
To generate differently matured DC as depicted in the correlation graphs, iDC were matured 
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with various pathogen-associated molecular patterns (PAMPs): TLR1/2 (Pam3CSK4), 
TLR2 (HKLM), TLR3 (poly(I:C) LMW/HMW, poly(A:U)), TLR4 (LPS E. coli K12), TLR5 
(flagellin), TLR 6/2 (FSL-1), TLR7 (imiquimod, gardiquimod), TLR7/8 (R848, CL075), 
TLR8 (ssRNA40, sspolyU, E. coli RNA) TLR9 (ODN2006, ODN2216, ODN2395, E. coli 
ssDNA), RIG-I/MDA-5 (poly(I :C) lyovec), NOD1 (tri-DAP), NOD2 (MDP), Dectin-1 
(β-glucan) in the presence of  IFN-γ, IL-4 and GM-CSF. DC were matured with single 
PAMPs or in combination with FMKp. All PAMPs were purchased from InvivoGen. In 
addition, iDC were matured with PGE2/TNF-α (+ IL-6/IL1-β) or TNFα/IL-1β/IFN-γ/
poly(I:C)/IFNα.
T helper cell isolation
Autologous CD4+CD45RA+ T cells were isolated by negative immunomagnetic separation 
(Miltenyi Biotec) as described previously 30. Purity of  the naive CD4+ T cells was ≥ 99.8% 
containing 0% CD4+CD45RO+ cells. 
NK cell isolation
NK cells were isolated from buffy coats or fresh peripheral blood-derived mononuclear 
cells (PBMC) by negative immunomagnetic cell separation (Miltenyi Biotec) according to 
the manufacturer’s instructions. Blood was obtained from Sanquin blood bank Maastricht, 
the Netherlands (project 2000-03AZM) from healthy donors after informed consent. NK 
cell purity routinely exceeded 95% CD56+CD3- as assessed by flow cytometry.
T helper cell polarization assays
APC-dependent T cell polarization assays were performed as previously described 30. The 
IL-12 supplementation experiments were performed with mature FMKp/IFN-γ-DC. iDC 
were matured in 6-well plates at 1x106 cells/ml with IL-4, GM-CSF, IFN-γ and FMKp 
(10µg/ml). After extensive washing, 2x104 24h-FMKp/IFN-γ-matured DC/well were 
cultured in serum-free medium in presence of  different concentrations of  rhIL-12 
(0-10.000pg/ml; R&D systems) and 5x104 naive T cells. In addition to collecting supernatant 
and storing the cells in RTL buffer for gene expression analyses, the cells were counted on 
day 5 using a coulter counter® (Z1; Beckman Coulter Inc., Brea, CA, USA) and analysed by 
flow cytometry.
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NK cell activation assays
Enriched NK cells were cultured in round-bottom 96-well plates (105 cells/well) in the 
presence of  washed cell-free supernatants of  differently matured DC. After 16h of  
incubation, supernatant was harvested to determine NK cell-derived IFN-γ secretion and 
the cells were analysed by flow cytometry for the expression of  different activation markers. 
NK cell activation with rhIL-12 (100ng/ml) and/or rhIL-18 (1000ng/ml; R&D systems) 
was performed in AIM-V® medium or washed FMKp/IFN-γ-DC supernatant as indicated 
in the figure legends.
Flow cytometry
All antibodies used to determine DC, T cell and NK cell purities as well as their surface marker 
expression were purchased from BD Biosciences (Franklin Lakes, NJ, USA). Antibodies 
were used, titrated to their optimal concentration, either as fluorescein isothiocyanate 
(FITC), phycoerythrin (PE), peridinin chlorophyll protein (PerCP), allophyocyanin (APC), 
allophyocyanin H7 (APC-H7), Horizon 450, Horizon 500, Alexa Fluor 488 or PeCy7. 
Analyses were performed with BD FACS Canto II and analysed by BD FACSDiva Software 
v6.1.2 (BD Biosciences).
qPCR
qPCR was performed as previously described 30. Primers for the Th1 lineage were used: 
T-bet (F: CCG-TGA-CTG-CCT-ACC-AGA-AT, R: ATC-TCC-CCC-AAG-GAA-TTG-
AC) and IFN-γ (F: GAA-GAA-TTG-GAA-AGA-GGA-GAG-TGA, R: TGG-ACA-TTC-
AAG-TCA-GTT-ACC-G) at their optimized annealing temperature (T-bet: 58°C; IFN-γ: 
62°C). Relative quantification was done by generating a standard curve of  a reference sample 
(cDNA of  total T cells). Each data point of  the graphs was generated by determining 
expression of  the gene of  interest on the different days in duplicate and normalizing these 
data to the corresponding expression of  CD3ε used as housekeeping gene in our assay. 
Cytokine detection
Quantification of  the Th1-specific cytokine IFN-γ in the supernatant of  the DC-T 
cell co-cultures on day 1, 3, 5 and 7 (day 1, 3 and 5 for the anti-CD3 culture) as well 
as NK cell-derived IFN-γ after overnight activation and the determination of  IL-12p70 
in the supernatant of  differently matured DC were performed by cytometric bead arrays 
(CBA; BD Biosciences) according to the manufacturer’s instructions. Measurements were 
performed with BD FACS Canto II and analysed by BD FACSDiva Software v6.1.2 and 
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FCAP array analysis software (version 1.0.1; Soft Flow Inc., St. Louis Park, MN, USA). 
Quantification of  IL-18 in DC-derived supernatants was performed by ELISA (MBL 
International Corporation, Woburn, MA, USA).
Statistical analyses
Statistical analyses were determined by Wilcoxon matched pairs test or by Mann-Whitney 
U test and the correlation was tested by nonparametric Spearman correlation; * P<0.05, ** 
P<0.01, *** P<0.001, **** P<0.0001. Data were analysed using GraphPad Prism Software 
(version 6; GraphPad Software, San Diego, CA, USA). 
RESULTS
Quantitative PRR-triggering during DC maturation enhances DC-induced Th1 and 
NK cell helper responses
We previously revealed that FMKp/IFN-γ-matured DC have the capacity to activate NK 
cells 31 and to polarize naive CD4+ T cells towards Th1 cells 30, 35. To address the question 
whether quantitative PRR-triggering enhances the capacity of  DC to polarize naive CD4+ T 
cells towards Th1 cells, we matured DC with two different concentrations of  FMKp (1 and 
10µg/ml; referred to as FI 1 and FI 10) using this established DC maturation protocol.
The maturation of  DC with different concentrations of  FMKp did not have an influence 
on the expression of  DC maturation markers and co-stimulatory molecules HLA-ABC, 
HLA-DR, CD80, CD83, and CD86 (data not shown). In Figure 1A the expression of  
T-bet (gene name TBX21) and IFN-γ as well as the IFN-γ secretion of  a 7-day co-culture 
is shown. DC matured with a higher dose of  the bacterial trigger induced a 4-fold higher 
T-bet mRNA and a 16-fold higher IFN-γ mRNA expression compared with the low dose. 
Additionally, changes in Th1 gene expression were observed at earlier time points indicating 
faster kinetics in the presence of  a higher dose of  FMKp. This was confirmed on the 
cytokine level; on day 7, T cells co-cultured with high dose FMKp-matured DC induced 
a 7-fold increase in IFN-γ levels compared with low dose FMKp-matured DC. Levels of  
IFN-γ secretion at day 7 of  the co-culture were significantly different between naive T cells 
cultured with different concentrations of  FMKp (Figure 1B). T cells of  donors having a 
moderate Th1 response with low dose FMKp-matured DC showed an increased IFN-γ 
secretion with high dose FMKp matured-DC.
Because we previously showed that NK cells facilitate Th1 polarization by providing an 
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early source of  IFN-γ 31, we investigated the effect of  quantitative PRR-triggering on NK 
cell activation. NK cells were activated overnight in washed cell-free DC supernatants. We 
analysed the expression of  the activation markers CD69 and CD25, as well as CD83, a 
phenotype marker for ′helper′ NK cells 21, and NKp30, an activating receptor being involved 
in DC editing and maturation 16, 36. 
NK cells activated in high-dose FMKp/IFN-γ-DC-derived supernatant showed the highest 
median expression of  CD69 compared with IFN-γ and FI1. Moreover, the percentages 
of  CD25+ and CD83+ NK cells were significantly increased when NK cells were treated 
with FI 10-matured DC supernatant (2.5 and 2.4-fold compared with FI 1-matured DC 
supernatant) (Figure 1C, S1). No differences were detected in the expression of  NKp30 
(Figure S1). In addition, we determined the NK cell-derived IFN-γ secretion after overnight 
incubation, which was significantly higher by NK cells activated in FI 10-DC supernatant 
compared with IFN-γ and FI 1-DC supernatant (Figure 1D). 
Figure 1 | PRR-triggering during DC maturation enhances both Th1 polarization and NK cell 
helper activation. (A) Th1-polarizing capacity of  IFN-γ-(■), FMKp (1µg/ml)/IFN-γ (FI 1)-(●) and FI 
10-(■) matured DC during a 7-day co-culture with autologous naive CD4+CD45RA+ T cells at a ratio of  
2:5 is shown by means of  T-bet and IFN-γ expression. IFN-γ production by naive T cells co-cultured with 
differently matured DC was determined in the supernatant of  the co-culture on day 1, 3, 5 and 7 by CBA. 
Representative data of  one out of  9 independent experiments are shown. (B) Combined IFN-γ secretion 
of  T cells at day 7 of  the co-culture of  9 independent experiments. (C, D) NK cells were activated 
overnight in washed DC-derived cell-free supernatants. Supernatant was generated by maturing iDC with 
IFN-γ, FI 1 or FI 10. (C) Flow cytometric evaluation of  CD69, CD25 and CD83 surface expression of  
differently activated NK cells. NK cells were gated on FSC/SSC on lymphocyte gate, excluding dead cells 
and doublets and selected for CD56+CD3- cells. MFI of  total NK cells for CD69 respectively percentages 
of  CD25+ NK cells of  14 independent experiments are shown including the median. Percentages of  
CD83+ NK cells of  12 independent experiments are shown. (D) NK cell-derived IFN-γ production 
measured in the culture supernatant by CBA. Combination of  12 independent experiments is shown. 
Wilcoxon signed-rank test significance * P<0.05; ** P<0.01; *** P<0.001; ****P<0.0001.
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Cooperative PRR-triggering during DC maturation enhances Th1 polarizing and 
NK cell activating capacities of  DC
Previously it has been shown that triggering of  multiple PRR-signalling cascades influences 
the DC cytokine profile and enables DC to modify their interaction with helper cells 25-27, 31. As 
FMKp contains only bacterial PAMPs, we addressed the question whether the combination 
with a viral PAMP would lead to DC being more potent in inducing both Th1 and NK 
′helper′ cell responses.
Poly(I:C) lyovec (further on described as poly(I:C)), a RIG-1/MDA-5 receptor complex 
trigger, was added to the FI-cocktail and first the effect of  this combined viral and bacterial 
triggering during DC maturation was studied on the Th cell polarizing capacities. T cells 
Figure 2 | Impact of  cooperative PRR-triggering during DC maturation on DC-induced Th1 
polarization and NK cell activation. (A, B) Monocyte-derived iDC were matured with FMKp/
IFN-γ (FI), poly(I:C) lyovec (poly(:C)) or the combination of  both (FI+poly(I:C)). 24h-matured DC 
were co-cultured with autologous naive CD4+CD45RA+ T cells and the expression of  T-bet and IFN-γ 
as well as the IFN-γ production were monitored during 7 days. (A) Th1-polarizing capacity of  FI-(●), 
poly(I:C)-(■) and FI+poly(I:C)-(■) matured DC of  one out of  6 representative experiments are shown by 
means of  T-bet and IFN-γ expression as well as IFN-γ secretion. (B) Average IFN-γ secretion of  T cells at 
day 7 of  the different co-cultures (n=6). (C, D) NK cells were activated overnight in washed DC-derived 
cell-free supernatants. (C) Flow cytometric evaluation of  CD69, CD25 and CD83 surface expression of  
differently activated NK cells. NK cells were gated in FSC/SSC on lymphocyte gate, excluding dead cells 
and doublets and selected for CD56+CD3- cells. MFI of  total NK cells for CD69 respectively percentages 
of  CD25+ NK cells of  10 experiments are shown. Percentages of  CD83+ NK cells of  7 experiments are 
shown. (D) NK cell-derived IFN-γ production measured by CBA in the culture supernatant. Combination 
of  16 experiments is shown. Wilcoxon signed-rank test significance * P<0.05; ** P<0.01; *** P<0.001; **** 
P<0.0001.
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co-cultured with FI+poly(I:C)-DC displayed an earlier transcriptional induction of  IFN-γ 
(day 4 vs. day 6 for FI-DC-T cell co-culture) and in line with this, a significantly higher 
secretion of  IFN-γ on day 7 (Figure 2A, B).
Next, we studied the effect of  cooperative PRR-triggering on NK cell activation. Both the 
expression of  CD69 on NK cells and the percentage of  CD25+ NK cells were increased by 
activation with FI+poly(I:C)-DC supernatant (Figure 2C). In contrast, the percentage of  
CD83+ NK cells was not significantly different between the groups. NK cells activated by 
both the bacterial and viral trigger showed significant increased IFN-γ secretion compared 
with those triggered by either of  the individual ligands in combination with IFN-γ 
(Figure 2D).
IL-12p70, the common factor of  quantitative and cooperative PRR-triggering
Both quantitative and cooperative PRR-triggering positively influenced the capacities 
of  DC to interact with Th and NK cells. Since the NK cells were activated in a cell-cell 
contact-independent milieu, we addressed the question whether a common soluble factor 
was responsible for the observed effects. We tested whether the amount of  IL-12p70 was 
the common factor up-regulated, as previous reports demonstrated the necessity of  this 
cytokine for both Th1 and NK cell responses 31, 37, 38.
Figure 3 | IL-12p70 production is influenced by quantitative PRR-triggering. IL-12p70 secretion by 
differently matured DC measured by CBA. iDC were matured for 48h with different cocktails at a density 
of  0.5x106 cells/ml in 24-well plates. (A) iDC were matured with different concentrations of  FMKp 
(1-50ug/ml) (●) or poly(I:C) (0.1-5ug/ml) (■) in presence of  IFN-γ. Representative data of  3 independent 
experiments are shown. (B) IL-12p70 values of  a titration curve with FI 1 plus increasing concentrations 
of  poly(I:C) (0.1-5ug/ml) (▲). Dotted grey line (♦) represents theoretical calculated IL-12p70 value by 
summing up the IL-12p70 concentration of  FI 1 with the different IL-12p70 concentrations of  poly(I:C) 
0.1-5ug/ml conditions. (C) Individual and median IL-12p70 secretion of  IFN-γ, FI 1, FI 10, poly(I:C), 
and FI+poly(I:C)-matured DC is shown. Mann-Whitney U test ** P<0.01. *** P<0.001; **** P<0.0001.
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Maturing iDC with increasing concentrations of  FMKp or poly(I:C) led to increased IL-12 
secretion with an optimum at 25µg/ml FMKp and 2.5µg/ml poly(I:C). Thus, in both cases 
quantitative PRR-triggering (with either FMKp or poly(I:C)), positively influences the 
IL-12 production by DC (Figure 3A). The combination of  FMKp and poly(I:C) generated 
DC producing up to 3-fold more IL-12 compared with DC matured with the respective 
theoretical concentrations of  the triggers alone (Figure 3B). In addition, supernatants 
of  the differently matured DC used to perform the above described experiments indeed 
showed differences in IL-12 levels. The median IL-12 levels of  FI 10-DC was 10.6-fold and 
the one of  FI+poly(I:C) 4.7-fold higher compared with FI 1-DC (Figure 3C).
IL-12p70 is sufficient to induce Th1 polarization but not NK cell activation
Since we showed that IL-12p70 is a factor that is influenced by quantitative and cooperative 
PRR-triggering, we investigated whether IL-12p70 is the common factor predicting Th1 
polarization and NK cell activation. Therefore, we studied whether the dose of  IL-12 has 
a positive influence on the magnitude and/or kinetics of  Th1 polarization and NK cell 
activation. 
Figure 4 | The quantity of  rhIL-12p70 positively influences the magnitude of  Th1 polarization. 
FMKp/IFN-γ (FI)-matured DC were washed after 24h and co-cultured with naive CD4+CD45RA+ T cells 
during 7 days in the presence of  different concentrations of  rhIL-12p70. (A) Flow cytometric evaluation 
of  T cells on day 5 of  the co-culture. FSC/SSC of  the different co-cultures are shown and the percentages 
of  enlarged CD4+ T cells are indicated in the plots. (B) The number of  total cells present in the co-cultures 
on day 5 as measured by coulter counter. (C) Expression of  T-bet and IFN-γ and total IFN-γ production 
by naive CD4+ T cells co-cultured with FI-matured DC in presence of  different concentrations of  rhIL-12 
are shown. Gradient from low to high IL-12 concentrations is illustrated as a colour gradient from light 
grey to black lines.
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First, we supplemented a DC-T cell co-culture with different concentrations of  recombinant 
human (rh) IL-12p70. Increasing doses of  IL-12 administered to the co-cultures correlated 
with higher percentages of  enlarged CD4+ T cells as depicted in FSC/SCC after flow 
cytometric analyses on day 5 of  the co-culture (Figure 4A). Additionally, we observed an 
increased number of  T cells in the conditions with higher doses of  IL-12 (Figure 4B), 
which was also observed in the culture wells (data not shown). Furthermore, the height 
and kinetics of  T-bet mRNA expression were not influenced by the amount of  rhIL-12 
supplemented to the co-cultures. T-bet mRNA expression was even induced without the 
addition of  rhIL-12 (Figure 4C). However, IL-12 levels dose-dependently correlated 
with IFN-γ mRNA expression and IFN-γ secretion. This could also be observed in an 
APC-independent assay, in which we cultured naive CD4+ T cells on anti-CD3-coated plates 
in the presence of  different concentrations of  rhIL-12 (Figure S2). As observed in the 
autologous co-culture, TCR-triggering and IL-12 administration were sufficient to induce 
Th1 polarization.
Second, to address the question whether IL-12p70 is a sufficient factor for the activation 
of  NK cells, we performed NK cell activation assays in which we activated enriched NK 
cells overnight with different concentrations of  rhIL-12 (Figure 5A). Concentrations of  
1000pg/ml IL-12 and higher led to a minor IFN-γ production by NK cells. Increasing doses 
of  rhIL-12 had a positive effect on the expression of  CD69 and NKp30 of  CD56+CD3- 
NK cells and also led to an increased CD25+ subpopulation in the presence of  rhIL-12 
above 100pg/ml. No effect was observed on the expression of  CD83. We observed a 
more prominent expression of  activation markers as well as higher NK cell-derived IFN-γ 
secretion when NK cells were activated with FI-DC-derived supernatant compared with 
IL-12-activated NK cells (Figure 2C, D).
Considering these observations together with previously published data on the necessity 
of  a two-signal requirement for NK cell activation 12, we further studied whether the 
supplementation of  rhIL-12 to FI-DC supernatant, containing more soluble factors than 
only IL-12, would increase the NK cell activation potential. We observed that all the analysed 
parameters were increased compared with NK cells activated with the corresponding 
dose of  rhIL-12 alone (Figure 5A). The increasing dose of  IL-12 supplemented into 
the FI-supernatant led to a dose-dependent increase of  the CD25+ NK cell population. 
Additionally, NK cell-derived IFN-γ secretion was positively influenced by the dose of  
IL-12. Thus, IL-12 had a superior potential to activate NK cells when combined with other 
soluble DC-derived factors. 
Another cytokine which has been shown by our group and others 21, 31 to be important 
for NK cell activation is IL-18. Since this cytokine is released in the synaptic cleft during 
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the NK-DC interaction, it is present in minor concentrations in the DC supernatant. 
In our supernatants the levels of  IL-18 were all below the ELISA detection limit of  
12.5pg/ml (data not shown). Nevertheless, we tested the influence of  rhIL-18 on the 
potential of  rhIL-12 to activate NK cells (Figure 5B). NKp30 as well as NK cell-derived 
IFN-γ secretion were up-regulated by adding IL-12 as single factor, whereas IL-18 as single 
factor was able to induce expression of  CD69 on total NK cells and to induce CD25+ and 
CD83+ subpopulations. For NK cells activated by the combination of  IL-12 and IL-18, a 
synergistic effect was observed for IFN-γ secretion and all the phenotypic markers except 
for NKp30 when comparing to single-cytokine activated NK cells.
The quantity of  IL-12p70 secretion by differently matured DC predicts the magnitude 
of  NK cell and Th1 helper responses
We observed quantitative differences among donors in the IL-12-producing capacity 
(Figure 3C). To study whether this cytokine-producing capacity correlates with their capacity 
to induce Th1 and NK cell helper activation, we correlated IL-12 levels of  FMKp-matured 
DC of  different donors against their corresponding Th1- and NK cell-derived IFN-γ 
Figure 5 | The quantity of  rhIL-12p70 positively influences NK-cell derived IFN-γ production. 
(A) Freshly isolated NK cells from PBMC were incubated overnight in a round-bottom 96-well plate 
with increasing concentrations of  rhIL-12p70 (0-100ng/ml) in serum-free AIM-V® medium (black bars) 
or FMKp/IFN-γ-DC-derived (grey bars) cell-free supernatant. NK cell-derived IFN-γ production was 
measured by CBA in the culture supernatants. Flow cytometric evaluation of  CD69, CD25, CD83, and 
NKp30 surface expression of  the differently activated NK cells is shown. NK cells were gated in FSC/
SSC on lymphocyte gate, excluding dead cells and doublets and selected for CD56+CD3- cells. MFI of  total 
NK cells for CD69 and NKp30 and percentages of  CD25+ and CD83+ NK cells are shown, respectively. 
Graphs are representative of  3 independent experiments. (B) NK cells were incubated overnight in 
serum-free medium in presence of  100ng/ml IL-12 or 1000ng/ml IL-18 or the combination of  both. 
NK cell-derived IFN-γ production was measured by CBA in the culture supernatant. Flow cytometric 
evaluation of  CD69, CD25, CD83, and NKp30 surface expression of  the differently activated NK cells 
of  one out of  3 representative experiments is shown.
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levels (Figure 6A). For both Th1 polarization and NK cell activation, a significant positive 
correlation was observed between IL-12 secretion and IFN-γ production. This indicates 
that the inter-individual difference in the capacity to produce IL-12 by monocyte-derived 
(mo)DC is correlated with the magnitude of  induced NK cell and CD4+ T cell helper 
responses.
We further aimed to prove that IL-12 can serve as a possible marker to predict the capacity 
of  differently matured DC to interact with Th1 and NK cells. To this end, we correlated the 
IL-12 levels of  differently matured DC with their corresponding Th1- and NK cell-derived 
IFN-γ levels (Figure 6B). Both graphs show a highly significant correlation between these 
two factors, illustrating the importance of  programming DC to produce IL-12p70. 
DISCUSSION
In the current study, we set out to investigate whether and how PAMP-matured moDC 
activate both NK helper cells and Th1 cells. We showed the existence of  at least one 
programme used by DC to induce potent cellular immune responses by stimulating both 
helper processes. The increased capacity of  DC to mount the helper responses appeared in 
absence of  up-regulation of  HLA- and co-stimulatory molecules; instead it was paralleled 
with the production of  IL-12p70. PRR-triggering can modulate the capacity of  DC to 
produce IL-12p70 and the amount of  IL-12 produced is important for the strength of  NK 
cell activation and the magnitude of  Th1 polarization. In addition, among the PRR-agonists 
we tested, the bacterial or viral triggers by which DC are programmed to produce IL-12 
seem to be of  minor importance. If  DC get programmed to produce IL-12, they will most 
Figure 6 | IL-12p70 correlates with the magnitude of  Th1 polarization and the degree of  NK 
helper cell activation. (A) IL-12p70 production of  DC matured with different concentrations of  FI (1 and 
10µg/ml) were correlated with corresponding IFN-γ values of  day 7 of  the DC-T cell co-culture or 
the NK cell-derived IFN-γ levels after overnight incubation in the FI-DC supernatants. (B) DC-derived 
IL-12p70 of  differently matured DC (each dot represents a different maturation cocktail) were correlated 
with the corresponding IFN-γ value of  day 7 of  the DC-T cell co-culture or the NK cell-derived IFN-γ 
levels after overnight incubation in the FI-DC supernatants. Spearman correlation test significance: P 
values are indicated in the graphs.
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probably be able to interact efficiently with both Th1 and NK helper cells. We manipulated 
the IL-12 production of  the DC in a range that was relevant for an increased interaction 
with Th1 and NK cells.
IL-12 being an important factor for Th1 polarization and NK cell-derived IFN-γ production 
is well known. Previous work by our group 31 and others 39, 40 has shown that NK cell-derived 
IFN-γ secretion is abrogated when blocking IL-12, suggesting that IL-12 is indispensable 
for eliciting NK cell helper responses. Furthermore, a study of  Athie-Morales et al. 37 
showed that sustained IL-12-signalling was necessary to induce efficient Th1 polarization 
of  naive CD4+ T cells and neutralization of  IL-12 in co-cultures of  differently matured DC 
with naive CD4+ T cells resulted in a reduced percentage of  IFN-γ+ cells combined with a 
shift towards IL-4+ Th2 cells 25. However, until now it has been unclear to what extent IL-12 
is a quantitative requirement for human cells. We extended these findings with exogenous 
supplementation studies and demonstrated that indeed the requirement of  IL-12p70 for 
both for Th1 polarization and NK cell derived-IFN-γ production is quantitative in a range 
in which it was also possible to manipulate the DC by using bacterial and viral PAMPs 
in maturation cocktails. In presence of  TCR-triggering, IL-12p70 is sufficient to induce 
Th1 polarization in naive CD4+ T cells both in an APC-dependent and -independent 
cultures. Notably, we observed that a higher dose of  IL-12 increased the IFN-γ expression 
and secretion by Th cells, however, the expression of  T-bet mRNA remained unchanged 
for all the conditions. Since we observed this phenomenon in both an APC-dependent 
and independent culture systems, we can exclude that contaminating DC are responsible 
for the detected T-bet expression levels. Even though T-bet expression is necessary for 
optimal Th1 induction 41, 42, our findings are in line with a previous study reporting that 
the T-bet expression did not correlate with IFN-γ secretion 43. Additionally, we previously 
showed that the expression of  T-bet is not necessarily associated with the induction of  
IFN-γ 30. Moreover, we showed that increasing doses of  IL-12 had a positive effect on 
T cell proliferation. We cannot exclude that the positive effect of  increasing IL-12p70 
concentrations on the total number of  cells is influenced by endogenous IL-2 production. 
However, an IL-2-independent, but IL-12p70-dependent proliferation was previously shown 
for Th cell clones 44. On NK cells, the expression of  CD25 and the IFN-γ production was 
induced by adding rhIL-12p70, but to a lesser extent when compared with the two-signal 
activation of  the NK cells. These findings are in line with previous studies showing a two-
signal requirement for both cytokine and chemokine production by NK cells 12, 45.
Our demonstration that DC are capable to influence the magnitude of  the NK cell helper 
response by virtue of  their IL-12 secretion taken together with recent data in literature 
provide a more comprehensive view on the importance of  the IL-12p70-pathway for 
NK cell responses. Besides their enhanced capacity to assist in T cell priming 31, 46 and 
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to induce effector cell recruiting chemokines 47, NK cells which have been activated ex 
vivo in the presence of  IL-12 show enhanced cytokine production and cytolytic activity as 
well as antibody-dependent cellular cytotoxicity 38. Helper NK cells possess the capacity to 
induce additional IL-12 production in DC 7 which suggests the existence of  an additional 
positive feedback loop by which NK cells potentiate the ability of  DC to mount both 
CD4+ and CD8+ T cell responses. Furthermore, in animal models DC-NK interactions 
were shown to synergize for CTL induction 23, and for homing of  T cells to the tumour 
microenvironment 45, 48, 49. At this point it remains to be established to what extent NK cells 
contribute to human adaptive immunity. However, the existence of  the helper pathway 
of  NK cells, the observations that its regulation is paralleled by Th1 induction and that 
it is conserved between human and mice 50 may point towards a similar role as previously 
demonstrated in mice 51. Furthermore, pathogen-recognizing APC attract NK cells to 
lymphoid organs where they serve as editors of  the DC repertoire 52, 53. In murine models 
it was shown that this editing by NK cells was required for the induction of  a potent 
anti-cancer immune responses 54.
Since the maturation of  DC by different PAMPs induces a unique cytokine and chemokine 
profile, the question arises whether the observed effects are the result of  IL-12p70 alone 
or of  a co-factor being regulated in parallel. For NK cells, two-signal activation is required 
for efficient activation 12. We previously showed that blocking of  IL-12p70 inhibited the 
production of  NK cell-derived IFN-γ 31. Kalinski et al. demonstrated the importance of  
IL-18 in the priming of  NK helper cells 21, 45, which facilitates DC maturation, DC-mediated 
Th1 polarization, and recruitment of  effector CD8+ T cells. Whereas IL-18 is able to 
upregulate activation markers such as CD69 and CD25 on a subpopulation of  NK cells, 
IL-18-conditioned NK cells only produced marginal IFN-γ levels as shown in this study and 
by others 17, 22, 55, 56. In addition, blocking IL-18 in DC supernatant conditioned NK cells only 
had marginal effect on NK-cell derived IFN-γ secretion 31, postulating that IL-12p70 is the 
necessary factor for this response. For Th cells, our data showed that IL-12 in combination 
with TCR-signalling is sufficient to induce Th1 polarization. Murine studies revealed that 
a possible co-factor IL-18 was not able to polarize naive CD4+ T cell into Th1 cells, but 
the enhancing effect was mainly exerted on already primed Th1 cells 57, which has been 
confirmed in human in vitro blocking studies 58. Thus, in vivo, the contribution of  other 
cytokines as possible co-factors to further enhance IL-12-induced type 1 immune responses 
cannot be excluded. However, our data together with previous studies strengthen the fact 
that IL-12 plays a crucial role as primary signal in the activation of  both helper responses 
irrespective of  the nature of  the pathogenic stimulus. 
The optimization and implementation of  more powerful therapeutic DC-mediated vaccines 
requires more insight into the interaction of  DC with other immune effector cells. Besides 
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the activation of  CTL, also helper cell activation is important for an effective anti-tumour 
response 14, 18, 54. Because of  the crucial role of  the dose of  DC-derived IL-12p70 for 
the induction of  helper responses, we anticipate that screening DC for IL-12-producing 
capacities will contribute to vaccine design, screening of  adjuvants and thus provide additional 
rational for the optimization of  cellular vaccines. The profound effect of  IL-12p70 together 
with the large variation of  DC from different healthy individuals to produce IL-12p70 may 
suggest an underlying additional reason for the poor clinical outcome observed so far in 
DC-based vaccines in clinical trials. It should be noted that the range in which we were 
able to manipulate the IL-12 production by different maturation stimuli in this study had a 
clear biological effect. This study illustrates that reaching superior IL-12 levels is desirable 
for the design of  DC-mediated vaccines. Recent studies by Okada et al. 59 and Carreno 
et al. 60 showed that the capacity of  DC to produce IL-12p70 correlated positively with time 
to progression in patients with recurrent malignant glioma and patients with melanoma 
and strengthens the importance of  high IL-12p70-producing DC. Thus, besides identifying 
potent IL-12-inducing maturation factors, an improvement of  DC-based vaccine strategies 
may also be achieved by engineering DC to express IL-12. Such an approach showed 
promising results in a murine liver cancer model 61.
Taken together, we revealed that moDC programmed by the selection of  PRR triggers 
tested in this study have the capacity to promote both NK cell and Th1 helper responses 
and that IL-12p70 is the key factor determining the magnitude of  these helper responses. 
Furthermore, we strengthened the findings on the importance of  IL-12p70 in the 
DC-mediated induction of  Th1 and NK helper cells responses. This knowledge may be of  
importance to design and evaluate a new generation of  DC-based vaccines against cancer 
and infectious diseases and for the in vivo activation of  DC.
ACKNOWLEDGEMENTS
We would like to thank Fraukje Mulders, Elsbeth Pekelharing, and Marijke I. Zonneveld 
for technical assistance. This work was supported by the ′Fonds National de la Recherche′, 
Luxembourg (project 1039369; T.O.). The funders had no role in study design, data collection 
and analyses, decision to publish, or preparation of  the manuscript.
92
Chapter 3
3
REFERENCES
1. Kalantari T, Kamali-Sarvestani E, Ciric B, et al. Generation of  immunogenic and tolerogenic clinical-
grade dendritic cells. Immunologic Research. 2011;51(2-3):153-160.
2. Gluckman JC, Canque B, Rosenzwajg M. Dendritic cells: A complex simplicity. Transplantation. 
2002;73(1):S3-S6.
3. Kapsenberg ML. Dendritic-cell control of  pathogen-driven T-cell polarization. Nature reviews 
Immunology. 2003;3(12):984-993.
4. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev. 
2008;222:129-144.
5. Marcenaro E, Dondero A, Moretta A. Multi-directional cross-regulation of  NK cell function during 
innate immune responses. Transpl Immunol. 2006;17(1):16-19.
6. Welsh RM, Waggoner SN. NK cells controlling virus-specific T cells: Rheostats for acute vs. persistent 
infections. Virology. 2013;435(1):37-45.
7. Kalinski P, Giermasz A, Nakamura Y, et al. Helper role of  NK cells during the induction of  anticancer 
responses by dendritic cells. Mol Immunol. 2005;42(4):535-539.
8. Andrews DM, Scalzo AA, Yokoyama WM, Smyth MJ, Degli-Esposti MA. Functional interactions 
between dendritic cells and NK cells during viral infection. Nat Immunol. 2003;4(2):175-181.
9. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of  natural-killer-cell surveillance and 
therapy of  cancer. Nat Rev Cancer. 2002;2(11):850-861.
10. Lee SH, Miyagi T, Biron CA. Keeping NK cells in highly regulated antiviral warfare. Trends Immunol. 
2007;28(6):252-259.
11. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol. 
2002;2(12):957-964.
12. Mailliard RB, Son YI, Redlinger R, et al. Dendritic cells mediate NK cell help for Th1 and CTL 
responses: two-signal requirement for the induction of  NK cell helper function. J Immunol. 
2003;171(5):2366-2373.
13. Strengell M, Matikainen S, Siren J, et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma 
production in human NK and T cells. J Immunol. 2003;170(11):5464-5469.
14. Van Elssen CH, Oth T, Germeraad WT, Bos GM, Vanderlocht J. Natural killer cells: the secret weapon 
in dendritic cell vaccination strategies. Clin Cancer Res. 2014;20(5):1095-1103.
15. Kalinski P, Mailliard RB, Giermasz A, et al. Natural killer-dendritic cell cross-talk in cancer 
immunotherapy. Expert Opin Biol Ther. 2005;5(10):1303-1315.
16. Vitale M, Della Chiesa M, Carlomagno S, et al. NK-dependent DC maturation is mediated by 
TNFalpha and IFNgamma released upon engagement of  the NKp30 triggering receptor. Blood. 
2005;106(2):566-571.
17. Srivastava S, Pelloso D, Feng H, et al. Effects of  interleukin-18 on natural killer cells: costimulation of  
activation through Fc receptors for immunoglobulin. Cancer Immunol Immunother. 2013;62(6):1073-
1082.
18. Ferlazzo G, Moretta L. Dendritic cell editing by natural killer cells. Crit Rev Oncog. 2014;19(1-2):67-
75.
19. Hanna J, Gonen-Gross T, Fitchett J, et al. Novel APC-like properties of  human NK cells directly 
regulate T cell activation. J Clin Invest. 2004;114(11):1612-1623.
20. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated 
human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol. 2004;173(6):3716-
3724.
21. Mailliard RB, Alber SM, Shen H, et al. IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med. 
2005;202(7):941-953.
22. Agaugue S, Marcenaro E, Ferranti B, Moretta L, Moretta A. Human natural killer cells exposed to IL-
2, IL-12, IL-18, or IL-4 differently modulate priming of  naive T cells by monocyte-derived dendritic 
93
IL-12p70 controls DC-induced Th1 and NK cell activation
3
cells. Blood. 2008;112(5):1776-1783.
23. Adam C, King S, Allgeier T, et al. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway 
for antitumor CTL induction. Blood. 2005;106(1):338-344.
24. Hardy MY, Kassianos AJ, Vulink A, et al. NK cells enhance the induction of  CTL responses by IL-15 
monocyte-derived dendritic cells. Immunol Cell Biol. 2009;87(8):606-614.
25. de Jong EC, Vieira PL, Kalinski P, et al. Microbial compounds selectively induce Th1 cell-promoting 
or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. Journal of  
immunology. 2002;168(4):1704-1709.
26. Spranger S, Javorovic M, Burdek M, et al. Generation of  Th1-polarizing dendritic cells using the 
TLR7/8 agonist CL075. J Immunol. 2010;185(1):738-747.
27. Walsh KP, Mills KH. Dendritic cells and other innate determinants of  T helper cell polarisation. 
Trends Immunol. 2013;34(11):521-530.
28. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic 
cells. J Biol Chem. 2001;276(40):37692-37699.
29. Ozinsky A, Underhill DM, Fontenot JD, et al. The repertoire for pattern recognition of  pathogens by 
the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci 
U S A. 2000;97(25):13766-13771.
30. Oth T, Schnijderberg MC, Senden-Gijsbers BL, Germeraad WT, Bos GM, Vanderlocht J. Monitoring 
the initiation and kinetics of  human dendritic cell-induced polarization of  autologous naive CD4+ T 
cells. PLoS One. 2014;9(8):e103725.
31. Van Elssen CH, Vanderlocht J, Frings PW, et al. Klebsiella pneumoniae-triggered DC recruit human 
NK cells in a CCR5-dependent manner leading to increased CCL19-responsiveness and activation of  
NK cells. European journal of  immunology. 2010;40(11):3138-3149.
32. Van Elssen CH, Vanderlocht J, Oth T, Senden-Gijsbers BL, Germeraad WT, Bos GM. Inflammation-
restraining effects of  prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are 
imprinted during DC maturation. Blood. 2011;118(9):2473-2482.
33. Luger R, Valookaran S, Knapp N, Vizzardelli C, Dohnal AM, Felzmann T. Toll-like receptor 4 
engagement drives differentiation of  human and murine dendritic cells from a pro- into an anti-
inflammatory mode. PLoS One. 2013;8(2):e54879.
34. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P. Development of  Th1-inducing 
capacity in myeloid dendritic cells requires environmental instruction. Journal of  immunology. 
2000;164(9):4507-4512.
35. Vanderlocht J, Van Elssen CH, Senden-Gijsbers BL, et al. Increased tumor-specific CD8+ T cell 
induction by dendritic cells matured with a clinical grade TLR-agonist in combination with IFN-
gamma. Int J Immunopathol Pharmacol. 2010;23(1):35-50.
36. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate 
resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J 
Exp Med. 2002;195(3):343-351.
37. Athie-Morales V, Smits HH, Cantrell DA, Hilkens CM. Sustained IL-12 signaling is required for Th1 
development. Journal of  immunology. 2004;172(1):61-69.
38. Lehmann D, Spanholtz J, Sturtzel C, et al. IL-12 directs further maturation of  ex vivo differentiated 
NK cells with improved therapeutic potential. PLoS One. 2014;9(1):e87131.
39. Ferlazzo G, Pack M, Thomas D, et al. Distinct roles of  IL-12 and IL-15 in human natural killer 
cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A. 
2004;101(47):16606-16611.
40. Borg C, Jalil A, Laderach D, et al. NK cell activation by dendritic cells (DCs) requires the formation of  
a synapse leading to IL-12 polarization in DCs. Blood. 2004;104(10):3267-3275.
41. Kanhere A, Hertweck A, Bhatia U, et al. T-bet and GATA3 orchestrate Th1 and Th2 differentiation 
through lineage-specific targeting of  distal regulatory elements. Nat Commun. 2012;3:1268.
42. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, 
94
Chapter 3
3
T-bet, directs Th1 lineage commitment. Cell. 2000;100(6):655-669.
43. Ylikoski E, Lund R, Kylaniemi M, et al. IL-12 up-regulates T-bet independently of  IFN-gamma in 
human CD4+ T cells. Eur J Immunol. 2005;35(11):3297-3306.
44. Maruo S, Toyo-oka K, Oh-hora M, et al. IL-12 produced by antigen-presenting cells induces IL-2-
independent proliferation of  T helper cell clones. J Immunol. 1996;156(5):1748-1755.
45. Wong JL, Berk E, Edwards RP, Kalinski P. IL-18-primed helper NK cells collaborate with dendritic 
cells to promote recruitment of  effector CD8+ T cells to the tumor microenvironment. Cancer 
research. 2013;73(15):4653-4662.
46. Morandi B, Bougras G, Muller WA, Ferlazzo G, Munz C. NK cells of  human secondary lymphoid 
tissues enhance T cell polarization via IFN-gamma secretion. Eur J Immunol. 2006;36(9):2394-2400.
47. Robertson MJ. Role of  chemokines in the biology of  natural killer cells. J Leukoc Biol. 2002;71(2):173-
183.
48. Wong JL, Mailliard RB, Moschos SJ, et al. Helper activity of  natural killer cells during the dendritic 
cell-mediated induction of  melanoma-specific cytotoxic T cells. Journal of  immunotherapy. 
2011;34(3):270-278.
49. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. alpha-type-1 polarized dendritic cells: a novel 
immunization tool with optimized CTL-inducing activity. Cancer research. 2004;64(17):5934-5937.
50. Colucci F, Di Santo JP, Leibson PJ. Natural killer cell activation in mice and men: different triggers for 
similar weapons? Nat Immunol. 2002;3(9):807-813.
51. Martin-Fontecha A, Thomsen LL, Brett S, et al. Induced recruitment of  NK cells to lymph nodes 
provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004;5(12):1260-1265.
52. Della Chiesa M, Vitale M, Carlomagno S, Ferlazzo G, Moretta L, Moretta A. The natural killer cell-
mediated killing of  autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, 
but lacking inhibitory killer Ig-like receptors. Eur J Immunol. 2003;33(6):1657-1666.
53. Wilson JL, Heffler LC, Charo J, Scheynius A, Bejarano MT, Ljunggren HG. Targeting of  human 
dendritic cells by autologous NK cells. J Immunol. 1999;163(12):6365-6370.
54. Morandi B, Mortara L, Chiossone L, et al. Dendritic cell editing by activated natural killer cells results 
in a more protective cancer-specific immune response. PLoS One. 2012;7(6):e39170.
55. Matikainen S, Paananen A, Miettinen M, et al. IFN-alpha and IL-18 synergistically enhance IFN-
gamma production in human NK cells: differential regulation of  Stat4 activation and IFN-gamma 
gene expression by IFN-alpha and IL-12. Eur J Immunol. 2001;31(7):2236-2245.
56. Leong JW, Chase JM, Romee R, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and 
a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. 
Biol Blood Marrow Transplant. 2014;20(4):463-473.
57. Stoll S, Jonuleit H, Schmitt E, et al. Production of  functional IL-18 by different subtypes of  murine 
and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur 
J Immunol. 1998;28(10):3231-3239.
58. de Jong EC, Vieira PL, Kalinski P, et al. Microbial compounds selectively induce Th1 cell-promoting 
or Th2 cell-promoting dendritic cells in vitro with diverse th cell-polarizing signals. J Immunol. 
2002;168(4):1704-1709.
59. Okada H, Kalinski P, Ueda R, et al. Induction of  CD8+ T-cell responses against novel glioma-
associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic 
cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients 
with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330-336.
60. Carreno BM, Becker-Hapak M, Huang A, et al. IL-12p70-producing patient DC vaccine elicits Tc1-
polarized immunity. J Clin Invest. 2013;123(8):3383-3394.
61. Vogt A, Sievers E, Lukacs-Kornek V, et al. Improving immunotherapy of  hepatocellular carcinoma 
(HCC) using dendritic cells (DC) engineered to express IL-12 in vivo. Liver Int. 2013.
95
IL-12p70 controls DC-induced Th1 and NK cell activation
3
SUPPORTING INFORMATION
Supplementary Figure S1 | Flow cytometric analyses of  DC supernatant-induced NK cell 
activation. NK cells were incubated overnight in washed supernatant of  differently matured DC and 
stained for CD25, CD69, NKp30 and CD83. NK cells were gated in the FSC/SCC on the lymphocyte 
gate and further selected on CD56+CD3- cells. Expression of  the different markers is shown in histograms 
for NK cells activated with IFN-γ, FI 1 and FI 10-DC supernatants. CD25 and CD83 showed a shift of  
a part of  the NK cell population and results were depicted as percentages in figure 1, 2, and 5. CD69 was 
upregulated on the entire NK population and was shown as mean fluorescence intensity (MFI) in Figure 1, 
2, and 5. The expression of  NKp30 was not affected by activating NK cells in different DC supernatants.
Supplementary Figure S2 | IL-12p70 is sufficient to induce Th1 polarization in an APC-independent 
setup. 5x104 naive CD4+CD45RA+ T cells were cultured in round-bottom 96-well plates on immobilized 
anti-CD3 (1µg/ml) for 5 days in the presence of  different rhIL-12p70 concentrations (0-10000pg/ml). 
Transcriptional induction of  T-bet and IFN-γ was determined over time.
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ABSTRACT
Natural killer (NK) cells play a crucial role in host defense by eliminating infected or 
malignantly transformed cells. Moreover, NK cells serve as modulators of  adaptive 
immune responses. Because NK cells express various pattern recognition receptors (PRR), 
we investigated whether direct sensing of  viral and bacterial motifs contributes to the 
response of  inflammatory dendritic cells (DC) against the same pathogenic stimuli.
We demonstrated that direct sensing of  pathogens by NK cells augments the 
pro-inflammatory cytokine profile of  DC via NK cell-derived soluble factors. Among 
viral motifs, the enhancement of  DC-derived IL-12p70 secretion was observed by TLR3, 
TLR7/8, and TLR8-activated NK cells. TLR8-triggering ligands showed different results; 
sensing of  ssRNA40 amplified the DC cytokine profile, whereas ssPolyU did not. TLR7 
agonists only induced a marginal activation of  NK cells. Additionally, we demonstrated that 
NK cells amplify the DC-derived IL-12p70 production upon recognition of  bacterial motifs, 
including TLR1/2, TLR2, TLR2/6, TLR4, and TLR5 triggers. DC-derived secretion of  
IL-1β, IL-6, CXCL9, and CXCL10 was also influenced in the presence of  NK cell-derived 
soluble factors. Notably, this amplification was dependent on the cytokine environment 
in which NK cells recognized the pathogen indicating the importance of  accessory cell 
activation for this mechanism. Furthermore, we showed that NK cells amplify the DC 
cytokine profile via a TNF-α-independent mechanism and relying on IFN-γ.
These findings display an important level of  interaction between different PRR-expressing 
immune cells. This is of  interest to modulate immune responses, for example for the 
selection of  adjuvants for vaccination strategies.
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INTRODUCTION
Natural killer (NK) cells are important players of  the innate immune system and are well 
described for their role in controlling viral infections and limiting tumour outgrowth by 
recognizing and eliminating altered self-cells 1-3. The activation of  NK cells is controlled by 
a tight balance of  activating and inhibitory receptors between the interacting cells according 
to ′missing-self′ or ′stress-induced self-recognition′-principle 4 and/or by the surrounding 
cytokine milieu 5, 6. The importance of  NK cells in host defence and control of  infections 
is supported by several studies with NK cell-deficient mice or mice having an impaired NK 
cell function, in which infections cause an increased viral load and lead to a higher mortality 
as compared to control animals 7. Moreover, patients with NK cell deficiencies have an 
increased susceptibility to recurrent viral infections (mainly herpes- and papillomavirus) 8-11. 
Interestingly, NK cell-deficient mice also displayed a higher bacterial load 12-14.
The presence of  viral or bacterial pathogens is sensed by pattern recognition receptors (PRR). 
These receptors recognize conserved microbial structures, the so-called pathogen-associated 
molecular patterns (PAMPs). A variety of  immune cells, such as antigen-presenting cells 
(e.g. dendritic cells; DC) express a specific repertoire of  these PRR allowing a coordinated 
response of  the different immune effectors cells against a particular pathogen 15-17. 
Likewise, PAMP-matured DC have the capacity to activate NK cells by soluble as well as 
contact-dependent factors. This indirect sensing of  pathogens includes enhancement of  
proliferation and survival as well as increased cytotoxic potential and cytokine secretion 18-21. 
Moreover, several studies revealed that NK cells also express a diverse repertoire of  PRR 
potentially allowing direct sensing of  pathogens. This repertoire includes expression of  
Toll-like receptors (TLR) 1-9 22-25 as well as members of  other PRR families: RIG-I, NOD-2, 
NRLP3, and MDA-5 26-28. Various authors showed the functional importance of  PAMP 
recognition with respect to the induction of  cytotoxicity. Triggering of  TLR2, 7, 8, and 9 
enhances NK cell cytolytic potential against various tumour cell lines 22, 29-31. Furthermore, 
TLR ligation can also influence the capacity of  NK cells to edit the DC repertoire by 
eliminating suppressive immature DC (iDC) 31. Thus, direct PAMP-sensing by NK cells 
is not only influencing direct elimination of  altered cells but can also modulate adaptive 
immune responses.
In recent years, another mechanism has been described by which NK cells can modulate 
immune responses. Besides their important cytotoxic role, NK cells have also been 
ascribed a helper function. These helper NK cells have a DC-activating capacity and 
induce type-1-polarizing DC. These DC are in turn able to produce high amounts of  
pro-inflammatory cytokines and to enhance Th1 and CTL responses 20, 21, 32, 33. Thus far, 
the induction of  these NK helper cells in vitro has been achieved by pro-inflammatory 
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cytokines. Whether the helper activity of  NK cells gets also induced upon direct sensing of  
pathogen remains understudied. A recent study by Wong et al. 34 showed that the addition 
of  a TLR3 trigger to a NK-DC co-culture led to an enhanced DC maturation with respect 
to co-stimulatory molecule expression and IL-12p70 as well as melanoma-specific CTL 
responses. It remains unclear whether this effect is influenced by the NK-DC crosstalk and 
whether the engagement of  other PRR can induce this response. Further investigation on 
the role of  PRR engagement by NK cells as an alternative activation pathway on the onset 
of  an immune response is needed.
In the current study we aimed to investigate whether the recognition of  specific viral and 
bacterial PAMPs contributes to an increased activation of  monocyte-derived (mo)DC 
exposed to the same trigger. Therefore, we first studied the capacity of  NK cells to respond 
towards diverse viral and bacterial PAMPs. Furthermore, we aimed at identifying by virtue 
of  which cytokines NK cells induce increased DC cytokine secretion and whether this 
mechanism differs between viral and bacterial activated NK cells.
MATERIAL AND METHODS
Generation of  DC
Monocytes were generated as previously described 35 and differentiated in serum-free 
AIM-V® medium (Life technologies, Carlsbad, CA, USA) supplemented with GM-CSF 
(400U/ml; Berlex Laboratories Inc., Montville, NJ, USA) and IL-4 (2000U/ml; Miltenyi 
Biotec GmbH, Bergisch Gladbach, Germany) at a density of  2x106 cells/ml. After 7 
days, iDC were harvested and frozen or immediately processed in NK cell-induced DC 
maturation assays.
NK cell isolation
NK cells were isolated from buffy coats or fresh peripheral blood-derived PBMC by 
negative immunomagnetic cell separation (Miltenyi Biotec) according to the manufacturer’s 
instructions. Blood was obtained from Sanquin blood bank Maastricht, the Netherlands 
(project 2000-03AZM) from healthy donors after informed consent. Isolated NK cells were 
≥ 95% CD56+CD3- (containing 0% CD14+ cells) as assessed by flow cytometry.
Activation of  NK cells
Freshly isolated NK cells were activated overnight in round-bottom 96-well plates 
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(2.5x105 cells/well) in serum-free AIM-V® medium supplemented with various PAMPs and 
if  indicated in the figure legends supplemented with different combinations of  cytokines: 
IL-2 (1000U/ml; Proleukin, Novartis, Basel, Switzerland); IL-2 and IL-18 (100ng/ml; MBL 
International cooperation, Woburn, MA, USA); IL-12 (10ng/ml; R&D systems, Minneapolis, 
MN, USA), IL-15 (20ng/ml; R&D systems) and IL-18. The following PAMPs were used 
in this study: poly(I:C)HMW (50µg/ml), poly(I:C)LMW (100 µg/ml), imiquimod (5µg/
ml), gardiquimod (5µg/ml), CL075 (5µg/ml), R848 (5µg/ml), ssPolyU (5µg/ml), ssRNA40 
(5µg/ml), Pam3CSK4 (5µg/ml), HKLM (108cells/ml), FSL-1 (1µg/ml), LPS (20µg/ml), 
flagellin (10µg/ml; all purchased from InvivoGen, Toulouse, France), and FMKp (10µg/
ml; Pierre Fabre Laboratories, Boulogne-Billancourt, France). As controls, additional wells 
on the same plate containing medium and PAMPs with or without cytokine cocktails 
were incubated overnight. After 16-18h of  incubation, cell-free supernatants and control 
wells were harvested and used to mature iDC. Additionally, NK cell-derived cytokine and 
chemokine profile was determined. The remaining cells were stained for various cell surface 
markers and were analysed by flow cytometry. If  indicated, the supernatant of  washed NK 
cells was used. For this purpose NK cells were first activated for 4h with PAMPs and then 
extensively washed, followed by additional incubation for a total of  16-18h in fresh serum-
free medium at 37°C/5% CO2.
NK cell-induced DC maturation
Supernatants of  activated NK cells and control supernatants (medium containing PAMPs 
with or without cytokines stored overnight in the incubator without the presence of  NK 
cells) were transferred into flat-bottom 96-well plates supplemented with IL-4 (500U/ml) 
and GM-CSF (500U/ml). To each well, 2.5x105 iDC were added. After 48h of  maturation, 
the supernatant was harvested and analysed for DC-derived cytokines and chemokines. 
Additionally, DC were harvested, stained for phenotypic surface markers and analysed by 
flow cytometry.
Blocking studies
Blocking studies were performed with cell-free supernatants obtained from freshly 
isolated NK cells activated overnight in serum-free AIM-V® medium and IL-2 
(1.000U/ml) supplemented with FMKp (10µg/ml) or poly(I:C)HMW (50µg/ml). The 
receptor-blocking was performed by pre-incubating iDC with blocking antibodies for 
20min before their addition into flat-bottom 96-well plates containing the cell-free NK cell 
supernatant supplemented with IL-4 (500U/ml) and GM-CSF (500U/ml). The following 
receptor blocking antibodies were used: IFNGR1 (20µg/ml), TNFR1 (20µg/ml), TNFR2 
(20µg/ml), or isotype control (all purchased from R&D systems). The blocking of  the 
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cytokines (IFN-γ and TNF-α) in the NK cell-derived supernatants was performed by pre-
incubating the supernatants with anti-TNF-α (20µg/ml; BD) or anti-IFN-γ (10µg/ml; 
BD) before adding the iDC. As reference value, iDC were incubated with NK cell-derived 
supernatant in absence of  blocking agents. As a negative control, iDC were incubated with 
medium supplemented with FMKp or poly(I:C) and IL-2. After 48h of  maturation, the 
supernatant was harvested to determine the DC cytokine and chemokine profile.
Supplementation studies
iDC were matured in 48 well plates (2.5x105 cells/well) in serum-free AIM-V® in the presence 
of  IL-4 (500U/ml) and GM-CSF (500U/ml) supplemented with different concentrations 
of  rhIFN-γ (0-50.000U/ml; R&D systems) or rhTNF-α (0-10.000U/ml; Life Technologies). 
The supernatant was harvested after 48h of  maturation and cytokines were analysed by 
cytometric bead array (CBA; see below).
Flow cytometry
All antibodies used to determine NK cell purities as well as the surface marker expression of  
NK cells and DC were purchased from BD Biosciences (Franklin Lakes, NJ, USA). Antibodies 
were used, titrated to their optimal concentration, either as fluorescein isothiocyanate 
(FITC), phycoerythrin (PE), peridinin chlorophyll protein (PerCP), allophyocyanin (APC), 
allophyocyanin H7 (APC-H7), Horizon 450 or PeCy7. Discrimination between dead and 
living cells was made based on LIVE/DEAD® Fixable Dead Cell staining (Aqua stain; Life 
Technologies). Analysis were performed with BD FACS Canto II and analysed by BD FACS 
Diva Software v6.1.2 (BD Biosciences).
Cytokine detection
Quantification of  DC- and NK cell-derived pro-inflammatory cytokine and chemokine 
profiles were performed by CBA flex set assay (BD Biosciences) according to the 
manufacturer’s instructions. Measurements were performed with BD FACS Canto II and 
analysed by BD FACS Diva Software v6.1.2 and FCAP array analysis software (version 
1.0.1; Soft Flow Inc., St. Louis Park, MN, USA).
Statistical analyses
Statistical analyses were determined by Kruskal-Wallis (NK cell analyses) or by Mann-
Whitney U test (DC analyses) and the correlation was tested by nonparametric Spearman 
correlation; * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001. Data were analysed using 
GraphPad Prism Software (version 6; GraphPad Software, San Diego, CA, USA).
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RESULTS
Viral PAMP recognition by NK cells induces activation in the presence of  IL-2
To evaluate whether NK cells recognize and get activated after engagement of  different viral 
PAMPs (triggering various TLR), we incubated NK cells with different viral TLR ligands: 
poly(I:C) (TLR3), gardiquimod (TLR7), CL075 and R848 (both TLR7/8), ssRNA40 and 
sspolyU (both TLR8). The production of  NK helper cell-derived regulatory cytokines, 
IFN-γ and TNF-α, was minimal after viral TLR ligation and did not differ between the 
different viral PAMPs. Furthermore, we determined the production of  the chemokines 
involved in attraction and enhanced cytotoxity of  NK cells 36, 37 as well as in the recruitment 
of  iDC 33: CCL3 and CCL5. The chemokine production was low and no differences were 
observed between the different triggers (Figure 1A). The expression of  activation markers 
CD69 and CD25 was upregulated by NK cells activated with the TLR3 trigger poly(I:C) and 
TLR7/8 trigger R848 (Figure 1B).
Since it has been previously reported that NK cells get more efficiently activated by the 
combination of  two signals 32, we investigated whether the addition of  IL-2 to the viral 
PAMPs during overnight incubation enhances PAMP-induced NK cell activation. The 
presence of  IL-2 led to an increase in CCL3, CD69, and CD25 in the control condition. 
By adding IL-2, we also observed differences in the ability of  NK cells to sense viral 
PAMPs and to induce cytokine and chemokine secretion as well as upregulation of  cell 
surface markers. Only triggering TLR3 by poly(I:C) in combination with IL-2 enhanced 
all the analysed parameters and was superior in cytokine secretion and surface marker 
expression compared to all the other triggers. R848 and ssRNA40 induced a significant 
increase in NK cell-derived IFN-γ (Figure 1A, B). The limited response towards TLR7 
trigger gardiquimod was observed as well as for another TLR7 PAMP, imiquimod. Notably, 
whereas of  the two TLR8 triggers ssRNA40 and ssPolyU, only ssRN40 induced IFN-γ 
production by NK cells, the induction of  the other parameters was comparable between 
these two PAMPs. 
These data show that NK cells are able to respond to different viral triggers, however, for 
efficient sensing NK cells require a pro-inflammatory environment (e.g. IL-2) to induce 
potent cytokine secretion. Additionally, we observed that the different TLR-triggering 
PAMPs, but also PAMPs triggering the same TLR (e.g. TLR8) differ in their potency to 
induce an NK cell response. So not only TLR3 triggers showed an NK cell stimulatory 
effect, but also other viral TLR triggers did, where TLR7/8 triggers induced cytokine 
production by NK cells most efficiently.
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Bacterial PAMP recognition by NK cells induces activation in the presence of  IL-2
In addition to viral PRR, NK cells are also equipped with TLR sensing bacterial PAMPs. 
Therefore, we investigated whether bacterial triggers activate and induce cytokine production 
by NK cells. We incubated NK cells with various bacterial PAMPs triggering diverse TLR: 
Pam3CSK4 (TLR1/2), HKLM (TLR2), FSL-1 (TLR2/6), LPS (TLR4), flagellin (TLR5), 
and FMKp (a lysate containing membrane fragments of  Klebsiella pneumoniae, triggering 
multiple PRR). In the absence of  IL-2, only FMKp-activated NK cells showed significant 
increased IFN-γ secretion levels as compared to control. This was even further increased in 
the presence of  IL-2 (Figure 2A). In the presence of  IL-2, also all other bacterial PAMPs 
induced superior IFN-γ secretion levels as compared to the control. Overall, the TNF-α 
secretion was low; HKLM and FMKp-triggered NK cells showed the highest secretion in 
absence of  IL-2. TNF-α secretion was enhanced in the presence of  IL-2 for all the triggers, 
except for HKLM. Moreover, bacterial TLR-triggering induced NK cell-derived chemokine 
production CCL3 and CCL5 in all the conditions. The addition of  IL-2 did not substantially 
enhance the production of  CCL5 (Figure 2A). In addition, we analysed surface marker 
expression of  the differently activated NK cells. Cell surface markers were increased by 
all bacterial PAMPs in the presence of  IL-2 as compared to the control. FMKp-activated 
NK cells showed the highest expression of  the activation marker CD69 and an increased 
CD25+ and CD83+ subpopulation in absence or presence of  IL-2 (Figure 2B). FSL-1 in 
presence or absence of  IL-2 induced as well a high percentage of  CD25+ and CD83+ NK 
cells, comparable to FMKp-activated NK cells.
Thus, NK cells are able to respond to different bacterial triggers, which requires similarly 
as for viral stimuli an additional pro-inflammatory environment for efficient sensing by NK 
cells.
PAMP-activated NK cells provide help for DC maturation
We showed that NK cells get activated by both viral and bacterial PAMPs triggering diverse 
TLR in the presence of  IL-2. Next, we studied whether these PAMP-activated NK cells 
Figure 1 | Sensing of  viral PAMP triggers NK cell activation and cytokine secretion. NK cells were 
activated overnight in round-bottom 96-well plates (2.5x105 cells/well) with viral PAMPs in the absence 
(white bars) or presence (grey bars) of  IL-2 in serum-free medium. As a negative control NK cells were 
incubated with medium alone. (A) After 16-18h of  incubation and IFN-γ, TNF-α, CCL3 and CCL5 were 
determined in the culture supernatant by CBA. (B) After 16-18h of  incubation cells were harvested and 
stained for CD69, CD25 and CD83. Expression of  these markers was analysed by flow cytometry. All 
data are presented as mean + SEM and are representative of  at least 4 independent experiments. Kruskal-
Wallis test significance as compared to negative control with and without IL-2, respectively. *P≤0.05, 
****P≤0.0001.
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can modulate immune responses by providing help for DC maturation. To this end, we 
investigated whether NK-cell derived soluble factors are facilitating DC pro-inflammatory 
cytokine responses. iDC were matured in the absence or presence of  NK cell-conditioned 
medium derived from NK cells activated with various PAMPs in the presence of  IL-2. 
In a previous study, we showed that DC-derived IL-12p70 production positively correlates 
with their capacity to activate NK cells and to induce Th1 responses 38 and thus playing a 
crucial role in coordinating potent type 1 immune responses. Therefore, we first analysed 
the capacity of  NK cells to enhance DC-derived IL-12 production. DC matured with the 
viral TLR3 and 7/8 triggers displayed enhanced IL-12p70 production in the presence of  
NK cell supernatant. A marginal effect was observed with TLR7 triggers gardiquimod 
(Figure 3A) and imiquimod (data not shown). Notably, only after stimulation with one of  
the two TLR8 triggers, ssRNA40, the DC-derived IL-12p70 production was enhanced in 
the presence of  NK cell-conditioned medium. DC matured in the presence of  conditioned 
medium derived from bacterial PAMP-triggered NK cells displayed all an enhanced capacity 
to produce IL-12p70 as compared to DC matured with the respective PAMPs alone; the 
highest increase was observed with FMKp (Figure 3A).
We further analysed the capacity of  DC to produce IL-1β (Figure 3B). The production was 
enhanced for both viral TLR7/8 triggers, CL075 and R848, and ssRNA40 in the presence 
of  NK cell-derived supernatant. The secretion of  IL-1β was enhanced in all the conditions 
for the bacterial PAMPs, however, the production levels were low compared to FMKp 
(Figure 3B). The secretion of  IL-6 was enhanced in all conditions in the presence of  
NK cell conditioned medium (Figure 3C). The IL-10-producing capacity of  DC was not 
influenced by the presence of  NK cell-conditioned medium (data not shown).
We next determined the secretion of  the chemokine CCL5 and of  the two CD8+ T cell-
recruiting chemokines CXCL9 and CXCL10. In the absence of  NK cell-derived cytokines, 
FMKp, LPS, flagellin and poly(I:C) did induce CCL5 secretion (Figure 4A). The production 
of  CCL5 was enhanced for all viral triggers in the presence of  NK cell supernatant except 
poly (I:C) and for the bacterial triggers HKLM, LPS, and FMKp. Both virally and bacterially 
activated NK cell supernatants enhanced the capacity of  DC to produce CXCL9 and 
Figure 2 | Sensing of  bacterial PAMP triggers NK cell activation and cytokine secretion. NK 
cells (2.5x105 cells/well) were activated overnight in round-bottom 96-well plates with various bacterial 
PAMPs in the absence (white bars) or presence (grey bars) of  IL-2 in serum-free medium. As a negative 
control NK cells were incubated with medium alone. (A) After 16-18h of  incubation and IFN-γ, TNF-α, 
CCL3 and CCL5 were determined in the culture supernatant by CBA. (B) After 16-18h of  incubation 
cells were harvested and stained for CD69, CD25 and CD83. Expression of  these markers was analysed 
by flow cytometry. All data are presented as mean + SEM and are representative of  at least 4 independent 
experiments. Kruskal-Wallis test significance as compared to negative control with and without IL-2, 
respectively. * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001.
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CXCL10 (Figure 4 B, C). In the absence of  NK cell supernatant only some of  the viral 
triggers (poly(I:C), ssPolyU, and ssRNA40) directly induced CXCL10 production by DC 
(Figure 4C). 
Figure 3 | Soluble factors derived from viral and bacterial-triggered NK cells help to increase the 
pro-inflammatory cytokine profile of  DC. NK cells (2.5x105 cells/well) were activated overnight in 
round-bottom 96-well plates with various viral and bacterial PAMPs (indicated on x-axis) in the presence 
of  IL-2. As control viral and bacterial PAMPs were stored overnight in the incubator without the presence 
of  NK cells. iDC were matured in these cell-free NK cell-derived supernatants (grey bars) or control 
supernatants (white bars) supplemented with IL-4 (500U/ml) and GM-CSF (500U/ml). After 48h, 
DC-derived cytokines were determined in the culture supernatant by CBA (A) IL-12p70 production. 
Mean + SEM of  n≥9 independent experiments is shown. (B) IL-1β production. Mean + SEM of  n≥7 
independent experiments is shown. (C) IL-6 production. Mean + SEM of  n≥3 independent experiments 
is shown. Mann-Whitney U test comparing absence and presence of  NK cell-derived supernatant (white 
vs. grey bars). * P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001.
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The potency of  the NK cell accessory effect after pathogen-sensing is determined 
by the cytokine milieu
It is well established that the activation of  NK cells is influenced by the local cytokine 
Figure 4 | Soluble factors derived from viral and bacterial-triggered NK cells help to increase the 
pro-inflammatory chemokine profile of  DC. NK cells (2.5x105 cells/well) were activated overnight 
in round-bottom 96-well plates with various viral and bacterial PAMPs (indicated on x-axis) in the 
presence of  IL-2. As control, viral and bacterial PAMPs were stored overnight in the incubator without 
the presence of  NK cells. iDC were matured in these cell-free NK cell-derived supernatants (grey bars) 
or control supernatants (white bars) supplemented with IL-4 (500U/ml) and GM-CSF (500U/ml). After 
48h, DC-derived chemokines were determined in the culture supernatant by CBA. (A) CCL5 production. 
(B) CXCL9 production. (C) CXCL10 production. Mean + SEM of  n≥3 independent experiments is 
shown. Mann-Whitney U test comparing absence and presence of  NK cell-derived supernatant (white vs. 
grey bars). * P≤0.05, ** P≤0.01.
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environment 5, 21, 39. We studied whether the cytokine milieu in which NK cells recognize 
the different PAMPs would also enhance the capacity of  NK cells to amplify the 
pro-inflammatory cytokine profile of  DC. We studied the effect of  cytokine environment 
with a bacterial trigger. To this end, we activated NK cells in the presence of  FMKp and 
different combinations of  cytokine cocktails, previously shown to be efficient inducers of  
NK cell activation on their own 21, 40, 41.
The DC-derived secretion of  IL-12p70 was enhanced by the cytokine milieu in which 
NK cells encountered FMKp; in presence of  IL-2 and IL-18 the secretion of  IL-12p70 
was significantly increased compared with control in the presence of  NK cell-conditioned 
medium. This was even further increased when NK cells encountered FMKp in the 
presence of  IL-12, IL-15, and IL-18. Additionally, also the production of  IL12-p40 and the 
T cell-attracting chemokines CXCL9 and CXCL10 was enhanced in the presence of  NK 
cell-conditioned medium. No additive effect was observed for the secretion of  IL-6 and 
CCL5 (Figure 5). It should be noted, that as seen in Figure 3C and 4A, FMKp-matured 
DC secreted IL-6 and CCL5 in the absence of  NK cell-conditioned medium and cytokines, 
and this did not further increase with NK cell help.
Accessory help for DC maturation of  PAMP-activated NK cells is not confined to 
the recognition of  the same microbial trigger
We showed that NK cells are able to amplify DC maturation against the same encountered 
PAMP via the release of  soluble factors. Next, we studied whether soluble factors derived 
from bacterial or viral PAMP-activated NK cells have the capacity to enhance the maturation 
of  DC which encountered a different pathogen. For this purpose, we activated NK cells in 
the presence of  IL-2 and various PAMPs and washed the triggers away after 4h. NK cells 
were incubated for an additional 12h, allowing cytokine and chemokine production. iDC 
were matured with the bacterial trigger FMKp in the presence of  the different washed NK 
cell-derived supernatants. IL-12p70 production by DC is depicted in Figure 6A. Not only 
soluble factors derived from NK cells activated by FMKp did enhance IL-12p70 production, 
but also NK cells activated by LPS, another bacterial trigger, as well as viral PAMP-activated 
NK cells. The latter differed in their capacities to induce IL-12p70 production with poly(I:C) 
showing best response followed by R848, CL075, and gardiquimod-activated NK cells. 
IFN-γ-mediated NK cell help for enhanced DC cytokine and chemokine secretion
Next, we wanted to identify which common soluble factors are responsible for the mediated 
help. Therefore, we first correlated the amount of  pro-inflammatory cytokine IFN-γ 
produced by the differently activated NK cells with their respective DC-derived IL-12p70 
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levels and showed a significant positive correlation (Figure 6B). Furthermore, besides IFN-γ 
also TNF-α has been described as a factor involved in DC maturation 42. By correlating the 
secretion of  NK cell-derived IFN-γ and TNF-α, we observed that the secretion of  TNF-α 
and IFN-γ was regulated in parallel (Figure 6B). To elucidate whether both NK-derived 
IFN-γ and TNF-α play a role in the mediated effect on DC maturation, we performed 
supplementation studies with rhIFN-γ and rhTNF-α. The addition of  increasing doses of  
IFN-γ to iDC in the presence of  FMKp led to increased production of  IL-12p70, IL-12p40, 
CXCL9 and CXCL10 by DC (Figure 6C). In contrast, the effect of  supplementation on 
IL-6, IL-1β and CCL5 production was marginal. The secretion of  the anti-inflammatory 
cytokine IL-10 was not influenced (data not shown). Furthermore, the supplementation of  
IFN-γ to poly(I:C)-matured DC showed similar results as FMKp-matured DC (Figure S1). 
However, no effect was observed by supplementing rhTNF-α during DC maturation 
(Figure S2).
To confirm these findings, we performed blocking studies. The supernatant of  FMKp and 
IL-2-activated NK cells was added to iDC in the absence or presence of  anti-IFN-γ or 
anti-TNF-α or presence of  receptor blockers (anti-IFNGR1, anti-TNFR1, or anti-TNFR2). 
Blocking of  IFN-γ by either capturing IFN-γ in the supernatant or IFNGR1 on the surface 
of  iDC dramatically reduced the capacity of  DC to produce IL-12p70 (remaining capacity 
by blocking with anti-IFN-γ: 1.67% ± 1.11), IL-12p40 (5.79% ± 2.09), CXCL9 (0.09% ± 
Figure 5 | Influence of  cytokine milieu. NK cells were activated overnight in serum-free medium in the 
absence or presence of  FMKp with or without different cytokine combinations (no cytokines; IL-2/IL-
18; IL-12/IL-15/IL-18). iDC were matured in presence or absence of  these NK cell-derived supernatants 
for 48h. DC-derived cytokine and chemokine secretion was determined in cell-free supernatants by 
CBA. (A) Cytokine profile. (B) Chemokine profile. Data are shown as mean + SEM of  n≥4 independent 
experiments. Mann-Whitney U test comparing absence and presence of  NK cell-derived supernatant 
(white vs. grey bars). * P≤0.05, ** P≤0.01.
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Figure 6 | NK cell-derived IFN-γ but not TNF-α is necessary to modulate the pro-inflammatory 
cytokine profile of  DC. (A) IL-12p70 secretion by FMKp-matured DC in the presence of  differently 
activated NK cell-derived supernatants. iDC were matured in a flat-bottom 96-well plate (2.5x105/well) 
with washed NK cell-derived supernatant supplemented with FMKp, IL-4 (500U/ml), and GM-CSF 
(500U/ml). Washed NK cell-derived supernatant was generated by activating NK cells with various 
PAMPs (indicated on x-axis). After 4h of  activation NK cells were extensively washed and activated for a 
total of  16-18h before harvesting of  the supernatant. As a negative control iDC were incubated without 
any NK cell supernatant and as positive control iDC were matured in the presence of  FMKp, IL-4, 
GM-CSF and rhIFN-γ (500U/ml). After 48h of  maturation, the DC culture supernatant was harvested 
and IL-12p70 was quantified by CBA. Representative graph out of  3 independent experiments is shown. 
(B) Correlation between NK cell-derived IFN-γ, respectively, TNF-α secretion (washed after 4h) and the 
corresponding DC-derived IL-12p70. Dots represent IFN-γ and TNF-α values of  NK cells activated by 
various PAMPs (x-axis panel A) and their corresponding DC-derived IL-12p70 values of  3 independent 
combined experiments. (C) Supplementation of  rhIFN-γ during DC maturation and its effect on cytokine 
and chemokine secretion is shown. iDC were matured in serum-free medium supplemented with FMKp, 
IL-4 and GM-CSF in the presence of  increasing concentrations of  rhIFN-γ. Cytokine and chemokine 
profiles were determined in the culture supernatants after 48h of  maturation by CBA. The individual 
donors are shown. (D) Blocking of  IFN-γ and TNF-α during DC maturation and its effect on cytokine
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0.07) and CXCL10 (3.12% ± 1.39) as compared to untreated DC matured in the presence of  
NK cell-conditioned medium (Figure 6D). In line with the supplementation of  rhIFN-γ, 
marginal or no effect was observed on the capacities of  DC to secrete IL-1β, IL-6 and CCL5. 
Furthermore, blocking of  TNF-α did not influence the cytokine secretion by DC. The same 
effect was observed for DC which have been matured in the presence of  poly(I:C)-activated 
NK cell-derived supernatant and blocking antibodies (data not shown). 
DISCUSSION
In the current study, we set out to investigate whether the direct sensing of  viral and bacterial 
pathogens would not only increase their cytotoxic potential as previously shown 22, 29-31, but 
also induce helper responses for DC maturation. We identified several viral and bacterial 
PAMPs able to induce functional activation of  NK cells (TLR1/2, TLR2, TLR2/6, TLR3, 
TLR4, TLR7/8, and TLR8 triggers) with respect to pro-inflammatory cytokine secretion 
(IFN-γ, TNF-α, CCL3, CCL5) and upregulation of  activation markers (CD69, CD25, 
CD83). We demonstrated that NK cells only showed limited responses towards TLR7 
triggers imiquimod and gardiquimod. The soluble factors released by these PAMP-triggered 
NK cells amplified the pro-inflammatory cytokine response of  moDC. This amplification 
of  DC responsiveness was dependent on the local cytokine environment in which the NK 
cells encountered the pathogen. Moreover, we demonstrated that NK cells mediated this 
helper activity via the release of  IFN-γ. 
Previously, a study of  Wong et al. 34 addressed the effect of  poly(I:C) on DC maturation 
during NK-DC co-culture. Here, we were interested in studying the contribution of  
TLR-triggered NK cells on DC maturation, rather than studying the effect of  TLR triggers 
on NK-DC crosstalk. We revealed that the helper activity of  both viral- and bacterial-
triggered NK cells on DC cytokine production, namely IL-12p70, IL-12p40, CXCL9, and 
CXCL10 was dependent on IFN-γ and not on TNF-α. The secretion of  IL-6, IL-1β and 
CCL5 was independent of  both cytokines. Previous studies postulated the importance 
of  TNF-α for DC maturation. Vitale et al. 42 showed that TNF-α was necessary for the 
upregulation of  CD83 on DC in a cell-cell contact-dependent setup. However, in our study 
no positive effect of  TNF-α was associated with the enhanced pro-inflammatory cytokine 
and chemokine secretion is shown. iDC were matured in the cell-free supernatant derived from FMKp-
activated NK cells in the presence of  IL-2. As indicated on the y-axis various blocking antibodies were 
added: anti-IFN-γ, anti-IFNGR1, anti-TNF-α, anti-TNFR1, and anti-TNFR2. iDC matured with NK 
cell-derived supernatant in the absence of  blocking antibodies (untreated) were used as reference value 
and set at 100% capacity to produce a cytokine/chemokine (x-axis). The negative control represents 
the capacity of  DC to produce the indicated cytokine upon maturation with FMKp in absence of  NK 
cell-derived supernatant. Mean + SEM of  3 independent experiments is shown.
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profile of  DC. An inhibitory role of  TNF-α on IL-12p70 production has previously 
been shown for mouse macrophages 43. It seems that TNF-α has a role in upregulating 
phenotype markers during DC maturation, but that IFN-γ is an essential factor controlling 
the pro-inflammatory cytokine release, mainly IL-12p70. Further studies are needed to 
reveal whether in a cell-cell contact-dependent setting, the helper activity of  NK cells is 
solely dependent on IFN-γ. The engagement of  TLR by NK cells and accessory cells can 
be accompanied by expression changes, such as the upregulation of  activating receptors and 
ligands 44, which could additionally boost NK cell responses in a contact-dependent manner. 
Moreover, the influence of  the cytokine milieu on the strength of  PRR-induced NK cell 
activation and the resulting helper properties suggest that the coordinated immune response 
induced by a particular pathogen can be influenced by all PRR-expressing immune cells. 
As such, an accessory cell can be triggered by a specific PAMP to release a defined set 
of  pro-inflammatory cytokines. In turn, these cytokines, e.g. IL-12, lead to an enhanced 
PAMP recognition by NK cells and their activation. Activated NK cells control the immune 
response by direct killing of  infected cells, Treg or by DC editing as well as providing 
cytokines and chemokines. TLR-activated NK cells are able to secrete CCL3, CCL4 and 
CCL5 to recruit iDC 33 as well as IFN-γ by which the DC maturation and Th1 polarization 
are further enhanced. Furthermore, those NK cells induce CXCL10 and CXCL9-producing 
CD8+ T effector cell-recruiting DC, which has been previously only observed with IL-18 
primed NK cells 33. The specific response against a pathogenic insult has thus different 
checkpoints, which act as regulators or amplifiers. We and others 22, 27 have shown that 
the recognition of  individual TLR by NK cells as well as the subsequent NK cell helper 
activity mostly requires the presence of  accessory cytokines. Thus, we propose that the 
direct sensing of  pathogens by NK cells functions as an amplifier of  the initiated immune 
responses, rather than initiator of  pathogen-specific immune responses. The accessory cells 
determine the local cytokine milieu and thus regulate the strength of  NK cell activation 
and subsequently the kinetics of  the NK helper cell-mediated augmentation of  immune 
responses.
The presence of  accessory cytokines was of  crucial importance for an optimal sensing of  
both bacterial and viral PAMPs and induction of  NK helper cell properties. Here we show 
that the addition of  IL-2, the combination of  IL-18 and IL-2, or IL-12, IL-15 and IL-18 
influence the activation of  NK cells and their helper activities, which were marginal in the 
absence of  these cytokines. NK cells briefly pre-activated by this combination of  cytokines 
(IL-12, IL-15 and IL-18) were previously shown to have a sustained effector function in 
tumour mouse models and an enhanced proliferative capacity as well as increased IFN-γ 
response over time in human in vitro studies 40, 41. We show that by adding FMKp, the helper 
capacity of  these NK cells to induce DC maturation can be further improved (up to 12-fold 
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increase in IL-12p70 secretion). 
We previously showed that DC-derived IL-12p70 was positively correlated with the 
capacity of  DC to induce Th1 responses and activate IFN-γ-producing NK helper cells 38. 
NK cell-derived IFN-γ production induced by DC-derived soluble factors was dependent 
on IL-12p70 20. Here, we showed that IFN-γ-producing NK helper cells can also be 
generated in the presence of  a TLR trigger and an accessory cell-derived cytokine, e.g. 
IL-2. This offers the possibility that cell-independent NK helper cell activation in vivo may 
occur via two different mechanisms, one being dependent on two signals of  which IL-12 is 
indispensable in the presence of  only soluble factors and the other independent of  IL-12 in 
the presence of  pathogenic triggers.
Among the different viral triggers tested in this study, poly(I:C) (TLR3 trigger), R848 and 
CL075 (both TLR7/8 triggers) activated NK cells most efficiently including the induction of  
helper properties. Previous studies showed that sensing of  these triggers stimulated cytolytic 
capacities 22, 31. Thus, sensing of  these PAMPs potentially induces both the helper and killer 
capacities of  NK cells. Nonetheless, the extent of  the induction of  both programmes may 
be dependent on the local cytokine environment in vivo. Notably, whereas both TLR7/8 
triggers induce NK helper properties, this effect was only observed for one of  the two 
TLR8 triggers and for none of  the TLR7 triggers. Even though, ssPolyU and ssRNA both 
induced NK cell activation to a similar extent (activation marker upregulation and chemokine 
secretion), ssPolyU failed at inducing IFN-γ production explaining the differences observed 
in providing help for DC-induced cytokine production. Activating human NK cells with 
imiquimod has previously been shown to enhance cytotoxicity of  NK cells, but not IFN-γ 
secretion 25. Furthermore, another study showed that both gardiquimod and imiquimod 
could enhance NK cell proliferation as well as cytotoxicity in mice 45. Yet another study 
observed enhanced IFN-γ secretion after activation of  NK cells with the TLR7 trigger 
loxoribine 29. Different from gardiquimod and imiquimod, which are both imidazoquinoline 
compounds, loxorobine is a guanosine analogue. Arguably, depending on the choice of  
compound to trigger TLR7, the NK helper programme will or will not get induced.
Previously, we showed indirect activation of  NK cells via DC that were matured in the 
presence of  bacterial pathogens 20. The current study confirms the findings of  other groups 
that NK cells have the capacity to directly respond to bacterial pathogens. In addition to 
these studies, we showed that the direct sensing of  bacterial pathogens by NK cells also 
enhances NK cell-mediated help for DC maturation and is not only limited to the induction 
of  their cytotoxic capacity. All the bacterial PAMP-triggered NK cells enhanced DC-derived 
IL-12 production. Possibly, the helper function may be a more important mechanism in 
response against bacterial pathogens than cytotoxic function. The strongest response 
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against bacterial PAMPs was induced by FMKp. In a previous study, we observed IL-18 
production by FMKp-matured DC 20. Together with the highest IL-1β production detected 
in the current study, this suggests the involvement of  inflammasome activation. Hence, 
a stronger response may be linked to simultaneous engagement of  multiple PRR, as the 
bacterial lysate FMKp possibly triggers a range of  different PRR. Arguably, autonomous 
activation of  NK cells by PRR occurs more easily upon multiple receptor stimulation as e.g. 
shown for HCMV infection or tuberculosis 46, 47.
Notably, we observed a large donor variation in response to the different triggers. Whereas 
some donors produced very high amounts of  IFN-γ after poly(I:C) stimulation, other 
donors hardly showed response. This is in line with previous work by our group revealing 
a large donor variation of  DC against a particular PRR trigger 38. Even though PRR are 
evolutionary conserved receptors, their expression levels vary substantially between 
different donors. Sivori et al. 48 and Marcenaro et al. 23 described varied expression levels 
of  TLR3, respectively TLR2, on NK cells from different individuals being a possible 
explanation between the heterogeneous responses observed. At this point it remains to be 
established whether or not other immune cell subsets of  these donors compensate for the 
low expression levels on NK cells, e.g. increased expression of  TLR3 by DC.
Taken together these data show that NK cells, besides their crucial role in host defence 
for the elimination of  virally infected or malignantly transformed self-cells, also serve an 
important role in the amplification of  adaptive immune responses. In the current study, we 
demonstrated that NK cells can sense viral as well as bacterial PAMPs, which is enhanced in 
the presence of  cytokines from accessory cells. TLR-induced NK helper cells can augment 
the pro-inflammatory phenotype of  DC via the production of  IFN-γ. The magnitude of  this 
amplification depends on the dose of  NK cell-derived IFN-γ and this dose is determined by 
the triggered PRR, the choice of  ligand for a particular PRR, and the cytokine environment 
in which the NK cell recognizes the microbial pattern. This illustrates once more the 
importance of  TLR network and how the invasion of  pathogens regulates a specific tailored 
immune response. Moreover, this knowledge can be of  importance to generate more potent 
and functional type 1-polarized cells in vitro and in vivo, e.g. for boosting vaccines.
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SUPPORTING INFORMATION
Supplementary Figure S1 | Supplementation of  rhIFN-γ during poly(I:C)/IFN-γ DC maturation 
and its effect on cytokine and chemokine secretion. iDC were matured in serum-free medium 
supplemented with poly(I:C), IL-4, and GM-CSF in the presence of  increasing concentrations of  rhIFN-γ. 
Cytokine and chemokine profiles were determined in the culture supernatants after 48h of  maturation by 
CBA. Three individual donors are shown.
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Supplementary Figure S2 | DC-derived pro-inflammatory cytokine and chemokine profile is not 
influenced by TNF-α. Supplementation of  rhTNF-α during DC maturation and its effect on cytokine 
and chemokine secretion is shown. iDC were matured in serum-free medium supplemented with FMKp, 
IL-4, and GM-CSF in the presence of  increasing concentrations of  rhTNF-α. Cytokine and chemokine 
profiles were determined in the culture supernatants after 48h of  maturation by CBA. Three individual 
donors are shown.
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ABSTRACT
Among prostaglandins (PG), PGE2 is abundantly expressed in various malignancies and is 
probably one of  many factors promoting tumour growth by inhibiting tumour immune-
surveillance. In the current study, we report on a novel mechanism by which PGE2 inhibits 
in vitro natural killer cell-dendritic cell (NK-DC) crosstalk and thereby innate and adaptive 
immune responses via its effect on NK-DC crosstalk. The presence of  PGE2 during 
FMKp/IFN-γ dendritic cell (DC) maturation inhibits the production of  chemokines 
(CCL5, CCL19, and CXCL10) and cytokines (IL-12 and IL-18), which is cAMP-dependent 
and imprinted during DC maturation. As a consequence, these DC fail to attract NK cells 
and show a decreased capacity to trigger NK cell IFN-γ production, which in turn leads 
to reduced T helper 1 (Th1) polarization. In addition, the presence of  PGE2 during DC 
maturation impairs DC-mediated augmentation of  NK cell cytotoxicity. Opposed to their 
inhibitory effects on peripheral blood-derived NK cells, PGE2-matured DC induce IL-22 
secretion of  inflammation-constraining NKp44+ NK cells present in mucosa-associated 
lymphoid tissue. The inhibition of  NK-DC interaction is a novel regulatory property of  
PGE2 that is of  possible relevance in dampening immune responses in vivo. 
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INTRODUCTION
Prostaglandins (PG) are potent immune modulators, which are produced during 
inflammation after the conversion of  arachidonic acid by cyclooxygenase (COX) 1. 
Furthermore, PG are also abundantly produced by various types of  tumours 2. COX2 
expression, which is correlated with a poor prognosis, is induced in a variety of  human 
premalignant and malignant tumours, including solid tumours as well as haematological 
malignancies 3-6. Several lines of  evidence demonstrate that COX2-derived PG are involved 
in the promotion of  tumour growth by regulation of  cancer cell proliferation, apoptosis, 
migration and invasion 7-11. PG are also produced by tumour-surrounding cells, creating a 
tumour-supporting environment by enhancing angiogenesis and inhibiting tumour immune 
surveillance 2, 11-14.
Of  all PG, PGE2 has a pivotal role in tumour immunosuppression. It has been hypothesized 
that this effect is caused by the induction of  a permanent state of  inflammation 2, 
resulting in phenotypic and functional changes of  T helper (Th) cells, cytotoxic T (CTL) 
cells, dendritic cells (DC), natural killer (NK) cells, and myeloid-derived suppressor cells 
(MDSC) 12. PGE2 has been shown to deviate Th cell skewing from an anti-tumour Th1 
response towards a Th2/Th17 response by directly binding to these cells 15-17. Additionally, 
PGE2 is responsible for shifting the balance of  IL-12/IL-23 production by DC towards 
IL-23, which is a very potent cytokine responsible for Th17 expansion and survival 18, 19. 
As a consequence, less IL-12 and other pro-inflammatory cytokines are produced, thus 
inhibiting Th1 polarization 17, 20. PGE2 also directly decreases the cytotoxic capacity of  CTL 
by inducing the expression of  inhibitory receptors on CTL 21 and indirectly by inhibiting 
DC maturation and antigen presentation 22, 23. Moreover, tumour-associated PGE2 has been 
reported to be responsible for the preferential attraction and induction of  regulatory T 
(Treg) cells, creating an immune-regulatory microenvironment 24, 25. 
Next to the modulating effects of  PGE2 on the effector mechanisms of  the adaptive 
immune response, PGE2 also has an effect on the innate immune response. NK cells, which 
are implicated in the innate defence against virally infected and malignantly transformed 
cells, have been reported to be affected by PGE2. It has been shown that PGE2 suppresses 
proliferation, cytokine secretion, migration, and NK cell-mediated cytotoxicity both in vivo 
and in vitro 26-30. 
Even though PGE2 has these direct effects on NK cells, it remains to be established whether 
PGE2 also has an effect on NK-DC crosstalk. We and others have previously reported on 
the importance of  NK-DC crosstalk in modulating adaptive immune responses 29, 31, 32. This 
crosstalk is characterized by DC-dependent recruitment of  NK cells and IFN-γ production 
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by NK cells, of  which the latter contributes to strong Th1 polarization 32. Additionally, DC 
augment NK cell-mediated cytotoxicity of  tumour cells. The DC-derived cytokines IL-12, 
IL-18, and IL-15 have been implicated in NK cell activation and IL-15 is also responsible 
for proliferation and survival of  NK cells 32, 33. 
In the current study, we investigated how PGE2 influences NK-DC interactions. We 
identified the effects of  PGE2 signalling on the production of  key chemokines and cytokines 
responsible for NK cell interaction with DC matured with IFN-γ and a membrane fraction 
of  Klebsiella pneumoniae (FMKp). We show that PGE2 not only has a direct effect on NK 
cells, but also indirectly alters DC-mediated NK cell effector functions. 
MATERIAL AND METHODS
Cell isolation
Mononuclear cells from peripheral blood (PBMC) of  healthy donors were isolated by 
density gradient separation using lymphoprep™ (Axis-Shield). NK cells and naive CD4+ 
T cells were negatively selected by immunomagnetic cell separation (Miltenyi Biotec). The 
purity of  isolated populations exceeded 95% as determined by flow cytometry. 
Human tonsils were obtained from the Department of  Otorhinolaryngology-Head & Neck 
Surgery, Maastricht University Medical Center. NK cells were isolated to a purity of  70-80% 
as described by Cella et al. 34. 
Generation of  DC
DC were prepared from peripheral blood-derived monocytes, isolated by density 
centrifugation and adherence as previously described 35. In addition, highly purified monocyte 
fractions obtained by elutriation of  leukapheresis products were used (purity >95%). 
Written informed consent was obtained from all leukapheresis donors in accordance with 
the Declaration of  Helsinki. For every experiment, DC from both isolation methods 
were used to avoid the effect of  contaminating NK cells (<5% in density centrifugation 
isolated monocytes) on the results. Differentiation of  monocytes was induced during 6 
days of  culture in AIM-V® medium (Gibco Life Technologies) containing 2000U/ml 
IL-4 (Strathmann Biotech) and 400U/ml GM-CSF (Berlex). DC were matured for 6h in 
AIMV® medium containing 500U/ml IFN-γ (Strathmann Biotech), 1µg/ml FMKp (Pierre 
Fabre) and different concentrations of  PGE2 (Sigma-Aldrich). After washing, to remove all 
maturation factors, DC were incubated for another 18h in medium only (total maturation 
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of  24h). Where indicated, 10µM butaprost (EP2 agonist), 35µM misoprostol (EP2/EP3/
EP4 agonist), 10µM sulprostone (EP1/EP3 agonist; Cayman Chemical), or 100µM of  
dibutyryl-cAMP (Alexis Biochemicals) were added. When selective EP-receptor agonists 
were compared, 10µM PGE2 was used. 
Flow cytometry
All antibodies for flow cytometry were obtained from BD Biosciences, except for CCR7, 
2B4, CXCR3, CCR5, NKp80, NKp44, IL-22 (R&D Systems), NKp30 (BioLegend) and 
NKG2A, NKG2D, CD158A, CD158B, CD158D, CD158E (Miltenyi Biotec GMbH). 
Cells were incubated with antibodies at proper dilutions for 30min at RT. Analyses were 
performed on a FACSCanto™ II (BD Biosciences) and analysed with BD CellQuest™ Pro 
Software (BD Biosciences), WinMDI (Joe Trotter, http://facs.scripps.edu/) or FlowJo 
(Treestar, Ashland, OR) software.
Migration assay
Migration of  NK cells was analysed as described previously 32. To analyse the effect of  
CCL5 reconstitution on NK cell recruitment, supernatant of  FMKp/IFN-γ-DC matured 
in the presence of  PGE2 was supplemented with 50ng/ml CCL5. Migration of  DC was 
analysed as described previously 35.
Cytokine and chemokine secretion by DC
Quantification of  IL-18, IL-12, IL-23, CCL5, CXCL10, and CCL19 in 24h maturation 
supernatants was performed using ELISA (MBL International Corporation and R&D 
Systems) according to manufacturer’s instructions. 
Cytokine production by NK cells
NK cell cells were either cultured in the presence of  PGE2 and stimulated with 
2.5µg/ml phorbol 12-myristate 13-acetate (PMA) and 2µg/ml ionomycin or with supernatant 
of  DC matured with different concentrations of  PGE2. To analyse the effect of  CCL5 
on NK cell recruitment, supernatant of  FMKp/IFN-γ-DC matured in the presence of  
PGE2 were supplemented with 2ng/ml IL-12 and/or 100pg/ml IL-18. Quantification of  
IFN-γ production was performed after 16h of  stimulation using an IFN-γ ELISA kit (R&D 
systems).
To evaluate IL-22 production by NK cells obtained from tonsils, NK cells were incubated 
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with DC in a 1:2 ratio. Flow cytometric analysis of  IL-22-secreting NK cells was performed 
as described by Cella et al. 34.
Th cell priming
In a 96-well plate, FMKp/IFN-γ-matured DC (0.4x105 cells/well) were coated with 1ng/ml 
Staphylococcal Enterotoxin B (SEB, Sigma-Aldrich) for 1h. SEB-coated DC, were washed 
and placed in culture with CD45RA+CD45RO-CD4+ T cells (105cells/well). Every other day 
stimulation medium was replaced with supernatant of  NK-DC cultures. In these NK-DC 
cultures, FMKp/IFN-γ-matured DC or FMKp/IFN-γ+1000ng/ml PGE2-matured DC 
(2x105 cells/well) were cultured with/without NK cells (105 cells/well). At day 10 the 
expanded Th cells were washed, plated in 96-well plates (105 cells/well), and stimulated 
with PMA/ionomycin (BD Biosciences). After 4h, cells were harvested and surface and 
intracellular staining was performed as described 32.
NK cell cytotoxicity assay
For NK cell-mediated lysis of  K562, unstimulated NK cells were co-cultured with K562 
cells for 4h in the presence of  different concentrations of  PGE2. For NK cell-mediated lysis 
of  Raji, NK cells were pre-activated for 18h by either supernatant of  FMKp/IFN-γ-DC 
matured in the presence of  different concentrations of  PGE2, medium alone or medium 
containing 1000U/ml IL-2 (Proleukin, Chiron Benelux BV). Target cells were labelled with 
3′-dioctadecyloxacarbocyanine (DiO) according to the manufacturer’s instructions (Sigma) 
and 2x104 target cells were incubated with pre-activated NK cells at various effector:target 
(E:T) ratios for 12h, each ratio in triplicate. Percentages of  killed target cells (PI+DiO+) were 
determined by flow cytometry. Percentages specific lysis were calculated as follows 36:
 % total target cell death - % spontaneous target cell death (PI+)
     % vital cells (% PI- cells not incubated with effector cells)
Statistics
Statistical significance of  differences between experimental samples was determined using 
Student’s t-test for paired samples, ANOVA or Wilcoxon signed-rank test. Significance was 
accepted at the * P<0.05, ** P<0.01, and *** P<0.001 levels. Data were analysed using Prism 
software version 5.0 (GraphPad Software).
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RESULTS
PGE2 directly inhibits NK cell cytokine production and NK cell-mediated cytotoxicity
We investigated whether PGE2 affects the expression of  inhibitory and activating receptors 
on the NK cell surface. To this end, freshly isolated NK cells were cultured for 24h in the 
presence or absence of  PGE2. As shown in Figure 1A, only expression of  NKG2D (NK 
cells: mean MFI 60.3±16 and NK cells + PGE2: mean MFI 34.8±9.7) and 2B4 (NK cells: 
mean MFI 103±4.5 and NK cells + PGE2: mean MFI 70.8±2.9) is significantly (P<0.05) 
reduced in six different donors (Wilcoxon signed rank test) due to PGE2 treatment. The 
expression of  the other activating and inhibitory NK cell surface markers, including specific 
Killer Immunoglobulin Receptors (KIRs), did not change. 
Figure 1 | Direct effect of  PGE2 on NK cell phenotype, cytotoxicity, and cytokine secretion. 
Freshly isolated NK cells were cultured for 24h in the presence of  PGE2. (A) Phenotypic analysis of  
NK cell surface receptor expression. Filled histograms, NK cells without PGE2; Black lines, NK cells 
with 1000ng/ml PGE2. Representative data of  one out of  6 different donors. (B) Flow cytometry-based 
NK cell cytotoxicity assay against K562 by NK cells cultured with different concentrations of  PGE2. 
Data shown are triplicates of  one representative experiment out of  4 different experiments. (C) IFN-γ 
production by NK cells cultured with different concentrations of  PGE2 and stimulated for 16h with PMA 
and ionomycin, as evaluated by ELISA. Results are presented as mean plus SEM and are obtained from 
3 different donors. * P<0.05.
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Additionally, the expression of  chemokine receptors CCR5, CXCR3, and CCR7 was 
evaluated, since these chemokine receptors are implicated in NK cell migration 29, 31. PGE2, 
however, had no effect on the expression of  these receptors. As PGE2 has been shown to 
enhance IL-23 receptor expression by Th17 cells 15, we evaluated if  PGE2 had the same 
effect on NK cells. Flow cytometric analysis showed that IL-23 receptor expression on 
NK cells was not altered. The effect of  PGE2 on surface expression of  the activating 
receptors 2B4 and NKG2D suggests that PGE2 has an inhibitory impact on NK cell 
effector functions. To evaluate this impact, cytotoxicity assays were performed in either the 
presence or absence of  PGE2. As target cells, K562 cells were used, since these cells fail 
to express HLA class I and are therefore efficiently killed by NK cells. A dose-dependent 
decrease in cytolytic activity was observed when PGE2 was present during the cytotoxicity 
assay (Figure 1B). Similar data have been reported previously 37. To evaluate the effect of  
PGE2 on IFN-γ production, a second NK cell effector function, NK cells were stimulated 
with PMA and ionomycin in the presence or absence of  different concentrations of  PGE2 
and 16h supernatant was evaluated by ELISA for the presence of  IFN-γ production. PGE2 
dose-dependently inhibited IFN-γ secretion (Figure 1C).  
Taken together these results show that PGE2 has a direct effect on NK cells, as it 
downregulates the expression of  the NK cell-activating receptors 2B4 and NKG2A and it 
dose-dependently inhibits NK cell-mediated cytotoxicity and IFN-γ secretion. 
Effect of  PGE2 on DC-derived chemokines is imprinted during maturation and 
inhibits NK cell recruitment 
NK cells can be recruited by mature DC ultimately leading to NK cell activation 31, 32, 38. 
This recruitment depends on DC-derived chemokines of  which CCL5, CXCL10 and 
CCL19 are the most important. To study whether PGE2 treatment of  DC influences NK 
cell recruitment linked to effects on the DC chemokine profile, we evaluated CCL19, 
CXCL10 and CCL5 secretion by DC after maturation in the presence or absence of  PGE2. 
To this end, monocyte-derived DC were matured with a membrane fraction of  Klebsiella 
pneumoniae (FMKp) and IFN-γ as previously described 35. DC were matured for 6h 
with FMKp/IFN-γ and different concentrations of  PGE2. After washing, to remove all 
maturation factors, DC were incubated for another 18h in medium only (total maturation 
of  24h). Effectiveness of  DC washing was evaluated by detection of  PGE2 by ELISA. In 
none of  the samples PGE2 was found (data not shown), indicating that FMKp/IFN-γ-
matured DC do not produce PGE2. Addition of  PGE2 during DC maturation did not affect 
upregulation of  HLA-DR and co-stimulatory molecules (CD80, CD83, CD86 and CD40), 
suggesting that addition of  PGE2 to the maturation cocktail did not hinder the development 
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of  mature DC (Figure S1 A). However, PGE2 did induce a significant increase in surface 
expression of  CCR7 (Figure S1 B). Increased CCR7 expression by TLR-triggered DC 
cultured in the presence of  PGE2 has been described previously 
39. FMKp/IFN-γ-matured 
DC also showed a dose-dependent increase of  CCR7 expression, which indeed resulted 
in functionally increased responsiveness to the lymph-node associated chemokine CCL19 
(Figure S1 C). 
Chemokine (CXCL10, CCL19 and CCL5) production was evaluated by culturing DC for 14h 
in the presence of  different PGE2 concentrations and quantified by ELISA (Figure 2A). 
Production of  these chemokines significantly decreased with increasing concentrations 
of  PGE2. Since CCR5 has been identified to be the most important chemokine receptor 
responsible for NK cell recruitment by FMKp/IFN-γ-matured DC 32, the negative effect of  
PGE2 on CCL5 production suggested a decrease in the capacity of  PGE2-matured DC to 
recruit NK cells. To test this hypothesis, migration assays were performed. Freshly isolated 
NK cells were allowed to migrate during 1.5h towards the supernatant of  DC matured in 
the presence of  different concentrations of  PGE2. NK cell recruitment was significantly 
decreased when increasing doses of  PGE2 were added during DC maturation (Figure 2B). 
Since DC were extensively washed after 6h of  maturation, DC supernatant did not contain 
any PGE2 anymore, therefore NK cells were not directly exposed to PGE2. This indicates 
that the negative effect on NK cell migration does not depend on an effect of  PGE2 on NK 
cell chemokine receptors, which has previously been described 29. After supplementing the 
supernatant of  PGE2-matured DC with CCL5, NK cell recruitment was restored, indicating 
that indeed the effect of  PGE2 on CCL5 production was responsible for decreased NK cell 
recruitment (Figure 2C).
DC have been shown to express all four different EP receptors 40. To evaluate which 
EP receptors mediate the effect of  PGE2 on chemokine production by DC, they were 
stimulated with specific agonists that preferentially bind to one or more EP receptors 
(Figure 2D). Stimulation with butaprost and misoprostol reduced CXCL10 and misoprostol 
also inhibited CCL5 secretion significantly, whereas sulprostone did not alter secretion of  
these chemokines. This indicates that mainly EP2 and EP4 signalling are responsible for 
the effect of  PGE2 on the reduced secretion of  CXCL10 and CCL5. In contrast, CCL19 
production was equally affected by mistoprostol and butaprost, demonstrating that EP2 
is the most important EP receptor involved in the inhibition of  CCL19 production. The 
addition of  the intracellular cAMP analogue dibutyryl-cAMP mimicked the effect of  PGE2 
for production of  all three chemokines, suggesting that the effect of  PGE2 was dependent 
on cAMP signalling. 
To evaluate whether the effect of  PGE2 on chemokine production by DC is imprinted 
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Figure 2 | PGE2 inhibits DC-derived CXCL10, CCL5 and CCL19 secretion. Monocyte-derived 
DC were matured with FMKp/IFN-γ in the presence of  different concentrations of  PGE2. After 6h 
maturation, DC were washed to remove the stimulation medium, and matured for an additional 18h 
in AIM-V® medium only. (A) Quantitative comparison of  CXCL10, CCL5 and CCL19 production as 
measured by ELISA. Results shown are the mean plus SEM of  combined data of  at least 5 different 
donors. (B) Percentage of  NK cells migrated in 1.5h towards cell-free supernatant of  FMKp/IFN-γ-DC 
matured in the presence of  different concentrations of  PGE2. Data were calculated as percentage of  
migrated NK cells. Results presented are the mean plus SEM of  combined data of  11 different donors. 
(C) Percentage of  NK cells migrated in 1.5h towards cell-free supernatant of  FMKp/IFN-γ DC matured 
in the presence of  PGE2 and supplemented with 50 ng/ml CCL5. Data were calculated as percentage of  
migrated NK cells, normalized to NK cell migration towards FMKp/IFN-γ-DC matured without PGE2. 
Results presented are the mean plus SEM of  combined data of  4 different donors. (D) Quantitative 
comparison of  CXCL10, CCL5 and CCL19 production after stimulation with different EP receptor 
agonists and cAMP as measured by ELISA. Results shown are the mean plus SEM of  combined data 
of  at least 4 different donors. (E) Quantitative comparison of  CXCL10, CCL5 and CCL19 production 
after stimulation with PGE2 either during or after DC maturation as measured by ELISA. Results shown 
are the mean plus SEM of  combined data of  at least 4 different donors. * P<0.05; ** P<0.01; *** P<0.001.
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during maturation or whether PGE2 can also exert its suppressive effect after initiation of  
maturation, chemokine production of  DC was analysed when PGE2 was added during or 
after the first 6h of  DC maturation. After a total of  24h maturation, chemokine production 
was evaluated (Figure 2E). A decrease in CXCL10 and CCL5 secretion could only be 
detected when PGE2 was present during the first 6h of  maturation. CCL19 production 
was also affected by PGE2 after the 6h maturation period, however the effect was less 
pronounced as compared to the effect of  immediate addition of  PGE2. 
These results indicate that the negative effect of  PGE2 on production of  DC-derived 
CXCL10, CCL5 and CCL19 is imprinted during maturation and depends on EP2/EP4-
mediated cAMP signalling. In addition, we show that the NK cell recruiting capacity of  DC 
is reduced due to the influence of  PGE2.
Effect of  PGE2 on DC-derived IL-12/IL-18 production is imprinted during 
maturation and inhibits NK cell-derived IFN-γ secretion 
We previously showed that production of  IL-12 and IL-18 by FMKp/IFN-γ-matured DC is 
needed to induce NK cell activation 32. To evaluate the effect of  PGE2 on NK cell activation, 
production of  these cytokines by FMKp/IFN-γ-DC stimulated with PGE2 was determined 
in 24h DC supernatant. As described previously, TLR-triggered DC produce less IL-12 
when matured in the presence of  PGE2 
17, 39. We show here that PGE2 also has this effect on 
IL-12 production by FMKp/IFN-γ-matured DC and, additionally, PGE2-triggering results 
in less IL-18 secretion (Figure 3A). Moreover, PGE2 exerted its effect on the secretion 
of  these cytokines only when it was present during DC maturation, as evidenced by lack 
of  inhibition of  IL-12 and IL-18 production when PGE2 was added after the 6h DC-
maturation period (Figure 3B).
NK cell activation, evaluated by IFN-γ production of  NK cells cultured for 16h in DC 
supernatant, was significantly reduced when DC were matured in the presence of  PGE2 
(Figure 3C). NK cell activation was completely restored after addition of  IL-12 to the 
supernatant of  FMKp/IFN-γ DC matured in the presence of  PGE2, indicating that the 
effect of  PGE2 on DC-mediated NK cell activation mainly depends on the inhibition of  
IL-12 secretion (Figure 3D). Although the decrease in DC-mediated NK cell activation 
is caused by the decrease in IL-12 secretion, these data do not exclude that other factors 
might contribute. One candidate cytokine produced by TLR-triggered DC in the presence 
of  PGE2 is IL-23, a cytokine implicated in the induction of  Th17 responses 
19. Also 
FMKp/IFN-γ -matured DC produce IL-23, which is enhanced when DC are matured in 
the presence of  PGE2 (Figure 3E), albeit with an apparent optimum at 50ng/ml PGE2. 
The addition of  IL-23 to DC supernatant during NK cell activation did not affect IFN-γ 
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production by NK cells (data not shown).
These data indicate that PGE2 added to the maturation of  DC is not only responsible 
for decreased production of  the NK cell-activating cytokines IL-12 and IL-18, but also 
enhances IL-23 secretion. 
Figure 3 | PGE2 inhibits DC-derived NK cell activation. Monocyte-derived DC were matured with 
FMKp/IFN-γ in the presence of  different concentrations of  PGE2. After 6h maturation, DC were 
washed to remove the stimulation medium, and matured for an additional 18h in AIM-V® medium only. 
(A) Quantitative comparison of  IL-12 and IL-18 production as measured by ELISA. Results shown are 
the mean of  combined data of  at least 4 different donors plus SEM (IL-12, n=16; IL-18, n=4). (B) 
Quantitative comparison of  IL-12 and IL-18 production after stimulation with PGE2 either during or 
after 6h DC maturation as measured by ELISA. Results shown are the mean of  combined data of  at least 
3 different donors plus SEM. (C) NK cell IFN-γ production, as measured by ELISA, after incubation 
for 16h with DC supernatant. Results presented are the mean plus SEM of  combined data of  11 
different donors. (D) NK cell IFN-γ production, as measured by ELISA, after incubation for 16h with 
DC supernatant, or DC supernatant supplemented with 2ng/ml IL-12, 100pg/ml IL-18 or both. Results 
presented are the mean plus SEM of  combined data of  6 different donors. (E) Quantitative comparison 
of  IL-23 production as measured by ELISA. Results shown are the mean plus SEM of  combined data of  
4 different donors. * P<0.05; ** P<0.01; *** P<0.001.
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Presence of  PGE2 during DC maturation stimulates IL-22 production by NKp44+ 
NK cells isolated from human tonsils 
Recent studies showed that in mucosa-associated lymphoid tissue, an NK cell subset 
with inflammation-restraining properties resides. This NKp44+ subset produces IL-22, 
IL-26, and LIF in response to IL-23 or after co-culture with TLR-matured DC and is 
not proficient at typical NK cell functions such as cytotoxicity and IFN-γ secretion 34. In 
contrast to conventional NK cells, that secrete cytokines in response to IL-12, this NK cell 
subpopulation produces IL-22 after IL-23 triggering and, to a lesser extent, after triggering 
with IL-6 and IL-15 34. Furthermore, these NKp44+ NK cells express the transcription 
factor RORγT and therefore show functional and phenotypic similarity to Th17 cells 41,42. 
Given the positive effect of  PGE2-matured DC on the induction of  Th17 cells 
15, we 
hypothesized that the addition of  PGE2 to FMKp/IFN-γ maturation of  DC may enhance 
activation of  NKp44+ cells. 
To test this hypothesis, NK cells were isolated from human tonsils and co-cultured for 
16h with DC that were matured in the presence or absence of  50ng/ml PGE2. Production 
of  IL-22 by NKp44+ NK cells was evaluated by flow cytometry. There was a significant 
increase in percentage of  NK cells accumulating IL-22 when NK cells were co-cultured 
with PGE2-stimulated DC as compared to co-cultures with DC matured in the absence of  
PGE2 (Figure 4A, B). Notably, the IL-22 producing NK cell subset expressed NKp44+ and 
did not accumulate IFN-γ. 
Taken together, these data indicate that PGE2 is responsible for the induction of  DC that 
activate inflammation-restraining NK cells. 
Figure 4 | Effect of  PGE2-matured DC on IL-22 production by NK cells residing in the tonsil. 
Monocyte-derived DC were matured with FMKp/IFN-γ in the presence or absence of  50ng/ml PGE2.
After 6h maturation, DC were washed to remove the stimulation medium, and matured for an additional 
18h in AIM-V® medium only. (A) Percentage of  NKp44+ NK cells isolated from tonsils, accumulating 
IL-22 after 16h of  co-culture as analysed by flow cytometry, gated on CD56+CD3- cells. Representative data 
of  one out of  6 independent experiments are shown. (B) NKp44+ NK cells accumulating intracellular IL-
22 of  7 different donors. In 6 out of  7 donors an increase in % of  IL-22 positive NK cells was observed. 
Wilcoxon signed-rank test significance, * P<0.05.
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Figure 5 | Effect of  PGE2-matured DC on NK cell functions. (A) FMKp/IFN-γ-matured DC 
with or without 5µg/ml PGE2 were cultured for 24h in the presence or absence of  freshly isolated NK 
cells. FMKp/IFN-γ-matured DC were coated with Staphylococcal Enterotoxin B and co-cultured with 
freshly isolated CD45RA+CD45RO-CD4+ Th cells. Every other day stimulation medium was exchanged 
with supernatant from FMKp/IFN-γ-matured DC (with or without 5µg/ml PGE2) cultured with or 
without NK cells. (B) Percentage of  naive CD4+ T cells accumulating IFN-γ after 10 days of  co-culture 
and stimulation with PMA/ionomycin for 4h as analysed by flow cytometry, gated on CD4+CD3+ T
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Decreased activation of  NK cells by PGE2-matured DC inhibits NK cell-dependent 
Th1 polarization and augmentation of  cytotoxicity
NK cell-derived IFN-γ has been implicated in the induction of  Th1 polarization 31, 43. 
Consequently, it can be anticipated that the decreased activation of  NK cells by DC matured 
in the presence of  PGE2 results in decreased Th1 polarization. To evaluate whether this 
hypothesis is true, DC (washed after 6h maturation) were matured with or without PGE2 and 
after 24h NK cells were added. In this experiment we were only interested in the effect of  
NK cell-derived cytokines on Th1 polarization and not in the previously reported negative 
effect of  PGE2-matured DC on Th1 skewing. Therefore, DC without PGE2 stimulation 
were coated with SEB and used in a T cell stimulation assay. To study the effect of  NK 
cell-secreted cytokines, T cell stimulation medium was exchanged every other day by the 
supernatant of  the NK-DC co-cultures (Figure 5A). Th1 polarization was detected by 
accumulation of  the Th1 cytokine IFN-γ (Figure 5B). Only T cells stimulated with medium 
of  NK-DC co-cultures, in which the DC were not triggered with PGE2 during maturation, 
benefited from the Th1 polarizing effect of  NK cells, as more IFN-γ producing T cells were 
detected (Figure 5C). 
Previously, we showed that FMKp/IFN-γ-matured DC are able to augment NK cell 
cytotoxicity, which is mediated by DC-derived IL-12 32. These observations opened 
the possibility that PGE2-triggering of  DC could abrogate the beneficial effect on NK 
cell cytotoxicity. To evaluate this, kill assays against the NK-cell resistant Raji cells were 
performed. Raji cells are insensitive for lysis by naive NK cells, however, if  NK cells are 
pre-activated, they become able to kill Raji cells. When DC were matured with increasing 
concentrations of  PGE2, NK cell-mediated lysis of  target cells decreased (Figure 5D). 
These data indicate that PGE2 does not only inhibit NK cell cytotoxicity via direct action 
on NK cells (Figure 1B), but also indirectly affects augmentation of  NK cell cytotoxicity 
via its effect on DC maturation. Taken together, these data show that PGE2 inhibits NK 
cell-mediated cytotoxicity via two independent mechanisms.
To determine whether activation of  NK cells by NK-DC crosstalk could overcome the 
cells. Representative data of  one out of  5 independent experiments are shown. (C) CD45RA+CD45RO-
CD4+ Th cells accumulating intracellular IFN-γ. Results are represented as mean of  combined data of  5 
different donors plus SEM. (D) Freshly isolated human NK cells and undiluted, filtered supernatants of   
FMKp/IFN-γ-DC matured in the presence of  different concentrations of  PGE2 were used for induction 
of  NK cell cytotoxicity. NK cell cytotoxicity towards Raji cells was assessed by a flow cytometry-
based kill assay. Data represent means ± SEM of  triplicate wells. Data shown are representative of  3 
independent experiments. (E) Cytotoxicity towards Raji cells without, after pre-incubation and early 
incubation of  NK cells with PGE2 and activation in DC supernatant. Data represent means plus SEM 
of  triplicate wells of  E:T ratio of  10:1. Data are representative of  3 independent experiments. * P<0.05.
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negative effect of  PGE2 on NK cell-mediated cytotoxicity, killing of  Raji cells was tested 
with either NK cells pre-incubated with PGE2 (pre-incubation) before stimulation with DC 
supernatant or NK cells triggered with PGE2 during stimulation with DC supernatant (early 
incubation). Flow cytometric analysis showed that NK cells pre-incubated with PGE2 are 
able to kill Raji cells when activated by DC (Figure 5E). When PGE2 was present during 
the NK cell activation, the killing of  Raji cells was decreased. However, when NK cells are 
pre-activated by DC, PGE2 had a minor inhibitory effect on NK cell cytotoxicity, indicating 
that the negative effect of  PGE2 on NK cells is partly overcome. 
In summary, these results show that PGE2-matured DC inhibit NK-cell mediated Th1 
polarization and also suppress augmentation of  NK cell killing capacity. 
DISCUSSION
COX2-derived PGE2 is abundantly expressed in various malignancies and is one 
of  many factors that directly promote tumour growth by regulation of  cancer cell 
proliferation, apoptosis, migration, and invasion 7-11. Moreover, PGE2 plays a pivotal role 
in immunosuppression creating a tumour supportive environment by inhibiting tumour 
immunosurveillance. Increasing the knowledge about the mechanisms by which PGE2 
mediates immunosuppression is crucial in understanding tumour formation and might lead 
to the development of  new immunotherapeutic strategies for cancer. 
In this paper, we report on a novel mechanism by which PGE2 inhibits NK cell effector 
functions. In addition to its inhibition of  NK cell activation by direct binding to NK 
cells, PGE2 also inhibits crosstalk with FMKp/IFN-γ-matured DC. This is mediated via 
modulation of  chemokine and cytokine secretion of  FMKp/IFN-γ-matured DC, which is 
responsible for inhibition of  NK cell recruitment and activation. We show that PGE2 has 
an inhibitory effect on the secretion of  CCL5, CXCL10, and CCL19, which are implicated 
in NK cell migration 31, 38. Decreased production of  DC-derived CCL19 (implicated in naive 
T cell recruitment) and CCL5 due to PGE2-triggering has recently been described 
22, 44. 
Interestingly, the effect of  PGE2 on chemokine secretion is imprinted during DC maturation 
as we show that PGE2 stimulation after maturation does not influence chemokine secretion.
Additionally, our data evidence that NK cell activation is altered due to the effect of  
PGE2 on FMKp/IFN-γ DC-derived cytokine secretion. PGE2-induced changes in the 
IL-12/IL-23 balance of  DC have been described to account for skewing of  Th1 responses 
towards Th2/Th17 responses 15, 16, 19. Here, we show that it is also responsible for decreased 
IFN-γ secretion by NK cells. In addition, PGE2 is responsible for decreased production 
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of  IL-18, which is besides IL-12 an important cytokine for NK cell activation. This is 
in apparent paradox to the reported IL-18-mediated induction of  PGE2 secretion in 
the synovial fluid of  osteoarthritis patients 45. Possibly, this represents a feed-back loop 
by which PGE2 constrains inflammation during a normal immune response. Mainly the 
decreased production of  IL-12 by FMKp/IFN-γ-matured DC due to PGE2 accounts for 
the inhibition on IFN-γ secretion, since addition of  IL-12 restores IFN-γ secretion by 
NK cells. However, our data do not preclude that other cytokines that have an inhibitory 
effect on NK cell activation are produced by DC in response to PGE2-triggering. As a 
functional consequence of  the DC-mediated effect of  PGE2 on NK cell activation, NK cell-
dependent Th1 polarization and tumour cell lysis are inhibited. Interestingly, the reported 
effect of  PGE2 on NK-DC interaction was not only demonstrated for monocyte-derived 
DC, but also for blood-derived BDCA-1+ DC that were matured with FMKp/IFN-γ in 
the presence of  PGE2 (Figure S2). Additionally, the effect of  PGE2 could also be induced 
by tumour cell-derived PGE2. Under different cell culture conditions the same tumour 
cells did not produce PGE2, but were still able, though less efficiently, to inhibit NK-DC 
crosstalk (Figure S3 A, B). A candidate for this inhibition is TGF-β, which is possibly one 
of  many immunosuppressive factors produced by this cell line (Figure S3 C). These data 
illustrate the redundancy of  different tumour-derived factors on NK-DC crosstalk during 
different culture conditions. We anticipate that among the many mechanisms tumours have 
to escape immunosurveillance, PGE2 is very potent to prevent NK-DC interactions because 
the application of  COX-inhibitors in tumour-bearing mice completely restores the reduced 
CCL5 and IL-12 production of  myeloid cells 14, 44. 
In relation to the enhanced production of  IL-23 by PGE2-stimulated DC, it is relevant to 
note that Cella et al. reported on an NK cell subset (NK-22 cells) that resides in mucosa-
associated lymphoid tissue, expresses NKp44 and produces IL-22 rather than IFN-γ upon 
IL-23, IL-6, and IL-15 stimulation 34. Additionally, they showed that these NK cells produce 
IL-22, IL-26, and leukemia inhibitory factor after contact with IL-23-producing monocytes 
that were stimulated with LPS. This NK cell subset was suggested to contribute to mucosal 
homeostasis, since IL-22 induces production of  the anti-inflammatory cytokine IL-10 by 
epithelial cells 34, 41, 46, 47. We show here that PGE2 is responsible for the maturation of  
DC that are capable of  inducing mucosal NKp44+, IL-22-secreting NK cells and not 
IFN-γ-secreting peripheral NK cells. Given the fact that NKp44+ NK cells produce IL-22 in 
response to IL-23, the increased IL-23 secretion of  PGE2-matured FMKp/IFN-γ DC could 
represent one of  several mechanisms by which DC induce IL-22 secretion of  these NK 
cells 34.In this light, it is interesting to note that IL-22 as well as tumour-derived PGE2 have 
the same immune-protective effects on epithelial cells, which is characterized by increased 
proliferation and decreased apoptosis 7. It can be hypothesized that the IL-22, secreted by 
NK cells, also has this effect on tumour cells (Figure S4). Future studies addressing this 
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question are of  significance to elucidate the function of  these NKp44+ NK cells in cancer.
As demonstrated by us and others, PGE2 induces expression of  CCR7 on DC and 
functionally increases their migratory responsiveness to lymph node-homing chemokines 
in vitro 22, 35, 39. Based on these observations, PGE2 is often incorporated in DC maturation 
cocktails used in clinical vaccination studies. Our data on the inhibitory effect of  PGE2 
on NK-DC interaction in combination with previous reports on enhanced Th17 and Th2 
induction by PGE2-matured DC and the decreased ability to induce antigen-specific CTL 
35 
argue against the use of  PGE2-matured DC in DC-based vaccines, as it does not contribute 
to in vivo DC migration and has detrimental effects on immune effector mechanisms. In 
addition, Muthuswamy et al. showed that increased CCR7 expression of  PGE2-matured 
DC, as compared to TLR-matured DC, correlates with their lack of  CCL19 production 48. 
If  TLR-matured DC that express low levels of  CCR7 are cultured in an environment with 
low concentrations of  CCL19, CCR7 expression is increased. Additionally, they showed 
in a clinical trial that PGE2-matured DC demonstrated no advantage over TLR-triggered 
DC in lymph node homing. In the current study, we show that the effect of  PGE2 is 
imprinted during FMKp/IFN-γ-DC maturation since cytokine and chemokine secretion is 
only affected by PGE2 in the first 6h of  maturation and this effect is mainly mediated via 
EP2 and EP4 and depends on cAMP signalling. In terms of  vaccination protocols, these 
data support the application of  ex vivo-matured DC in patients with tumours secreting 
PGE2. Moreover, our data indicate that PGE2 does not induce permanent changes in NK 
cell cytotoxic capacity, since the suppressive effect of  PGE2 on NK cells can be easily 
overcome by DC-induced NK cell activation. However, to effectively activate NK cells, 
NK-DC interaction should take place in an environment with low concentrations of  PGE2, 
emphasizing the need of  NK cell recruitment by DC. Our results also open the possibility 
to combine DC vaccination with COX2-inhibitory therapy, which has previously been 
shown in mouse models to enhance the efficacy of  cancer vaccines 49, 50. 
In conclusion, we report on a novel immunosuppressive effect of  PGE2, mediated by 
FMKp/IFN-γ-matured DC, on NK cell function. These current data help to understand 
the complex role of  PGE2 in the regulation of  immune responses during inflammation. 
The extent of  the PGE2-effect on the immune system in relation to other tumour-derived 
factors and thereby the redundancy of  this mechanism is yet not completely elucidated and 
in vivo studies should be performed to answer this question. However, we show in vitro that 
the immunosuppressive effect of  PGE2 on NK-DC interaction possibly represents one of  
many tumour-mediated mechanisms to hamper acute immune responses. 
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SUPPORTING INFORMATION
Supplementary Figure S1 | Effect of  PGE2 on surface expression of  maturation markers by DC 
matured with FMKp/IFN-γ and migration toward CCL19. Monocyte-derived DC were differentiated 
for 6 days by IL-4 and GM-CSF into immature DC. Maturation was induced by FMKp/IFN-γ in the 
presence or absence of  5μg/ml PGE2. After 6h maturation, DC were washed to remove the stimulation 
medium. DC were matured for an additional 18h in AIM-V® medium only. (A) Surface expression of  
HLA-DR, CCR7, CD80, CD83, CD86 and CD40 was evaluated by flow cytometric analysis. Grey filled 
histograms represent immature DC, solid black lines FMKp/IFN-γ-matured DC and grey lines represent 
FMKp/IFN-γ-matured DC in the presence of  5μg/ml PGE2. Representative data of  one out of  four 
different donors. (B) Expression of  CCR7 as evaluated by flow cytometry. Results are presented as mean 
MFI plus SEM and are obtained from 3 different donors. (C) Percentage of  DC specifically migrated 
towards a CCL19 gradient (250ng/ml). Results are presented as mean plus SEM and are obtained from 3 
different donors that were analysed in triplicate. ANOVA significance, * P<0.05, ** P<0.01.
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Supplementary Figure S2 | Phenotype, cytokine production and NK cell-activating properties 
of  blood-derived BDCA-1+ DC. BDCA-1+ DC were isolated from 500ml of  fresh blood using an 
immunomagnetic, negative isolation kit (Miltenyi Biotec). Cells were seeded at a density of  5x105  
cells/ml in a 24-well plate and matured with FMKp/IFN-γ or with FMKp/IFN-γ in the presence of  
PGE2. 6h after maturation induction, the maturation stimuli were removed by extensive washing and 
DC were incubated in serum-free medium for 42h. (A) Flow cytometric characterization of  differently 
matured BDCA-1+ DC. Grey, filled histograms represent the surface expression observed in non-matured 
BDCA-1+ DC, black line histograms represent the FMKp/IFN-γ-matured BDCA-1+ DC and grey line 
histograms represent FMKp/IFN-γ-BDCA-1+ DC matured in the presence of  PGE2. Representative data 
of  2 independent experiments are shown. (B) CCL5 production by differently matured BDCA-1+ DC as 
measured by ELISA. Data show the mean+SD of  2 independent experiments. (C) IFN-γ secretion of  
NK cells cultured in the supernatant of  the three differently matured BDCA1+ DC. Fresh NK cells were 
cultured in the supernatant of  differently matured BDCA1+ DC. After 24h the supernatant was harvested 
and IFN-γ was quantified with ELISA. NK cells from 2 different donors were cultured in supernatants of  
2 different BDCA-1+ DC donors (ANOVA significance, *P<0.05).
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Supplementary Figure S3 | Effect of  A549 cell-derived factors on NK-DC interaction. (A) IL-12 
secretion of  FMKp/IFN-γ matured DC in serum-free or A549 tumour cell-conditioned medium with or 
without PGE2. The A549 cell line was cultured for 48 h in serum-free AIM-V
® medium in presence or 
absence of  (250µM) arachidonic acid (AA). Immature DC were matured either in tumour cell-conditioned 
medium (PGE2-producing or not) or in AIM-V
® supplemented with FMKp/IFN-γ in the presence 
or absence of  rhPGE2. After 6h, maturation stimuli were washed away and DC were incubated for an 
additional 18h in AIM-V®. Supernatant was collected and IL-12 was determined by ELISA. Data show the 
mean of  2 donors. (B) NK cell-derived IFN-γ production in supernatant of  FMKp/IFN-γ-DC matured 
in AIM-V® or tumour cell-conditioned medium in presence or absence of  PGE2 (recombinant or tumour 
cell-derived). Freshly isolated NK cells were co-cultured for 16h with differently matured DC. IFN-γ was 
quantified using Cytometric Bead Array (CBA). Shown results represent the mean plus SEM of  NK cells 
from 2 different donors added to the supernatants of  2 different DC donors (n=4). (C) The A549 cell 
line was cultured for 4 days in serum-free medium with (250µM) or without AA. TGF-β and PGE2 were 
quantified using ELISA.
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Supplementary Figure S4 | Model of  the inflammation-restraining effects of  PGE2 on NK-DC 
interaction on tumour development. Presence of  tumour-derived PGE2 during DC maturation inhibits 
the production of  NK cell-recruiting chemokines (CCL5, CCL19, and CXCL10) and thereby decreases 
NK cell recruitment. Additionally, PGE2 reduces IL-18 production by DC and shifts the IL-12/IL-23 
balance toward IL-23 production. This results in decreased IFN-γ production and cytotoxic capacity of  
peripheral blood NK cells and enhanced secretion of  IL-22 by NK cells residing in mucosa-associated 
lymphoid tissue. Decreased IFN-γ production of  NK cells together with the altered cytokine profile of  
PGE2-matured DC is responsible for inhibition of  Th1 polarization. Tumour development is possibly 
stimulated by three independent effects of  PGE2: 1) Direct effect of  PGE2 on tumour cell proliferation 
and apoptosis, 2) decreased killing of  tumour cells by NK cells that were either directly stimulated with 
PGE2 or interacted with PGE2-triggered DC and 3) effects of  IL-22, produced by NK cells that interacted 
with PGE2-stimulated DC, on tumour cell proliferation and apoptosis.
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INTRODUCTION
In 2011, Hanahan and Weinberg published ′the next generation of  hallmarks of  cancer′ in 
which the classical hallmarks were extended from six to eight core hallmarks and two enabling 
characteristics 1. Evasion of  immune destruction is one of  the newly recognized hallmarks 
and tumour-promoting (chronic) inflammation represents an enabling characteristic. This 
indicates on the one hand emerging complexity of  tumour cell biology, but on the other 
hand also great progress in understanding initiation, sustainment, and progression of  cancer. 
The role of  the immune system in the elimination but also in the development and 
progression of  cancer as well as possible treatment target has been explored by scientists 
since the early 1890’s. In the majority of  the cases, the immune system recognizes and 
eliminates invading pathogens as well as altered cells and ensures protection of  the host, 
(immunosurveillance). This concept was proven to hold true in several studies using 
genetically engineered mice, e.g. lacking IFN-γ receptor, which showed higher tumour 
incidence as compared to their immunocompetent counterparts 2. In case of  cancer, the 
concept of  immunosurveillance has been extended to cancer immunoediting, including 
the elimination phase (immunosurveillance), the equilibrium phase (survival of  poorly 
immunogenic cells which undergo editing) and the escape phase (edited tumour cells grow 
out) 2, 3. As the immune system can both antagonize and enhance tumour progression, its 
targeting represents an interesting therapeutic approach. 
Immunotherapy aims to stimulate or modulate the body’s own immune response to 
specifically recognize and attack the tumour cells. This is different from conventional anti-
cancer treatment regimens (e.g. chemotherapy, radiotherapy and surgery) whose primary 
goal is the direct targeting of  the tumour; thus immunotherapy presents a different 
treatment approach. The development of  cancer immunotherapy dates back more than a 
century and includes various strategies (recombinant protein technologies and cell-based 
therapies) as the tumour employs various strategies to evade immune-mediated attack. 
Several immunotherapeutic treatments have been approved as cancer treatment in the 80’s 
and 90’s including monoclonal antibodies (mAb) as well as cytokines, however, it is only 
more recently that a revival of  cancer immunotherapy has occurred. The FDA-approval of  
the first therapeutic cellular vaccine Provenge® (2010) was followed by the approval of  two 
different checkpoint inhibitors (anti-CTLA-4 and PD-1) 4. The latter target a receptor mainly 
expressed on T cells, which ligation would normally prevent the effector cells to attack 
tumour cells, a phenomenon sometimes referred to as ′releasing the breaks′. Anti-CTLA-4 
(ipilimumab) treatment in patients with advanced melanoma increased the median survival 
by 4 months compared with patients treated with an experimental vaccine (gp100; 10 vs. 6 
months median survival) 5. Results for anti-PD-1 treatment were even more promising, in 
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which 30% of  patients with metastatic melanoma showing significant tumour regression 6. 
Moreover, another cell-based therapy, the chimeric antigen-receptor (CAR) therapy, which 
aims to program the T cells to kill the cancer cells, displayed promising results in clinical 
trials 7. Altogether, these novel approaches with very promising success rates of  clinical 
studies did lead to the designation of  cancer immunotherapy as breakthrough of  the year 
in 2013 8. 
As mentioned earlier several approaches of  immunotherapy exist, which are currently under 
development and optimization, among them cellular therapeutic vaccines, exemplified 
by the Provenge®. The advantage of  such a specific active immunotherapy (as mono- or 
combination therapy) using dendritic cells (DC) is besides the potential modulation of  
existing memory responses (also achieved e.g. by checkpoint blockers) mainly the priming 
of  de novo anti-tumour-specific immune responses and the induction of  immunological 
memory to prevent tumour relapse. This requires the coordinated induction of  innate and 
adaptive immune responses including cytotoxic T lymphocytes (CTL), T helper 1 (Th1) and 
natural killer (NK) cells. Even though the feasibility of  this approach was demonstrated in 
several studies, there is still need to increase its efficacy. Understanding and translating the 
knowledge on how DC induce and cooperate with innate and adaptive immune responses 
in vivo upon pathogen encounter a possible approach.
The coordinated cellular interplay is of  crucial importance in host defence against pathogens. 
In this thesis, we explored the interaction of  DC, NK and Th1 cells under the influence of  
a variety of  pathogen-associated molecular patterns (PAMPs). Specific pattern recognition 
receptor (PRR)-triggering during the maturation of  DC enabled them to enhance Th1 as 
well as NK helper cell responses. This effect was positively correlated with the amount of  
IL-12p70 released by the DC. Moreover, we showed that PAMPs could also directly activate 
NK helper cells. PAMP-activated NK cells were able to amplify the pro-inflammatory 
cytokine profile of  DC via the release of  IFN-γ. The knowledge on how PAMP recognition 
can directly (or indirectly) modulate the different effector cells of  the immune system is of  
importance for the design of  preventive and therapeutic vaccines and will be discussed in 
this chapter. Moreover, since specific PAMP-matured DC were efficient inducers both Th1 
and NK cell responses, we will discuss their potential role in optimizing DC-based vaccines. 
Moreover, we revealed direct inhibitory effects of  tumour-derived suppressive factors on 
the NK-DC crosstalk. In the last part of  this chapter, we will discuss the role tumour 
microenvironment (TME) in vaccination efficacy and how it can be reversed.
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ADJUVANTS: CRITICAL COMPONENTS IN ALL VACCINATION 
STRATEGIES 
The prevention of  infectious diseases through the implementation of  vaccination is one of  
the milestones of  modern medicine saving countless lives. One of  the key compounds of  
vaccines are adjuvants, which are added to induce, shape, enhance, accelerate, and prolong 
the immune responses against a desired vaccine antigen (Ag). These immunomodulators 
can be divided into three classes: delivery systems (non-immunogenic) increasing the 
delivery to target cells and influencing Ag-presentation, immune-stimulatory compounds 
(e.g. ligands of  immune receptors) and the combination of  both. The switch of  modern 
vaccines from live attenuated or inactivated vaccines (mostly containing natural adjuvants) 
to the use of  recombinant Ag and thus purified, defined, and safer components requires 
the inclusion of  (defined) adjuvants to increase their immunogenicity. The change from 
natural to defined adjuvants requires the knowledge of  their working mechanisms. Several 
parameters may influence the selection as well as the induced responses, such as properties 
of  the Ag, vaccination route, and target population 9. Interestingly, the mechanisms of  
action of  aluminium salt, the oldest adjuvant used in vaccination strategies, are still not yet 
completely elucidated. 
DC represent a crucial target of  most vaccine adjuvants, both in preventive and therapeutic 
vaccination strategies 10, 11. Depending on the environmental stimuli DC encounter, they 
transmit signals to immune effector cells inducing immunogenic or tolerogenic immune 
responses. Identifying how DC perceive danger signals leading to the generation of  de novo 
immune responses against disease-associated Ag and which signals induce and enhance the 
interaction of  DC with different immune effector cells is important to increase the efficacy 
of  vaccination strategies.
Defining optimal adjuvants is important to e.g. (I) reduce number of  immunizations, 
(II) ensure a rapid response towards pathogens, (III) reduce amount of  Ag needed, (IV) 
to broaden the induced antibody (Ab) response, and (V) to guide the induced immune 
responses and ensure the most effective and suitable response towards a particular Ag 9, 12.
PRR-triggering agents: Next-generation adjuvants in preventive vaccination?
Over the last decades it has become clear that adjuvants such as oil-in-water emulsions 
and alum are a requirement for the effectiveness of  vaccines against certain pathogens. 
However, these most frequently used adjuvants only induce suboptimal cellular immune 
responses. More recently, the use of  selected innate triggers (PAMPs), which have been 
naturally part of  live attenuated or inactivated vaccines, has been tested in clinical trials 
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exploring the safety and effectiveness of  these innate adjuvants on the promise they induce 
superior cellular immune responses 13, 14.
The induction of  Th cells is a crucial step for vaccination efficacy. CD4+ T cells are 
important for helping both the cellular as well as the humoral arm of  immune responses. 
Moreover, they are necessary for the induction of  CD8+ T cells as well as B cell memory 15. 
Th cell polarization is influenced by antigen-presenting cells (APC), such as DC. Both the 
subset of  DC being activated as well as the encountered trigger will influence the fate of  Th 
cells. Even though a lot of  promising adjuvants are revealed in experimental studies, clinical 
trials with beneficial outcome are scarce (reviewed in 16). This discrepancy is at least in part 
explained by crucial differences between the animal models used and the complexity of  the 
human immune system in vivo. For instance, TLR expression pattern and ligand specificity 
differ between mice and men 9, 17, 18. Therefore, it is important to study the polarization 
kinetics of  naive CD4+ T cells by differently matured DC in an autologous human system, 
as set up in chapter 2. We provided proof-of-principle for the applicability of  this assay for 
monocyte-derived (mo)DC as well as for the naturally circulating plasmacytoid DC (pDC). 
This assay can also be applied to study myeloid DC subsets. Even though it is a non-antigen-
specific assay, such a method can be easily used to test different potential adjuvants (e.g. new 
classes of  PRR triggers) on various DC subsets and monitor the resulting Th cell responses. 
This may confirm candidate adjuvants tested in animal models or identify new ones to be 
further evaluated in clinical trials. Furthermore, this assay can possibly be extended to study 
B cell class switching capacities of  DC-induced Th cell subsets, another important aspect 
of  adjuvants. The defined impact of  the different adjuvants on CD4+ T cell responses and 
subsequent induction of  humoral responses may help to predict vaccine adjuvant responses 
in vivo. However, in vitro cell culture systems still have the disadvantage of  not being able 
to take into account the complex environment the adjuvant will exert its activities in vivo. As 
such, they are good tools to define the responses on a specific cell type level, but not taking 
into account contributions of  inflammatory cytokines released, e.g. by non-circulating tissue 
cells due to adjuvant interaction.
In chapter 4, we showed that NK cells can also be directly targeted by TLR which enables 
NK cells to amplify DC responses and possibly enhances subsequent type-1 immune 
responses. The promotion of  NK-DC crosstalk is an important parameter to consider 
during the selection process of  an appropriate adjuvant. NK-DC crosstalk is important 
to enhance Th1 responses by providing IFN-γ 19, 20. In this line, the yellow fever vaccine, a 
live attenuated vaccine, induces potent memory responses upon a single injection. Vaccine 
injection induced upregulation of  TLR on NK cells, increased activation, and enhanced 
IFN-γ levels 21. Arguably, NK cells play a crucial role as amplifiers of  vaccine-induced 
responses. Unpublished data by our group also showed the potential of  TLR-activated 
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NK cells to enhance cytokine secretion of  pDC. Thus, if  potent cellular responses are 
desired (e.g. against intracellular pathogens), the choice of  adjuvant should have direct NK 
cell-activating properties as well as indirect capacity via maturation of  APC and enhancement 
NK-DC crosstalk.
T cells also express PRR and their expression pattern varies according to T cell subset and 
maturation status 22. CD4+ T cells do express a range of  TLR; expression levels are low 
on naive CD4+ T cells but are upregulated upon TCR-signalling 23-28. The stimulation of  
TLR acts as a co-stimulatory signal and enhances the proliferation, survival, and cytokine 
production of  these cells. Likewise, triggering TLR2, TLR5 and TLR7/8 on human 
CD4+ T cells enhances proliferation and IFN-γ secretion 23, 29. Importantly, the effect of  
TLR-triggering required TCR-stimulation of  CD4+ T cells. Also CD8+ T cell responses 
can be modified by TLR recognition 30. Thus, the potential direct effect of  adjuvants on 
T cells may offer a potent additional way to enhance vaccine-induced immune responses. 
However, more studies are still needed that focus on the direct effect of  TLR- and other 
PRR-triggering on human T cell responses.
The key to determine the optimal use of  TLR triggers as adjuvants lies most probably in 
vivo. During a pathogenic insult, the invader is able to trigger several PRR (on various cell 
types) leading to the induction of  multiple signalling pathways and an optimal cooperation 
between different immune cells. As such, several experimental studies revealed additive 
or synergistic activation of  DC and a resulting enhanced interaction with immune cells 
when multiple PRR pathways were stimulated 31-34. This is in line with our data described 
in chapter 3, in which moDC triggered with a combination of  TLR2, 3, and 4 induced 
more efficiently Th1 and NK cell responses compared to the single triggers. Likewise, live 
attenuated vaccines, such as yellow fever vaccine, can naturally trigger various TLR and 
thus multiple receptors on one DC or on different DC subsets and probably also directly 
stimulate other immune effector cells 35. Strategies to optimize adjuvants by employing 
innate mechanisms of  TLR-triggering should target multiple receptors. Therefore, there is 
rational to investigate which PRR triggers can be combined to activate synergistic signalling 
pathways. We screened various PRR triggers for their capacities to activate moDC by 
determining the expressing of  costimulatory molecules and IL-12p70 production. It is 
plausible that several combinations will also be of  inhibitory nature, e.g. when combining 
triggers of  two different classes of  pathogens. Possibly, a mixed response is induced in 
these cases. Moreover, recent evidence suggests that targeting non-immune cells, such as 
stromal cells, influences Th1 and CD8+ T cell responses, which is mediated by the release 
of  type I IFNs after stimulation of  MDA-5 on stromal cells 36-39. This complex expression 
pattern of  TLR/PRR on various immune and non-immune cells offers new combination 
strategies to maximize adjuvant capacities. As such, modern adjuvant selection could benefit 
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from identifying potential synergic combinations of  PRR triggers to enhance the induced 
immune responses against a particular Ag. Possibly, choosing a specific PRR trigger allows 
to better predict the induced responses in vivo as compared with the rather non-specific 
molecules (e.g. alum, MPL).
PAMPs as tool to improve anti-cancer immunotherapy
Despite great success of  prophylactic vaccination against external pathogens, until now the 
application of  therapeutic cancer vaccination is less effective. Even though, a stabilization 
of  disease and prolonged survival were observed in some cases, limited effect on eliminating 
bulky tumours was observed 40-43. The challenge of  therapeutic vaccination is not only to 
induce memory, but also homing of  appropriate immune cells into the tumour environment, 
inducing killing of  tumour cells and avoiding immune suppression. 
In order to obtain these desired immunologic responses it is an attractive strategy to exploit 
the nature’s own mechanisms for inducing these responses under pathogenic threats. The 
recognition of  PAMPs by cells of  the immune system readily programs these mechanisms 
in vivo and therefore the use of  carefully selected PAMPs holds promise for the application 
in therapeutic cancer immunotherapy. PAMPs can be used as stand-alone therapy, 
vaccine adjuvant, modulator for ex vivo DC generation or in combination strategies with 
radiotherapy, chemotherapy or targeted therapies in the treatment of  cancer 44. 
Various TLR agonists have been applied as stand-alone therapies mainly in patients with 
melanoma but also other cancer types (table 1 in 44). Overall the success of  these therapies 
has been limited and up-to-date only BCG (TLR2, 4, 9), MPL (TLR2, 4) and imiquimod 
(TLR7) have been approved by the FDA as TLR anti-cancer agents. One of  the main 
differences between preventive and therapeutic use of  PAMPs to stimulate the immune 
system is the presence of  an immunosuppressive environment induced by the TME. The 
tumour is embedded in a complex microenvironment formed by lymphoid myeloid cells, 
stromal cells, vasculature, lymphatic vessel, cytokines and chemokines. The tumour itself  
can interfere by the expression of  inhibitory ligands (e.g. PD-L1), creation of  a tolerogenic 
environment (e.g. expression of  IDO), and recruitment of  regulatory cells (e.g. Treg, myeloid-
derived suppressor cells [MDSC], tumor-associated macrophages[TAM]). Apparently, these 
suppressive mechanisms of  the TME prevail over the immunostimulatory mechanisms that 
are boosted if  PAMPs are used as stand-alone therapy. Optimally, as illustrated in Figure 1, 
the desired effects of  PAMPs used in anti-cancer therapeutic strategies should induce direct 
and indirect stimulatory effects on mainly APC, CD4+ T cells, CD8+ T cells and NK cells. 
Ideally, therapies should be able to reverse the inhibitory effects of  the TME (breaking the 
tolerance).
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Notably, tumour cells have been reported to express various PRR enabling them to respond 
to PAMPs and damage-associated molecular patterns (DAMPs) 45-50. The induced effects 
by PRR-triggering are, however, still controversial. Several reports show that triggering of  
TLR on tumour cells leads to induction of  apoptosis or potentiation of  the tumour cells 
to be more easily killed by CTL or chemotherapeutic drugs. The latter is also referred to as 
′tolerized′ state of  the tumour cell, induced by a strong stimulation of  TLR. These cells were 
reported to be incapable to produce pro-inflammatory cytokines upon re-stimulation 45, 46. 
However, engagement of  TLR by tumour cells has not only anti-tumour effects but can also 
induce pro-tumour effects. The expression levels of  TLR by the tumour has been associated 
with poor prognosis 47-49. The induced effects seem to be partly dependent on the type of  
cancer as reviewed in 31, 50. Moreover, the TME in which tumour cells encounter PAMPs may 
also influence the outcome, such as hypoxia, as well as a possible heterogeneous expression 
level on tumour cells. In vivo, the outcome of  intra-tumoral injection of  TLR may be 
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Figure 1 | Desired immune interactions upon PAMP stimulation. PAMPs should directly trigger 
cells involved in anti-tumour responses (NK cells, CD4+ and CD8+ T cells, DC). Moreover, the cytokine 
milieu generated by their activation can break the tolerizing effects of  the TME. Also, by choosing the 
proper PAMPs, a direct negative effect can be mediated on tumour cells and Treg.
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dependent on the balance of  tumour-infiltrating lymphocytes (TIL) and TME that can be 
tumour-specific.
Besides the dual function of  TLR-triggering on tumour cells, the stimulation of  TLR 
on Treg also has consequences for tumour progression. Similarly to effector T cells, also 
Treg cells express various TLR and were shown to enhance or inhibit suppression. Many 
studies analysed the expression pattern and addressed functional consequences of  Treg-
triggering in mice. Until now, human studies are limited; in one study, flagellin (TLR5 ligand) 
increased the suppressive capacity of  Treg 51. The triggering of  TLR8 on CD4+CD25+ 
Treg cells inhibited their regulatory effect 52. Another study showed that the presence of  
TLR7/8, 2, 4 or 9 trigger inhibited the suppressive effect of  Treg on CD4+ and CD8+ T cell 
proliferation 30. However, a more straightforward comparison of  TLR expression on Treg 
and functional relevance in the human setting is needed to clearly allocate a role of  these 
receptors in immune surveillance.
Even though TLR are by far the best described and characterized family of  PRR, a down-side 
of  applying TLR-triggering PAMPs as stand-alone therapy or as vaccine adjuvants may be 
their broad induction of  immune responses targeting not only APC, NK, CD4+ or CD8+ T 
cells. The selection of  single or a combination of  TLR triggers requires careful consideration 
of  expression pattern by tumour cells and Tregs as well as their functional effects on these 
cells. Moreover, even if  some triggers are very potent immunomodulators, an accompanied 
toxicity upon systemic administration may limit the usage of  the most effective dose or may 
require modulation of  the PAMP to be less toxic. Predicting the effect of  a specific TLR or 
a combination of  several TLR being induced in a complex environment may be difficult; in 
vivo the interaction of  different immune cells in combination with non-haematological cells 
as well as tumour type and TME composition potentially influences the outcome observed 
in vitro. However, the combination of  TLR with other strategies aiming to reduce the 
immunosuppressive TME may be the key to success.
One way to counteract the immunosuppressive effects of  the TME is the local delivery of  
IL-12 or IFN-α. Whereas the systemic administration of  these cytokines is toxic, intra-tumoral 
injection of  PRR ligands may be used to locally produce these factors. Interesting in that 
respect is that some cytoplasmic receptors are expressed by almost all nucleated cells 53. 
Engaging for instance RIG-I could locally lead to increased type I interferon production, 
but also block Treg suppression and induce the apoptotic programme in tumour cells 
54, 55. Apoptotic material released from tumour cells may be taken up by DC favouring 
antigen-specific anti-tumour immune responses. This selective RIG-I trigger is currently 
tested in several experimental models. Exploring such tumour-targeting adjuvants having 
the properties to reverse suppressing TME and additionally have pro-apoptotic function on 
159
General discussion
6
tumour cells may be more successful than APC (non-tumour)-targeting adjuvants. 
Another approach to strengthen the effect of  PPR ligands as adjuvants is coupling them 
to long synthetic peptides and assure their direct delivery to DC. Even though promising 
results have been shown by using CpG and Pam3CSK4 as carriers by means of  enhanced T 
cell responses and cross-priming 56-58, using TLR may be suboptimal due to their non-APC 
specific expression. Other receptors specific for different DC subsets involved in Ag-
uptake are better candidates for direct in vivo targeting of  DC (e.g. DC-SIGN, DEC205, 
Mannose-1 receptor) as reviewed in 59-61.
To conclude, the key approach of  using PAMPs as stand-alone therapy or adjuvants in the 
setting of  cancer relies in selecting triggers able to stimulate immune effector cells, to provide 
simultaneously a pro-inflammatory environment, and avoid pro-tumour activities and Treg 
activation. Moreover, the PRR ligand effect should be combined with other strategies to 
enhance the responses. Possibly, TLR triggers may not be the most appropriate PAMPs.
INTERPLAY WITH HELPER CELLS AS A TOOL TO IMPROVE DC 
VACCINATION
Since the first clinical trial with DC vaccination in 1996 62, much effort on improving the 
efficacy of  this potentially powerful anticancer therapeutic approach has been made. In 
2010, the FDA approved the first DC-based vaccine against advanced prostate cancer 42, 
called Provenge®. This vaccine is prolonging the patient’s progression-free survival for 
several months. Different ongoing clinical trials testing DC-based vaccination exemplify 
the potential role of  DC-based vaccines in future standard treatments. However, the limited 
overall benefit on clinical outcome is indicative for the need of  further optimizations. 
Importance of  IL-12 – is it all we need?
Whereas initial research focused on generating mainly tumour-specific CTL responses, it is 
becoming increasingly clear that the activation of  multiple immune effector cells is the key 
to success for curative cancer vaccination. Ex vivo-matured DC should have the capacity to 
interact with endogenous immune cells of  the patient and induce a potent type-1 immune 
response enabling the elimination of  the tumour cells 61. The criteria which a potent vaccine 
should fulfil are challenging, including co-activation of  CD4+ and CD8+ T cells, priming of  
naive cells and modulating anergic memory CD8+ T cells, crosstalk with DC subsets and 
NK/NKT cells, and induction of  long-lived memory. One way DC control and modulate 
adaptive immune responses is by their secretion of  cytokines and chemokines. Different 
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from signal 1 (TCR-MHC) and 2 (co-stimulation) required for proper tumour-antigen-
specific T cell activation 63, 64, signal 3 (cytokines) is not only able to polarize T helper cells 
into a specific lineage, but can also recruit and activate other immune cells, such as NK 
cells 19, 65-70. Furthermore, the delivery of  signal 4 (homing properties) is important to ensure 
recruitment of  activated T cells 71.
In chapter 3 of  this thesis, we observed a significant positive correlation between the 
amount of  IL-12 produced by moDC and the resulting polarization of  naive CD4+ T 
cell into Th1 cells and the induction of  IFN-γ-producing NK cells. Even though IL-12 is 
known to be an essential factor driving Th1 responses 67, 72, this quantitative requirement 
needs to be taken into account while screening for new superior maturation cocktails or 
methods. These findings are strengthened by recent studies indicating a positive correlation 
between high IL-12p70-producing-DC and time to progression 73, 74. Moreover, older 
studies tested the systemic application of  IL-12 and revealed a positive anti-cancer effect. 
However, the implementation of  rhIL-12p70 in cancer treatment approaches was hindered 
by its dose-limiting toxicities 67, 75-80. Altogether, these findings emphasize the use of  
IL-12p70-producing DC to ensure local production and delivery of  this cytokine to come 
one step closer to successful vaccination strategies.
The failure of  DC to produce (′high enough′) IL-12p70 could be one of  the factors 
explaining the marginal effects of  DC-based vaccination clinical trials applying mainly 
PGE2/TNFα (± IL-6, IL-1β)-matured DC (listed in 
81). We tested various DC maturation 
cocktails used in clinical trials (PGE2/TNF-α [± IL-6, IL-1β], alpha-DC and LPS/IFN-γ) 
and we observed significantly less IL-12p70 levels compared to FMKp/IFN-γ-matured DC 
(unpublished data). FMKp/IFN-γ-DC were by far the highest IL-12-producers compared 
with other PRR triggers used in combination with IFN-γ. Moreover, in chapter 2, the 
importance of  IL-12 on de novo generation of  Th1 responses is underpinned, as only 
FMKp/IFN-γ-DC were able to polarize and induce IFN-γ production in naive CD4+ cells 
after co-culture. Such FMKp/IFN-γ-matured DC also induced the highest NK cell-derived 
IFN-γ production, followed by LPS/IFN-γ and alpha-DC-activated NK cells. Of  note, 
soluble factors derived from PGE2/TNF-α (± IL-6, IL-1β)-matured DC did not lead to NK 
helper activation (unpublished data and 19). 
Besides the finding that PGE2 exerts a direct inhibiting effect on DC-derived IL-12p70 
production (chapter 5) another possible explanation for the PGE2-cocktail not to induce 
IL-12 production in DC is the absence of  IFN-γ in the maturation cocktail. It has been shown 
in several reports that IFN-γ boosts DC cytokine production 82 and additionally prevents 
DC from exhaustion status. In chapter 4, we demonstrated that rhIFN-γ dose-dependently 
determined the magnitude of  IL-12p70 production (and production of  T cell recruiting 
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CXCL9 and CXCL10) by DC, whereas TNF-α had no effect on the DC-derived cytokine 
and chemokine production during the priming phase . However, TNF-α was shown to be 
important for the up-regulation of  co-stimulatory markers on DC 83. 
Different strategies to maximize the IL-12 production can be applied. One approach is the 
genetic manipulation of  the dendritic cells ex vivo which was demonstrated to shape key 
immunological outcome parameters. Another approach is the use of  PRR triggers during 
the ex vivo maturation of  DC. Several murine and human in vitro studies illustrate that the 
combination of  multiple PRR triggers and thus engaging multiple PRR-signalling pathways 
leads to synergistic effects on DC maturation 39, 84. As such, the selection of  appropriate 
PAMPs for priming of  DC having capacities to induce type-1 immune responses is desired. 
In chapter 3, we showed that the strength of  PRR-signalling by a single trigger can 
considerably enhance the IL-12p70 production. Furthermore, cooperative PRR-signalling 
by using the bacterial trigger FMKp and the viral trigger poly(I:C) (chapter 3) or CL075 85 
leads to synergistic IL-12p70 production, followed by increased helper cell induction. 
This approach requires a thorough search for the most optimal combination of  PAMPs 
of  different origins (bacterial, viral, fungal) or triggering different PRR families (TLR, 
NOD, CLR, RLR). As illustrated in a publication of  Jensen et al. 82, the choice of  pro-
inflammatory cytokines incorporated into the maturation cocktails can lead to further 
optimization of  cytokine-producing DC. In this line, NK cell-derived cytokines do have 
a decisive influence on DC-derived IL-12p70 production as illustrated in chapter 4. An 
increased IL-12p70 production can be achieved by simply adding higher concentrations 
of  rhIFN-γ to a particular PRR-containing cocktail. This provides proof-of-principle that 
pro-inflammatory cytokines can be applied to fine-tune the maturation conditions. In a 
similar approach, Berk et al. 86, 87 recently showed the possibility to use the supernatant 
of  activated lymphocytes to induce maturation of  DC including up-regulation of  
phenotype markers, IL-12p70 and CXCL10 production. These crosstalk features of  
DC with immune helper cells can be exploited to further boost the potential of  moDC. 
 
Even though high IL-12-producing DC can be generated in vitro by manipulating the 
composition of  the maturation cocktail, one crucial criterion for efficient induction of  
immune responses is the production of  IL-12p70 (and other cytokines and chemokines) in 
vivo upon DC re-administration into the patient. The cytokine measurement in the studies 
of  this thesis were performed on 24/48h-matured DC. Most of  the cytokines produced by 
moDC are released within the first 24h 88. In addition, we and others previously showed that 
the cytokine induction programme is irreversibly primed in 6h-matured DC 19, 89, 90. Clinical 
trials employ diverse strategies to mature DC; several studies use 24h/48h-matured exhausted 
DC which are not able anymore to produce IL-12p70, but regain this capacity after T cell 
encounter and the ligation of  CD40. Others employ 6h maturation protocols, generating 
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semi-mature DC retaining the capacity to produce IL-12 even before the encounter with 
T cells in vivo 91. The latter approach is favorable since DC should retain the capacity to 
produce NK cell-recruiting chemokines well as NK cell-activating cytokines upon injection. 
 
As diverse polymorphisms affect the IL-12p70 production of  DC 92-95, another option is to 
engineer DC via the usage of  RNA, DNA or recombinant viruses to constitutively produce 
IL-12. mRNA electroporation of  DC has been shown to be efficient and a clinically safe 
transfection method 96, 97. Another advantage of  engineering DC is the specific selection of  
'desired' cytokines produced by DC without the production of  anti-inflammatory cytokines, 
e.g. IL-10, or silencing undesired properties. Interestingly, a study by Lipscomb et al. 
described an IL-12p70-independent mechanism for Th1 polarization when DC expressed 
ectopic T-bet (via adenoviral infection) 98. These findings were translated into engineering 
syngeneic T-bet and IL-12p70 expressing DC. Injection of  these DC into mice bearing 
subcutaneous tumours led to synergistic and robust Ag-specific type 1 immune responses 
including tumour rejection, cross-priming of  Ag and infiltration of  CD8+ T cells 99. Thus, 
engineering DC provides a multitude of  intervention points 100 and displays a powerful 
approach to ensure long-lasting provision of  cytokines, possibly in combination with other 
signals (enhancing stimulating or blocking negative modulators) in the TME.
Although we showed the importance of  high IL-12p70-producing moDC for the induction 
of  Th1 and NK cells responses, also other cytokines were shown in several studies to 
contribute in an additive or synergic manner to improved helper responses (e.g. IL-15, 
IL-18, IFN-α). In chapter 2, we showed that pDC activated by diverse PAMPs lead to the 
polarization of  naive CD4+ T cells into Th1 cells. pDC can produce IL-12p70, however, 
compared to moDC and myeloid DC (myDC), their IL-12p70 production levels are very 
limited. Other mechanisms have been shown to facilitate IFN-γ production, such as IL-18, 
IFN-α, and IL-27 101, 102. Possibly, different DC subsets employ adjusted pathways to activate 
NK cells or Th1 cells. IFN-α-secreted in high amount by pDC was shown to induce T-bet 
expression, however, this pathway is less stable compared to IL-12 induction. It remains to 
be established whether the potency of  the different subsets to polarize naive cells into Th1 
cells is comparable or whether high IL-12-producing DC subsets favour this induction. 
Also for NK cell activation, a two-signal activation is much more effective 103, 104. Likewise, 
IL-15 can potently enhance proliferation and survival of  NK and T cells, as well as enhance 
NK-DC crosstalk 105, 106. Arguably, by choosing appropriate maturation stimuli, the DC 
cytokine profile can be fine-tuned or alternatively DC can be engineered to produce the 
'optimal' cytokine combination.
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Choosing the ‘proper’ DC subset
Since DC are the starting point of  inducing appropriate adaptive immune responses, such as 
generating Th cell responses, the DC subset choice is depending on the desired response. In 
therapeutic cancer vaccination type 1 immune response is desirable. Different DC subsets 
have been allocated with the induction of  specific Th responses; CD14+ DC induce Tfh, 
LC prime Th2 and CD1c+ DC lead to Th17 induction 107, 108. This knowledge is of  crucial 
significance for DC vaccination approaches such as in vivo DC targeting or generating ex 
vivo-matured DC.
The discovery of  methods to generate large numbers of  monocytes and differentiate 
them into moDC ex vivo was the starting point for their use in cellular vaccines 109, 110. 
As a consequence, the vast majority of  clinical trials has been using moDC as source of  
DC 81. Depending on the maturation stimuli applied, these inflammatory DC are able to 
induce type 1 immune responses including among others the secretion of  pro-inflammatory 
cytokines (e.g. IL-12, IL-18), T and NK cell-recruiting chemokines, induction of  Th1 
polarization and CTL responses, and crosstalk with NK cells. Together with improvements 
in Ag-loading, maturation stimuli, administration regimens, and the measured clinical 
outcomes, ongoing and planned clinical trials applying ′next′ generation DC vaccines may 
result in better and more promising clinical outcomes.
Compared to the naturally circulating DC, myDC and pDC, inflammatory moDC have all 
the functional capacities required to induce proper type 1 immune responses. One major 
difference with naturally circulating DC is the limited production of  IFN-α. pDC are able 
to secrete large amounts of  this cytokine upon viral triggering which is important for the 
activation of  B cells, T cells, and NK cells 111, 112. pDC are able to mediate direct cytotoxicity, 
but also play a role in cross-priming and T cell activation like myDC 113-120. IFN-α has been 
shown to have adjuvant properties on innate and adaptive anti-tumour immunity 121-124, 
however, the systemic administration of  IFN-α as cancer treatment has been accompanied 
by toxic side-effects 120, 121, 125, 126. Thus, a more targeted delivery could be achieved by applying 
pDC as subset for ex vivo generated DC. pDC have been applied as DC-based vaccination 
approach in patients with melanoma 114. The administration of  pDC did lead to increased 
IFN-α levels as well as to the mounting of  T cell responses. Interestingly, a recent study 127 
showed that the electroporation of  moDC with IFN-α mRNA enhanced NK cell responses 
as well as WT-1-specific CTL compared to control DC. As moDC used in this study 
were matured with PGE2/TNF-α, it would be interesting to study the effect of  a type-1 
inducing DC maturation cocktail (e.g. FMKp/IFN-γ) inducing IL-12p70-producing DC in 
combination with IFN-α mRNA electroporation on immune effector cells. In addition, as 
one mechanism of  action of  pDC in vivo is thought to be the activation of  myDC 128-130 
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and thus enhancing anti-tumour responses, it would be interesting to study whether these 
engineered moDC are also able to interact with myDC.
Each subset is specialized in mediating appropriate immune responses upon pathogen 
encounter which is predicted by their repertoire of  PRR. A logical step would be to 
combine naturally circulating DC and moDC obtained from one elutriation product as 
cancer vaccination and exploit their complementarity. Different scenarios are conceivable; 
likewise pDC and myDC cells can be activated together as it has been shown that the 
crosstalk between these two cell types enhances their activities 128-131. For this approach 
the identification of  common maturation conditions and optimal activation time frames as 
well as administration regimens has to be considered. The different subsets could also be 
activated separately and injected at different intervals in order induce the crosstalk only at 
the moment of  injection. 
Besides ex vivo generation or manipulation of  DC, another more broadly applicable strategy 
is the in vivo targeting of  naturally circulating DC and the reversal of  their dysfunctionality 
in patients with cancer. In this respect, the administration of  TLR9 trigger CpG did induce 
re-activation of  impaired pDC in patients with multiple myeloma 132. The use of  TLR to 
stimulate DC in vivo has been discussed earlier. Thus instead of  exploring the use of  different 
DC subsets for the application of  ex vivo-generated DC, improving in vivo-targeting of  DC 
could be a more broadly applicable approach of  future standard anti-cancer treatments. 
As DC population consists of  a heterogeneous combination of  subsets able to efficiently 
communicate with each other and instruct immune effector cells, several approaches can be 
applied to boost their anti-tumour inducing capacities; the choice of  the proper subset as 
well as DC vaccine approach may be selected upon the cancer type and/or stage, as well as 
patient’s immune system and TME.
Importance of  CD4+ T cells – more than helpers?
Numerous lines of  evidence indicate the crucial role of  CD4+ T cells in the generation of  
different aspects of  adaptive immune responses. They are mainly important for the induction 
of  potent CTL responses and for the generation of  long-lived memory responses 133. 
Furthermore, they also play an important role in modulating DC maturation by providing 
diverse cytokines. In mice, CD4+ T cells were shown to be required for improved tumour 
elimination by CD8+ T cells 134, 135. CD4+ T cells enhanced the clonal expansion of  CD8+ 
T cells in secondary lymphoid tissue after vaccination and tumour-specific CD4+ T cells 
also facilitated recruitment, proliferation, and effector function of  CD8+ into the TME 
by secretion of  IFN-γ and IL-2. Therefore, it is widely assumed that immunotherapeutic 
approaches require the involvement of  CD4+ T cells. In vivo targeting of  DC or ex vivo 
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maturation of  DC should enable them to prime Th1 responses. As mentioned earlier, we 
set up an assay to screen the capacity of  differently matured DC (of  different subsets) to 
induce the polarization of  naive CD4+ T cells. This system allows to monitor DC-mediated 
direction, potency, and kinetics of  Th cell differentiation. As such not only the Th fate 
can be determined, but also valuable insight on the initiation of  a de novo Th response 
can be obtained. It allows studying the effect of  different PRR stimuli on DC-induced 
T cell polarization taking into account the interaction of  all DC-derived soluble factors 
together with co-stimulatory molecules during priming of  naive CD4+ T cell responses. 
Moreover, the effect of  environmental factors, such as tumour-derived soluble factors, as 
well as immunomodulatory drugs on the priming phase of  naive CD4+ T cell polarization 
can be studied. Another interesting aspect is the possibility for the parallel study of  different 
T helper cell subsets. As such, we revealed that PGE2/TNF-α which has been mostly used 
in clinical studies induces a Th2-like response. Furthermore, in chapter 3, we screened 
over 40 different DC maturation cocktails for their capacity to promote Th1 responses. We 
observed a huge difference in Th1 polarization between the different DC, highlighting once 
more that the selection of  appropriate DC maturation cocktails is a delicate task.
Recently, the targeting of  CD4+ cells by vaccination with polytope mRNA vaccine 
(encoding immunogenic mutant class II epitopes) has shown to be very efficient in mice by 
meditating strong anti-tumour responses 136. The vaccination led to reversal of  TME and to 
the induction of  CTL. Adding a human leukocyte antigen (HLA)-class II-targeting signal 
(DC-LAMP) to mRNA encoding tumour antigens will also activate Th1 and CTL responses 
137. These findings highlight the importance of  CD4+ T cells in immunotherapy and consist 
a very promising approach to be applied in the clinic.
Importantly, CD4+ T cells are also directly involved in tumour killing 138, 139. Such CD4+ 
CTL, comprise a subset of  CD4+ T cells that loose the expression of  ThPOK, a 
transcription factor repressing cytolytic development in MHC class II-restricted CD4+ 
cells during development in the thymus. These CD4+ CTL have also been described as 
important players in viral infections. Similar to what occurs in CD8+ CTL, the termination 
of  ThPOK expression by CD4+ effector cells results in the up-regulation of  granzyme B, 
perforin and IFN-γ secretion. The importance of  this CD4+-dependent killing mechanism 
remains to be established but the association between a reduced number of  CD4+ CTL 
and survival in patients with hepatocellular carcinoma indicates that this may be a major 
mechanism of  tumour control in certain malignancies 140. Regarding their potential role in 
direct tumour killing, investigating how these cells can be primed and targeted in vivo could 
be an interesting target for enhanced anti-tumour responses.
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Importance of  NK cells
Whereas previous approaches to optimize DC vaccination were mainly based on maximizing 
intra-tumoral T cell responses, also other players of  the immune system may be important 
in the process of  tumour cell elimination. NK cells are able to exert direct cytotoxic 
effects on tumour cells or iDC and indirectly modulate the adaptive immunity by cytokine 
secretion and communication with other immune cells 141-144. In the past decade allogeneic 
NK cells were shown to be effective after haplo-identical stem cell transplantation in acute 
myeloid leukemia (AML) patients 145, 146. Moreover, low cytolytic activity of  NK cells has 
been associated with 40% increased cancer risk compared to individuals with NK cells 
having high cytolytic activity 147. Likewise, levels of  intra-tumoral NK cells and NK cell 
activity are positively correlated with clinical outcome 148-151. In patients with cancer, NK cell 
functions are often impaired displaying reduced cytolytic and cytokine-secreting capacities 
and reduced DC editing 152-155. This can be partly explained by immune suppressive TME 
and the use of  escape mechanisms by tumour cells.
The reciprocal effects of  NK-DC interaction provide a strong rationale for the combined 
use of  NK cells and DC in immunotherapeutic strategies to overcome dysfunction and 
enhance anti-tumour responses. With our recent understanding of  the NK-DC interaction, 
one could argue that DC used in vaccination strategies should be matured in vitro in the 
presence of  NK cells or NK cell-derived factors 156 to maximize their maturation. These 
findings are strengthened in chapter 4 of  this thesis, in which soluble factors derived 
from PAMP-activated NK cells did enhance the cytokine and chemokine profile of  ex 
vivo-matured moDC.
From another point of  view, there is rationale to optimize ex vivo maturation of  DC as 
such that they are able to optimally recruit and activate NK cells 19, 157. The capacity of  
DC vaccination to efficiently interact with NK cells is influenced by multiple parameters 
such as the differentiation and maturation of  DC, as well as the choice and delivery of  
Ag. We and others have shown that for optimal NK cell activation and recruitment, DC 
maturation protocols should contain TLR agonists. Also the cytokines used during the 
differentiation of  monocytes (e.g. IFN-α or IL-15) can have an effect on the capacities of  
DC to recruit and activate NK cells 157-161. PGE2, another DC-activating molecule produced 
during inflammation, has a negative effect on NK-DC cross-talk as shown in chapter 5. 
Of  note, in a study of  Jensen et al. 82 investigating the effect of  different combinations of  
recombinant human cytokines with PRR triggers, revealed that PGE2 production by moDC 
could also be induced upon selected maturation stimuli. The alpha-DC cocktail described 
by Mailliard et al. 162 was among the PGE2-inducing cocktails. Despite the reports on the 
negative effects of  PGE2-mediated DC maturation, most clinical trials use PGE2-matured 
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DC. The rationale behind this is the in vitro capacity of  these DC to migrate 163. However, 
in in vivo studies, these DC migrate just as poor as non-PGE2-matured DC 164. The lack 
of  migratory capacity of  TLR-matured DC in combination with their NK cell-recruiting 
capability opens the possibility for the combination of  NK-DC therapy. In these therapies, 
NK cells and DC can be either simultaneously injected or only DC are injected to recruit 
NK cells. For the simultaneous injection of  NK cells and DC, intra-tumoral injection may 
represent an attractive strategy. NK cells lyse tumour cells (NK cell-sensitive tumours), 
thereby making antigenic material available for DC to be taken up and presented. In 
addition, NK cells induce maturation of  bystander DC and lyse inappropriately matured 
DC or iDC. Reciprocally, mature DC can activate NK cells to proliferate, secrete cytokines, 
and augment NK cell cytotoxicity. Another option is the injection of  NK cells and DC in 
the tumour-draining lymph nodes where the Th1-polarizing capacity of  the NK cells can be 
used to its fullest in this T cell-rich environment. 
In addition to the simultaneous injection of  both cell types, we propose a different strategy 
to enhance NK-DC interaction in DC vaccination: the development of  a tertiary lymphoid 
structure (TLS). The density of  such lymphoid islets adjacent to tumours in combination 
with mDC correlates with Th1/CTL TIL phenotype and with positive outcome 165, 166. In this 
strategy, only DC are administered and this option is based on the capacity of  TLR-matured 
DC to produce chemokines and, thereby, selectively recruit effector cells 167. Moreover, 
to ensure potent NK cell activation, selected TLR triggers could be co-administered with 
DC-based vaccines to ensure enhanced activation of  NK cells as demonstrated in chapter 
4. Even though, in a previous study we showed the requirement of  IL-12 for efficient NK 
cell-derived IFN-γ-production activated by TLR-triggered DC, the co-administration of  an 
additional PRR trigger as adjuvant could circumvent this need. In chapter 4, we showed 
that NK cells could also be activated by TLR triggers in the presence of  another cytokine 
or a combination of  cytokines different from IL-12p70. Because of  the lack of  in vivo DC 
migration, DC could be injected in tumour-draining lymph nodes or into the tumour vicinity, 
where they can recruit and interact with NK cells. DC-mediated chemokine production is 
also attractive for recruitment of  CTL and Th1 cells 168-170. We hypothesize that by recruiting 
all these effector cells by DC, the same interactions that take place in lymph nodes can be 
induced extranodally in a TLS. Whether the immunosuppressive effect of  the TME has 
detrimental effects on effector cell induction by DC remains to be elucidated.
Besides targeting endogenous NK cells via DC vaccination or improving DC-based 
vaccination by NK cell-derived soluble factors, another approach is the adoptive transfer 
of  NK cells. Even though adoptive transfer of  NK cells is a separate line of  anti-cancer 
immunotherapy, the proper manipulation of  NK cells before administration to the patient 
could lead to enhancement of  endogenous naturally circulating DC. Currently these 
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optimizations aim to enhance the cytotoxic capacity of  NK cells by the addition of  various 
cytokines during expansion and the selection of  appropriate allogeneic donors having 
KIR-ligand mismatched NK cells favouring their cytotoxic capacities. In chapter 4, we 
showed that the activation of  NK cells in the presence of  certain pathogenic triggers, such 
as poly(I:C) or FMKp, increased the helper function of  NK cells. Moreover, increasing 
evidence in literature describes enhanced cytolytic capacities of  NK cells after activation 
by PRR triggers 171, 172. Incorporation of  TLR triggers to activate NK cells before injection 
could enhance the NK cell-mediated effects in vivo.
Notably, not all tumours are sensitive for NK cell-mediated cytotoxicity. Thus exploring 
the role of  NK-DC crosstalk to enhance anti-tumour immunity besides the well-known 
lytic capacity of  NK cells strengthens the importance of  NK cells in immunotherapeutic 
approaches. Cytolytic capacity of  NK cells is hampered by tumour cell evasion, which 
includes up-regulation of  inhibitory ligands (MHC class I expression) and down-regulation 
of  activating ligands for NK cell receptors 173-178. Tumour-released factors, such as 
TGF-β, can down-regulate activating receptors on NK cells 179 and additionally hamper 
NK cell-mediated lysis. Also the expansion of  Treg in the TME was shown to constrain 
proliferation, cytolytic activity (NKG2D-dependent) and cytokine secretion of  NK cells 
(via NK-DC crosstalk) 180, 181. Interestingly, the inhibiting effect of  Treg on NK cells may be 
hampered depending on the activation of  NK cells. Treg failed to repress IFN-γ secretion 
by NK cells if  they were activated by IL-2Rγ-signalling (e.g. IL-2, IL-15) 181. Furthermore, 
under specific circumstances, NK cells were shown to inhibit Treg expansion in an early 
phase of  the immune response against intracellular pathogens 182. Arguably, the mode of  
NK activation in combination with the tumour load may enhance direct and indirect NK 
cell-mediated effects during anti-tumour responses. Further research on how to stimulate 
Treg-resistant NK cells could, in addition to Treg-depleting regimens, increase NK 
cell-mediated anti-tumour effects.
NK-DC crosstalk, however, exerts not only immunostimulatory effects. In this line, a recent 
study of  Sarhan et al. 183 showed that NK-DC crosstalk is inhibited in the presence of  IL-2 
affecting NK cell-derived IFN-γ production, cytolytic activity, and proliferation. IL-2 led 
to the phosphorylation of  STAT3, which is in combination with p38 MAPK pathways 
known as negative regulator on DC function 184. As consequence a reduced production of  
IL-12 and LT-α and increased secretion of  the inhibitory cytokine TGF-β were observed. 
Blocking of  STAT3, as well as the addition of  rhIL-12 reversed the IL-2 inhibiting effect 
on NK-DC crosstalk. Because NK helper cells will mostly interact with DC in the lymph 
nodes surrounded by naive T cells and Th1 cells and thus IL-2, this is an important aspect 
to consider for vaccination strategies. This could mean to select maturation cocktails leading 
to IL-12-producing DC with low STAT3 phosphorylation or pre-treating the DC with 
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JAK/STAT inhibitor prior injection.
INTERFERENCE OF TUMOUR MICROENVIRONMENT
The direct effect of  the TME on DC as well as the indirect effect on the DC-activated 
immune effector cells remains a major hurdle in therapeutic anti-cancer DC vaccine 
strategies and cancer immunotherapy in general. There is growing evidence that the host’s 
immune system plays a crucial role in tumour progression 149, 185-187 and that the clinical 
outcome of  treatment is dependent on the patient’s TME acting as rheostat on induced 
immune responses. In this line, patients at the same stage of  disease do display different 
clinical outcomes after intervention 188. 
The tumour is embedded in a complex microenvironment formed by lymphoid myeloid 
cells, stromal cells, vasculature, lymphatic vessel, cytokines and chemokines. The tumour 
itself  can interfere by the expression of  inhibitory ligands (e.g. PD-L1), creation of  a 
tolerogenic environment (e.g. expression of  IDO), and recruitment of  regulatory cells 
(e.g. Treg, MDSC, TAM) 189, 190. Different approaches exist to turn the immunosuppressive 
environment into an immunosupportive milieu, which should avoid high amounts of  
TNF-α, IL-1, IL-6, and IL-8 production and thus limiting chronic inflammatory state 191.
Myeloid-derived suppressor cells
Cancer-derived factors, like G-CSF, GM-CSF, IL-1β, PGE2, TNF-α, and VEGF, favour 
the generation and expansion of  myeloid-derived suppressor cells (MDSC) 192, 193. 
This heterogeneous population of  immature myeloid cells differentiates under normal 
physiological conditions into dendritic cells, neutrophils or macrophages. In the context 
of  cancer and other pathologies, these cells can be recruited to the tumour site by CCL2, 
CXCL12 and CXCL5. Activated MDSC induce chronic tissue inflammation and immune 
suppression by producing factors such as reactive oxygen species (ROS), arginase-1, inducible 
nitric oxide synthase (iNOS), nitric oxide (NO), indoleamine 2, 3-dioxygenase (IDO), and 
immune suppressive cytokines 194-197. These suppressive mediators affect the proliferation of  
T cells, increase apoptosis, induce anergic T cell status 198-203 and promote the recruitment, 
induction and expansion of  Treg 182, 204. Moreover, also NK cell functions are affected mainly 
via expression of  TGF-β by MDSC lowering the expression of  NKG2D, cytolytic activity, 
and IFN-γ production 205, 206. MDSC also negatively influence the phagocytosis, maturation, 
migration, and T cell stimulating capacities of  DC. Furthermore, MSDC can also promote 
the differentiation of  monocytes into TAM which release IL-6, IL-1β, IL-10, TGF-β and 
arginase-I 193, 202, 207 and thus increase the tumour supportive environment. Altogether, these 
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modulations on DC, T and NK cells responses (mainly in a non-antigen-specific manner) 
together with a balance shift towards Treg in the TME 208, 209, favour tumour progression. 
Thus, MDSC may be a component of  the tumour environment responsible for the limited 
response induced by cancer vaccination. Importantly, in the absence of  tumour-derived 
factors, MDSC retain the capacity to differentiate into mature myeloid cells. Hence, targeting 
MDSC may help to revert their immunosuppressive state. Cancer vaccination was shown 
to be more efficient in mouse models applying the blockage of  MDSC 210. Since the impact 
of  MDSC is quite broad, multiple intervention strategies can be applied to reverse the 
mediated effects, including deactivation or differentiation into mature cells, inhibition of  
their development or depletion of  MDSC 211.
Several strategies to target MDSC are under investigation in the human setting for various 
types of  cancer. Promoting the differentiation of  MDSC seems to be an attractive approach 
to on the one hand restore the immune supportive tumour environment and on the 
other hand increase anti-tumour activity by generation of  intra-tumoral mature myeloid 
cells. This approach was tested by using all-trans retinoic acid in patients with metastatic 
renal cell carcinoma and vitamin D3 in patients with head and neck cancer 32, 212. In mouse 
models it has been shown that IL-12 or IFN-α were able to convert MDSC into functional 
APC 213-215. Furthermore, the administered IL-12 favours up-regulation of  co-stimulatory 
molecules, limits the infiltration of  MDSC and supports CTL recruitment induction and 
their survival 216, 217. This effect was also observed in a murine model of  liver metastasis 
and a treatment consisting of  gene transfer of  IL-12 and chemotherapy 218. A similar effect 
was shown by IFN-α favouring differentiation and maturation of  MDSC and favouring an 
effector T cell-supportive environment 219. Interestingly, CTL responses generated in the 
presence of  IL-12 were shown to be more efficient in controlling the tumour due to lower 
levels of  PD-1 expression as compared to CTL induced in IFN-α environment 220.
Of  note, MDSC have been shown to not only influence the outcome of  injected DC-based 
vaccines, but they can also interfere during the preparation of  ex-vivo-generated DC 221. 
Cancer patients show increased numbers of  circulating MDSC which negatively correlate with 
clinical outcome. Using standard operating procedures to isolate monocytes from patient’s 
elutriation product, co-isolate these HLA-DR- MDSC. As the presence of  MDSC during ex 
vivo differentiation and maturation influences the maturation status of  DC, Ag uptake, and 
induced T cell activation, it is desirable to monitor the purity of  obtained monocytes and 
if  necessary perform additional purification steps before inducing differentiation into DC.
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Treg
Chemokines released by tumour cells and immune cells present in the TME also attract 
lymphocytes (TIL). Low numbers of  CD8+ TIL and high number of  Treg TIL are associated 
with poor prognosis 222. The presence of  abundant numbers of  Treg in the tumour, tumour-
draining lymph nodes and peripheral blood is one of  the interfering components hampering 
DC-induced activation and expansion of  type-1 immune responses 223. Treg can efficiently 
suppress innate and adaptive arms of  anti-tumour immune responses on multiple levels. 
Likewise, Treg interfere with NK cell responses, by limiting their recruitment, proliferation, 
cytolytic activity and IFN-γ secretion. Moreover they suppress proliferation of  naive T cells, 
and negatively interfere with antigen-presenting functions of  DC and macrophages as well 
as B lymphocytes. Hence, the depletion or functional modulation of  these cells is a possible 
way to restore the immunosuppression which can be accomplished by modulating Treg 
activity according to their surface marker expression. 
Treg are characterized as CD4+CD25+CCR4+GITR+ cells. The depletion based on CD25 
can be achieved with e.g. monoclonal Ab (mAb) against CD25 or denileukin diftitox 
(an immunotoxin conjugated to IL-2). However, this CD25-based depletion also affects 
other (effector) T cell populations which upregulate CD25 as a consequence of  their 
activation 224, 225. The chemokine receptor CCR4 is highly expressed on effector Treg cells 
and displays low expression on naive Treg and non-Treg cells 226. This selective expression 
makes CCR4 an interesting target to deplete Treg by using anti-CCR4 mAb. Another 
possible approach consists in targeting co-stimulatory molecules specifically expressed 
on Treg, such as GITR or OX40. Application of  agonist anti-GITR mAb, respectively 
anti-OX40, led to attenuation of  suppressive function of  Treg and increased effector anti-
tumor T cell functions in several studies 227-231. Another way to ensure depletion of  Treg is 
the administration of  immune checkpoint inhibitors, e.g. anti-CTLA-4, which is discussed 
later on in this section. The blocking of  Treg by stimulating OX40 or GITR to reverse 
immunosuppressive milieu in the tumour may be a more safe approach than depleting Treg. 
However, depleting Treg according to their CCR4 expression displays another possibility as 
naive Treg are not influenced and as such the induction of  autoimmunity can be limited by 
such treatments.
Soluble factors
Tumour cells as well as cells residing in the TME secrete various immunosuppressive soluble 
factors among which are IL-10, IL-6, M-CSF, GM-CSF, TGF-β, VEGF, lactic acid and 
prostaglandins. The effects of  tumour-derived factors on the different APC functions (e.g. 
migration, survival, interaction with T and NK cells) are extensively reviewed in 232.
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Several studies addressed the effect of  these immune modulators on DC differentiation 
and maturation 233-236. In chapter 5 of  this thesis we showed that the influence of  an 
immunosuppressive factor, PGE2, is imprinted during DC maturation. Once DC maturation 
was induced, PGE2 had no negative effect on cytokine and chemokine secretion. However, 
the negative effect of  PGE2 on NK-DC crosstalk persisted. Besides PGE2 also other 
tumour-derived soluble factors have been shown to negatively affect DC maturation status 
and cytokine profile such as IL-10, IL-6, and M-CSF 232, 234, 236. This argues for the use of  
ex vivo-matured DC for cancer therapy instead of  stimulating DC in vivo ensuring at least 
proper DC maturation and Ag processing and presentation.
Dying tumour cells release ATP; this extracellular ATP can be catabolized in several steps 
into adenosine via CD39 and CD73 expressed by tumour cells or lymphocytes such as 
Treg 237, 238. Adenosine can bind to adenosine receptors expressed by various immune 
cells. Binding of  adenosine to A2aR on T cells leads to their inhibition and to FOXP3 
expression in CD4+ T cells 239. Moreover, cytotoxicity (perforin and FasL-mediated) and 
cytokine production (IFN-γ, MIP-1α, TNF-α) of  NK cells is inhibited through binding 
of  adenosine 240. Blocking of  CD73-adenosine pathway or receptor-binding demonstrates 
promising results to reverse the inhibitory effect on anti-tumour responses 241-246.
In general, by taking into account the multitude of  different inhibitory factors in the TME, 
arguably the best option is to target the source rather than the individual components. In 
this respect, the previously described possibilities to reverse immunosuppressive TME by 
targeting directly MDSC or Treg are more attractive approaches.
Inhibitory receptors on tumour-infiltrating lymphocytes 
Besides the presence of  immune suppressive MDSC and Treg in the tumour environment, 
effector cells recruited to the tumour site upregulate inhibitory receptors (mainly T cells). 
Activated CD8+ T cells express molecules such as CTLA-4, PD-1/2, LAG-3, and TIM-3 
which can interact with ligands expressed by tumours cells and thus impede tumour 
antigen-specific T cell responses. These inhibitory pathways are responsible to regulate the 
immune responses under physiological conditions and control self-tolerance, duration and 
magnitude of  the induced responses. Tumours are able to co-opt these immune inhibitory 
pathways to increase their immune resistance. These so-called checkpoints can be controlled 
by checkpoint-inhibitors. This approach has gained a lot of  attention in the past few years. 
To date antibodies against two checkpoints have been approved by the FDA: Ipilimumab 
(anti-CTLA-4), pembrolizumab and nivolumab (both anti-PD-1). The principle of  most 
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checkpoint inhibitors is to reverse the inhibitory effect of  Treg and T cell anergy.
The CTLA-4 checkpoint inhibitor Ipilimumab was the first one to be approved by the 
FDA and its success led to further research on targeting possible other inhibitory receptors. 
In effector T cells, intracellular granules containing CTLA-4 are transported to the cell 
membrane upon Ag recognition 247, 248. On Treg cells, CTLA-4 is constitutively expressed. 
It binds to costimulatory molecules CD80/CD86 expressed on APC and exerts its effects 
via different suppressive mechanisms. The first one is competition with CD28 for binding 
of  CD80/CD86 249. Second, the binding to CD80 allows T cells to co-opt ligands and to 
internalize them and thus leaving APC with less co-stimulatory signals 250. Third, binding of  
CTLA-4 reduces the duration of  immune synapses 251. Fourth, the triggering of  CTLA-4 
activated protein phosphatases, which are able to inhibit MHC-TCR-mediated signalling 
effect in the T cells. Fifth, the triggering of  CTLA-4 is involved in the activation of  Treg 252. 
Hence, the application of  CTLA-4 checkpoint inhibitors reduces the activity of  Treg and 
positively influences the clinical outcome 253. Several studies showed that the observed effect 
is mainly attributable to the depletion of  Treg via macrophage-mediated ADCC rather 
than blocking the inhibitory pathway on CD4+ and CD8+ T cells 254-256. The integration of  
CTLA-4 in a DC-based vaccine treatment regimen could enhance its efficacy by reversing 
Treg-mediated inhibitory effects as well as preventing exhaustion of  de novo T cell 
responses. Thus, administration of  CTLA-4 should be performed before and after injection 
of  DC-based vaccines. However, even Ipilimumab is very effective, it is accompanied by 
many severe side effects 257. Therefore, the utilization of  another checkpoint-inhibitor, e.g. 
PD-1 (described below), is more attractive. 
PD-1 (programmed cell death; CD279) is another inhibitory receptor which belongs to 
the CD28 family and is more broadly expressed than CTLA-4 258. PD-1 is upregulated on 
activated T cells 258, 259, NK cells, and B cells 260, 261 and cells acquire an exhausted phenotype 
upon interaction with PD-1 ligands as well as facilitating their apoptosis. Two ligands for 
PD-1 have been identified up-to-date, PD-L1 (B7-H1) and PD-L2 (B7-DC), which are 
part of  the B7 family. Whereas PD-L1 is broadly expressed by various tissues (including 
various human tumours) 262-265 and is inducible upon IFN-γ and type I interferons 265-267, 
PD-L2 expression is restricted to activated DC, macrophages, and several tumours (e.g. 
B cell lymphoma) and is involved in down-regulation of  T cell activation 268, 269. PD-1-
PD-L1/PD-L2 interactions down modulate immune responses via activation of  tyrosine 
phosphatases SHP-1/2 which deactivate signal 1 (CD3/CD28-TCR) 270-273. Under 
physiological conditions, this pathway prevents autoimmunity by reducing activation, 
cytokine secretion, and adhesion of  T cells 274 as well as limiting the proliferation of  NK 
cells 261. However, in the case of  cancer, this interaction inhibits anti-tumour activity. 
Expression of  PD-L1 on tumours cells is heterogeneous and can be either present initially 
174
Chapter 6
6
on tumour cells (innate immune resistance) or be upregulated in the course of  anti-tumour 
responses (adaptive immune resistance). In the latter case the infiltrating immune effector 
cells, such as CD8+, CD4+ and NK cells, will lead to a local increase of  IFN-γ, which not 
only promotes tumour elimination but also leads to upregulation of  PD-L1 on tumour 
cells and thus inhibition of  PD-1-expressing TIL 275, 276. Expression of  PD-L1 by tumours 
is associated with poor prognosis and blocking of  this pathway in cancer has a positive 
influence on anti-tumour responses 277, 278. Blocking this pathway has broader influence on 
immune cells than CTLA-4 and has also been associated with less cytotoxicity. Thus using 
PD-1 blockage in combination with DC-based vaccine represents a promising strategy.
Other inhibitory receptors are currently under investigation as promising target strategy, 
such as LAG-3, B7-H3, B7-H4 and TIM-3, but will not be further discussed here.
COMBINATION THERAPIES: NECESSITY OF MULTILEVELED 
THERAPIES
Almost 20 years after the results on the first therapeutic anti-cancer DC-based vaccine trial 
have been published, DC vaccination has been proven to be a safe and non-toxic approach 
to treat cancer. Even though, in the majority of  patients an increased immune response was 
observed after vaccine administration, this effect could not yet be reflected in the overall 
outcome. Many improvements have been made on the choice of  TAA, the loading of  Ag, 
optimal administration sites and intervals, cell numbers and maturation protocols. Clinical 
trials applying these optimized DC-based vaccines are currently ongoing or starting within 
short period of  time. 
A major problem with previous vaccination strategies could be the hampering of  efficient 
responses by the natural occurring regulating mechanism induced by immune system 
activation. This escaping phenomenon is described as immunoediting and can be divided 
into three phases: elimination, equilibrium, escape. Each time an anti-tumour treatment 
induces a potent anti-tumour response by inducing diverse immune effector cells, the 
pressure on the tumour cells to adapt and to survive is increased. Thus, each treatment 
will induce partial resistance of  the tumour due to its heterogeneity and leads to selective 
outgrowth of  surviving cells (less immunogenic cells). As such, the tumour adapts its 
phenotype over time 279-282. 
The key to success of  immunotherapy will most probably be to circumvent the inhibition 
and escape mechanisms of  the tumour. Whereas various single-targeted approaches have 
shown partial success in tumour remission or increase in overall survival, the solution may be 
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a multileveled treatment approach combining non-specific (adjuvants, cytokines, checkpoint 
inhibitors, and conventional therapies) and specific treatment regimens (vaccination), but 
also the inclusion of  conventional anti-cancer therapies. Especially checkpoint inhibitors 
have gained great attention. mAb against inhibitory molecules expressed on T cells like 
CTLA-4 and PD-1 block the brake of  the immune system, resulting in longer lasting 
immune responses. Although very encouraging clinical results have been obtained as recently 
reviewed by Mahoney et al. 283, the treatment is still accompanied by toxicity issues 284 that 
remain to be solved.
The biggest challenge in this approach is the lack of  biomarkers predicting when to apply 
which therapy, as tumour biopsies are not always available. A recent study by Hannani 
et al. 285 revealed that elevated levels of  soluble CD25 detected in the serum of  patients 
with melanoma are predictive for resistance to Ipilimumb (anti-CTLA-4) treatment. If  
biopsies are available, in addition to histopathology, also immunophenotyping should be 
performed because of  the involvement of  the immune host defence in tumour progression. 
This will facilitate better prognosis and clinical decision. This approach was defined as 
′immunoscore′ 187 and consists in detecting TIL in the centre and invasive margin of  the 
tumour (number of  CD3/CD8 or CD8/CD45RO). As TIL are heterogeneous between 
tumours and patients, this analysis of  immune contexture will help to give a better 
prognosis and make better clinical decisions. Even though this strategy only considers T 
cells, it provides good survival prognosis 286. Patients with low immunoscore, meaning low 
infiltration of  CD8+ T cells in the tumour, would be good targets for adjuvant therapy to 
increase immunogenicity of  the tumour.
Another key factor is the tumour burden at the start of  the intervention. Low tumour 
burden seem to be more effectively killed by immunotherapeutic approaches. Likewise, an 
initial treatment of  tumour with conventional therapies may be necessary to remove the 
majority of  the tumour burden. An exception to this seems to be the checkpoint blockers; 
they also reached high response rates even in patients with advanced melanoma, with anti-
PD-1 being most favorable 4, 6.
Considering the large heterogeneity between tumour types, disease stages but also between 
patients makes the definition of  a golden standard therapy approach questionable. A 
possible option for applying DC-based vaccines is considering a basic treatment approach 
around a DC-based vaccine (or in vivo targeting of  DC) which has to be adjusted and 
complemented with different combination strategies depending on both histopathological 
features as well as the characterization of  the TME of  the patient (if  possible). The rationale 
for combination therapies is also reflected in ongoing clinical trials applying DC vaccine 
strategies and as such a DC-vaccine in combination with anti-CTLA-4 is currently evaluated 
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in clinical trials. A general prerequisite for the application of  checkpoint inhibitors is the 
immunogenicity of  tumours. 
Presumably this immunogenicity can and should be enhanced locally e.g. by the 
(intra-tumoral) administration of  RIG-I triggers inducing direct toxicity on tumour cells 
and generating an immunosupportive environment. Also chemotherapeutic agents as well as 
radiotherapy will continue to have a crucial role in the pre-conditioning of  the tumour. The 
subsequent administration of  a DC vaccine would enhance anti-tumour specific responses. 
Once initiated, blocking e.g. PD-L1 could retain anti-tumour specific cells in an active state. 
However, timing will be a crucial factor in any multileveled approach.
CONCLUSIONS
In this thesis, we provided an assay to study naive CD4+ T cell responses in a human setting. 
We studied the interaction of  DC with both Th1 and NK cells and revealed that high 
IL-12p70-secreting DC have the capacity to activate both helper responses. Additionally, 
we provided evidence that NK cells act as amplifiers during viral and bacterial infections to 
enhance cytokine production by DC. Furthermore, we showed that one of  the mechanisms 
by which TME inhibits immune responses is the blocking of  NK-DC crosstalk. Moreover, 
we identified a promising new combination of  TLR triggers to mature DC showing 
enhanced capacities to interact with NK cells and to induce Th1 polarization in vitro. 
Here, we discussed which criteria should be taken into account when selecting PAMPs as 
adjuvants for vaccination. Moreover, we provided an overview of  multiple factors explaining 
the so far overall limited clinical outcome of  immunotherapy and specifically of  DC-based 
vaccination. Immunotherapy as stand-alone approach may not reach the expected results 
as the TME is an adaptive environment possessing multiple redundant pathways to inhibit 
initiated anti-tumour immune responses. Combinations of  immunotherapy, including e.g. 
checkpoint inhibitors, with chemo- and/or radiotherapy will yield better results, overcoming 
the suppressive TME by attacking multiple pathways to initiate and elongate desired 
anti-tumour immune responses.
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SUMMARY
During a pathogenic insult, the efficient cooperation of  innate and adaptive immunity 
is needed to eradicate the invader. Pathogen recognition receptors (PRR), expressed on 
various types of  immune cells, are important components of  the innate immunity and are 
responsible for sensing and instructing appropriate and coordinated immune responses. 
The main cell type expressing these PRR and thus linking innate and adaptive immunity 
are antigen-presenting cells, such as dendritic cells (DC). Because of  their importance and 
unique properties of  instructing various immune effector cells, DC have been considered as 
promising targets in immunotherapeutic strategies against cancer. 
Besides the conventional cancer treatments such as surgery, radiation-, and chemotherapy, 
immunotherapy has been implemented into standard treatment regimens for certain types 
of  cancer, e.g. monoclonal antibodies like Rituximab for non-Hodgkin’s lymphoma. Cancer 
immunotherapy aims to stimulate the patient’s immune responses to eliminate tumour cells. 
One approach of  cellular immunotherapy is DC-based vaccination, which has been proven 
to be safe and non-toxic. Nonetheless, the limited overall positive clinical outcome monitored 
is indicative for the need of  further optimizations. Initial studies focused on generating DC 
having the potential to efficiently induce anti-tumour cytotoxic T lymphocyte responses. 
However, increasing evidence indicates that the induction of  more complex type 1 immune 
responses, including also T helper 1 (Th1) and natural killer (NK) cells, is crucial for the 
induction of  efficient anti-tumour responses.
The main aim of  this thesis was to study the cellular interplay of  DC, NK cells and T 
helper cells after PAMP encounter with main focus on type 1-induced helper responses. 
Identifying which signals induce and enhance the interaction of  DC with different immune 
effector cells is important to increase the efficacy of  DC vaccination strategies. 
In the human setting, standardized autologous DC-dependent systems to study de novo 
polarization of  naive CD4+ T cells and the associated molecular events occurring during the 
initiation phase are lacking. In chapter 2, we describe the development of  an assay allowing 
the comparison of  different pathogen-triggered human DC for their capacities to instruct 
functional polarization of  autologous naive CD4+ T cells in a TCR-restricted manner. We 
demonstrated that differently matured DC can be evaluated according to kinetics, direction, 
and magnitude of  the induced naive CD4+ T cell response. Comparing the capacity of  
three (pre-) clinical DC maturation cocktails used for the generation of  ex vivo-matured 
DC for DC-based vaccines (PGE2/TNF-α, LPS/IFN-γ, and FMKp/IFN-γ), we revealed 
that only FMKp/IFN-γ-matured DC efficiently polarized naive CD4+ T cells into Th1 cells. 
PGE2/TNF-α-matured DC, a maturation cocktail frequently used in early - and current - 
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DC vaccine clinical trials, induce a Th2-like polarization. Moreover, we demonstrated 
that the applicability of  this methodology is not limited to the study of  T cell-polarizing 
capacity of  monocyte-derived DC but also of  low-frequency blood-derived DC subsets, 
exemplified by plasmacytoid DC. This is a valuable tool to gain more insight into molecular 
mechanisms occurring in the early phase of  T cell polarization and may allow the study of  
pharmacological agents on DC-dependent T cell polarization.
For the induction of  potent type 1 immune responses, mature DC should be able to polarize 
CD4+ T cells towards Th1 cells as well as activate NK (helper) cells. In chapter 3, we studied 
the influence of  specific PRR-triggering during the maturation of  DC on their capacity to 
stimulate these helper processes. Moreover, we investigated whether the induction of  helper 
responses is coupled and thus mediated by the same PRR-matured DC. We demonstrated 
that DC matured with a cocktail containing bacterial fragments of  Klebsiella pneumoniae 
(FMKp) mounted Th1 as well as NK helper responses in a PRR trigger dose-dependent 
manner as determined by their capacity to produce IFN-γ. This effect was also observed 
by triggering an additional PRR pathway (FMKp+poly(I:C)). We revealed that both 
quantitative and cooperative PRR-triggering modulated the capacity of  DC to produce 
IL-12p70 and that this cytokine is the key determinant of  the DC-induced Th1 and NK cell 
helper responses. In addition, all PRR triggers able to induce IL-12-producing mature DC 
were sufficient to induce these helper responses. This knowledge can be of  importance to 
select proper PRR triggers in preventive and therapeutic vaccine design.
NK cells do not only play crucial roles in eliminating virally infected and malignantly 
transformed cells, but have also been described as modulators of  adaptive immune 
responses. Like DC, NK cells express various PRR. In chapter 4, we studied whether NK 
cells could directly sense bacterial and viral motifs and whether these PAMP-activated NK 
cells could enhance the maturation of  DC via the release of  soluble factors. We revealed 
that both bacterial- and viral-activated NK cells augment the pro-inflammatory cytokine 
profile of  monocyte-derived DC via NK cell-derived soluble factors. Among viral and 
bacterial motifs, the enhancement of  DC-derived IL-12p70 secretion was observed by NK 
cells directly sensing TLR1/2, TLR2, TLR2/6, TLR3, TLR4, TLR5, TLR7/8 and TLR8-
triggers. Notably this amplifying effect was not observed for TLR7-triggers. Moreover we 
revealed that not all PAMPs triggering one specific TLR induce similar responses. Besides 
IL-12p70 secretion, also DC-derived production of  IL-6, IL-1β, CXCL9 and CXCL10 was 
enhanced. The helper capacity of  NK cells was dependent on the cytokine milieu in which 
they recognized the pathogens and thus influenced by accessory cell activation. Moreover, 
we revealed that NK cells amplify the DC cytokine profile via a mechanism independent of  
TNF-α and relying on IFN-γ. In addition to the results described in chapter 3, the direct 
sensing of  different PRR triggers by NK cells can be of  interest to modulate immune 
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responses and could be applied in search of  more potent adjuvants for vaccination strategies. 
In the context of  cancer, the cellular interactions described in chapters 2-4 can be modulated 
by factors released in the tumour microenvironment (TME). In chapter 5, we studied the 
effect of  such a factor, prostaglandin E2 (PGE2), on the NK-DC crosstalk. We showed that 
PGE2 directly inhibits cytolytic and cytokine-producing capacity of  freshly isolated NK 
cells in a dose-dependent manner. In this line, PGE2 directly influences cytokine (IL-12, 
IL-18) and chemokine (CCL5, CCL19, CXCL10) secretion by FMKp/IFN-γ-matured DC 
reducing their capacity to recruit and activate NK cells. Consequently, NK cells were not 
able to provide help for Th1 polarization. The capacity of  DC to interact with NK cells is 
imprinted during the early maturation phase, as 6h-matured DC were unsusceptible to the 
inhibitory effect of  PGE2.
Chapter 6 reflects the most important findings described in this dissertation in the context 
of  vaccine adjuvants and the possible impact of  helper cells in future DC vaccination 
strategies. Moreover, the impact of  TME on the efficacy of  immunotherapy is discussed.
To conclude, the findings described in this dissertation contribute to the understanding on 
how different PAMPs can be applied to modulate immune responses with respect to DC 
maturation and subsequent helper cell induction as well as the direct effects on the NK helper 
cells. These findings contribute to the optimization of  current cellular immunotherapeutic 
strategies.
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ZESUMMEFAASSUNG
Kriibs ass eng vun deenen heefegsten Doudesursaache weltwäit. 2012 goufe 14.1 Milliounen 
nei Fäll an 8.2 Milliounen Doudeger registréiert. Et gëtt sech erwaart, dass d’Zuel vun neie 
Fäll an deenen nächsten 20 Joer ëm 70% klëmmt op ronn 24 Milliounen. Verbesserunge 
souwuel an der Fréierkennung wéi och an der Chirurgie, Chemo- a Radiotherapie hunn 
derzou bäigedroen, dass d’Stierflechkeet an deene leschte Jore liicht zréckgaangen ass. 
Trotzdem bleift e groussen Deel vun de Kriibspatienten onheelbar. Nieft dem Optimiséiere 
vu Screening Methoden an de klasseschen Therapien, ginn och nei Therapieméiglechkeete 
gebraucht, déi manner schiedlech an toxesch sinn. Dëst ass wichteg fir dem Patient eng 
besser Liewensqualitéit ze erméiglechen. An deene leschte Joren huet d’Immuntherapie 
groussen Interessi gewonnen als Alternativ an der Kriibsbehandlung. Immuntherapie besteet 
aus ville verschiddene Formen an Usätz; de Grondprinzip besteet doraus, dat natierlecht 
Ofwiersystem vum Patient ze stimuléieren/manipuléieren, soudass dëst d’Kriibszellen 
ugräift a schlussendlech futtimécht.
D’Ofwiersystem (och nach Immunsystem genannt) besteet ënner anerem aus verschiddene 
wäisse Bluttkierpercher, déi alleguer eng spezifesch Aufgab hunn. D’Immunsystem kann 
ënnerdeelt ginn an een onspezifeschen (ugebuerenen) an ee spezifeschen (ugeléierten) Deel. 
Eist ugebuerent Immunsystem wierkt direkt, och wa mir zum Beispill nach ni mat engem 
bestëmmte Mikrob konfrontéiert gi sinn. Déi spezifesch Immunitéit besteet aus Zellen, déi 
geziilt just bestëmmte Bakterien an Viren erkennen kënnen. Bei engem bakteriellen/viralen 
Infekt oder kierpereegene béisaartegen Zelle ginn dës wäiss Bluttkierpercher alarméiert, 
an duerch eng koordinéiert Kommunikatioun gi bestëmmte wäiss Bluttkierpercher geziilt 
op déi Plazen am Kierper geschéckt, wou d’Gefor ass a se gebraucht ginn. Am Normalfall 
gëtt den Eindringling sou bekämpft an de Mënsch gëtt erëm gesond. Falls de Mënsch nach 
eemol mat deemselwechte Mikrob konfrontéiert gëtt, da gëtt dësen Alarméierunsprozess 
méi séier ausgeléist, doduerch dass mir een immunologescht Gediechtnes opgebaut hunn. 
Dëst besteet aus de spezialiséierten Zellen. Op dësem Prinzip sinn och d’Impfstoffer 
opgebaut. An deene meeschte Fäll kann eist Ofwiersystem d’Mikroben an déi béisaarteg 
Zellen erkennen a se eliminéieren. Am Fall vum Kriibs ass dës Balance zerstéiert an déi 
béisaarteg Zelle kënnen ongestéiert wuessen.
Zellen, déi am Mëttelpunkt stinn an d’Bréck tëschent der ugebuerener an der ugeléierter 
Immunitéit maachen, sinn d’dendritesch Zellen. Dës wäiss Bluttkierpercher ginn aktivéiert 
duerch d’Erkenne vun bestëmmte Mierkmoler, déi spezifesch si fir Mikroben (sougenannte 
PAMP – pathogen-associated molecular patterns), mee net fir mënschlech Zellen. Dëst féiert 
derzou, dass d’dendritesch Zelle räifen a kleng Stécker vun de Mikroben (Antigener) op hirer 
Surface presentéieren. Räif  dendritesch Zellen aktivéieren aner Zelle vum Ofwiersystem 
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duerch engersäits d’Produktioun vu Moleküllen an anerersäits duerch d’Expressioun vun 
den Antigener déi duerch aner Zellen erkannt ginn. Op dës Manéier suergen dendritesch 
Zelle fir eng efficace a geziilten Ofwierreaktioun géint ee spezifesche Microorganismus. 
Betraffen Zelle sinn ënnert anerem natierlech Killer Zellen (NK Zellen), déi souwuel direkt 
Kriibszelle kënne futtimaachen, wéi och duerch d’Produktioun vu Moleküllen eng positiv 
Réckkopplung un dendritesch Zellen ginn an dës stäerken. Eng aner Zort sinn d’T Helfer-
Zellen, dës Zellen hëllefen den toxeschen T Lymphozyten méi effektiv ze schaffen an 
d’Kriibszelle méi efficace futtizemaachen.
Engersäits sinn dendritesch Zelle wichteg fir eng optimal an effektiv Ofwierreaktioun 
ze induzéieren. Anerersäits sinn dës Zelle bei Kriibspatienten zum gréissten Deel an 
engem onräifen Zoustand a kënnen d’Ofwiersystem net méi sou effektiv steieren. Well 
dës Zellen esou wichteg sinn, ass eng vun de Strategien an der Kriibs-Immuntherapie, 
dendritesch Zellen als therapeuteschen Impfstoff  ze gebrauchen. Heifir gëtt ee Virleefer 
vun den dendriteschen Zellen aus dem Blutt vum Patient isoléiert. Dës Zelle ginn dann 
am Labo esou stimuléiert, dass se zu dendriteschen Zellen eruräifen, déi eng spezifesch 
Ofwierreaktioun géint Kriibszellen ausléise kënnen. Dës dendritesch Zelle ginn dem Patient 
da wéi een Impfstoff  gesprëtzt. Als Resultat heivunner sollen aner Immunzellen am Kierper 
aktivéiert ginn an esou d’Kriibszellen attackéieren. Dës dendritsch Zell-Impfstoffer si 
schonn a klinesche Studië getest ginn. 2010 ass deen éischten Impfstoff  géint Prostatakriibs 
op de Maart komm. Trotz de villverspriechende Resultater muss d’Efficacitéit vun dësen 
Impfstoffer nach verbessert ginn.
Eng Manéier, wéi dës Impfstoffer kënne verbessert ginn, ass de Räifungsprozess vun den 
dendritschen Zellen am Labo ze optiméieren. Sou wéi an enger normaler Ofwierreaktioun 
géint Mikroben, sollen och dës manipuléiert dendritesch Zelle mat verschiddenen 
Immunzelle kënnen interagéieren, fir eng optimal Immunreaktioun géint d’Kriibszellen 
auszeléisen. An deene leschte Joren ass spekuléiert ginn, dass d’Helfer-Zellen heibäi eng 
wichteg Roll solle spillen. 
An dëser Thees ′PAMPering immune responses – Spotlight on helper cells for dendritic cell 
vaccination′ gëtt, wéi den Titel et seet, d’Roll vun Helfer-Zellen (NK Zellen an T Helfer-
Zellen) am Kontext vun der Optimiséierung vun dendriteschen Zell-Impfstoffer géint 
Kriibs ënnersicht. Mir wollten haaptsächlech erausfannen, wéi een Afloss déi verschidden 
Aktivéierungspartikelen op d’Interaktioun vun den dendriteschen Zelle mat den Helfer-
Zellen hunn. Heifir hu mir d’dendritesch Zellen ′verwinnt′ (pampering), wat heescht, dass 
mir versicht hunn, eng optimal Simulatioun ze fanne fir de Räifungsprozess, an dass mir 
heifir kleng Partikelen, déi spezifesch fir Mikroben - PAMP - sinn, gebraucht hunn. Zur 
Räifung vun den dendritschen Zellen gehéiert och, dass se trainéiert ginn, fir eng spezifesch 
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Ofwierreaktioun just géint Kriibszellen auszeléisen. Dësen Aspekt ass an dëser Thees net 
behandelt ginn.
Am Kapitel 2 hu mir eng Method entwéckelt, fir d’Interaktioun tëscht den dendriteschen 
Zellen an den T Helfer-Zellen ze studéieren. Méi genee erméiglecht dës Method et, fir 
d’Induktioun vun naiven (d.h. neien) T Helfer-Zellen, déi duerch ënnerschiddlech aktivéiert 
dendritesch Zellen induzéiert ginn, an hirer Stäerkt an an hirer Vitesse ze beuerteelen. Dëst 
ass enorm wichteg, well bis elo keng Methode bestan hunn, fir dëst ausserhalb vum Kierper 
(an der Zellkultur, d.h. in vitro) mat mënschlechen Zellen ze erfuerschen. Mat dëser Method 
hu mir erausfonnt, dass d’Aktivéierungspartikelen, déi bis elo am heefegste gebraucht gi 
sinn fir d’Räifung vun den dendriteschen Zellen fir d’Impfstoffer, net sou efficace sinn. Mir 
weisen hei och, dass dendritesch Zellen, déi mat engem PAMP vu bakteriellem Ursprong 
(Klebsiella pneumoniae - FMKp) aktivéiert ginn, dat am Géigesaz ganz gutt kënnen.
Am Kapitel 3 hu mir ënnersicht, ob dendritesch Zellen in vitro kënne sou manipuléiert 
ginn, dass se souwuel NK Zellen, wéi och T Helfer-Zellen aktivéiere kënnen. Heifir hu mir 
verschidde bakteriell a viral PAMP als Aktivéierungspartikele fir dendritsch Zelle gebraucht. 
FMKp-aktivéiert dendritesch Zellen hunn dëst Potenzial. Desweidere war et méiglech, 
dëst Potenzial nach weider ze verstäerken, andeems 2 Aktivéierunsgpartikele gläichzäiteg 
benotzt gi sinn. Dës Method fir eng verbessert Räifung vun den dendriteschen Zellen 
hu mir patentéiere gelooss. D’Capacitéit vun dendritschen Zelle, fir d’Helfer-Zellen ze 
aktivéieren, gëtt gesteiert duerch ee Stoff, deen dës Zelle produzéieren: Interleukin-12. Wat 
méi Interleukin-12 produzéiert gëtt, ëmsou méi performant ginn d’Helfer-Zellen aktivéiert.
NK Zelle kënnen och direkt Mikroben erkennen. Dofir hu mir am Kapitel 4 analyséiert, ob 
NK Zellen de Räifungsprozess vun dendriteschen Zelle positiv beaflosse kënnen. PAMP-
aktivéiert NK Zelle produzéieren ee bestëmmtent Moleküll - Interferon-gamma - dat ee 
positiven Afloss op d’dendritesch Zellen huet.
Ee Problem bei der Immuntherapie ass d’Ëmfeld vum Kriibs. Fir sech géint d’Zelle vum 
Immunsystem ze schützen, huet de Kriibs verschidden Ofwierstrategien entwéckelt. 
Eng dervun ass d’Produktioun vu verschiddene Moleküllen, déi een negativen Effekt op 
d’Aktivitéit vun den Immunzellen hunn. Ee Beispill heifir ass Prostaglandin E2. Am Kapitel 5 
hu mir d’Konsequenze vum Prostaglandin op dendritesch Zellen an NK Zellen analyséiert. 
Mir hunn een direkten negativen Effekt op déi zwou Zellpopulatioune festgestallt, souwéi 
op d’Interaktioun tëscht deenen zwee. Interessanterweis waren dendristesch Zellen, déi in 
vitro geräift goufen an dunn eréischt a Kontakt komm si mat Prostaglandin, immun géint 
d’negativ Effekter.
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An dëser Thees hu mir beschriwwen, dass bakteriell oder viral Aktivéierungspartikelen eng 
interessant Approche duerstellen, fir d’Interaktioun vun dendriteschen Zellen an den Helfer-
Zellen ze optiméieren. Virun allem d’Produktioun vun IL-12 duerch dendritesch Zellen ass 
heifir elementar. Dëst ass enorm wichteg, fir d’Impfstoffer mat dendriteschen Zelle géint 
Kriibs ze verbesseren. Dës verbessert Impfstoffer wäerten Ufank 2017 a klinesche Studien 
mat Longekriibspatienten a Patiente mat Multipel Myelom duerch d’Biotech Firma CiMaas 
getest ginn.
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Cancer is one of  the leading causes of  death worldwide. In 2012, 14.1 million new cancer 
cases (101.210 cases in NL) and 8.2 million deaths (43.666 deaths in NL) have been 
registered with the majority of  both incidence and mortality reported in less developed 
countries 1-3. The number of  new cases is expected to rise by 70% in the upcoming 20 years 
to 24 million 4. In 2008, an estimated 83 million years of  ′healthy life′ were lost due to early 
death and disability caused by cancer. This implies an immense economic and social burden. 
Besides the direct costs for cancer treatment, also these indirect costs due to morbidity are 
included in the economic burden. As such, cancer accounts for the biggest economic impact 
worldwide among the leading causes of  death 5. Moreover, cancer diagnosis does not only 
affect the patients themselves but also their families and caregivers, and thus has an even 
broader physical, psychosocial, and economic impact 6. 
Early detection and current treatment strategies, such as surgery, radiotherapy and 
chemotherapy have been improved substantially during the last decades, leading to a decline 
of  mortality. Nonetheless, a considerable high number of  cancer cases remain incurable. 
Besides further improving screening methods as well as current anti-cancer treatments, 
there is need for developing innovative less invasive and non-toxic treatment options to 
ensure a better quality of  life for patients with cancer.
The field of  immunotherapy has gained particular interest among researchers for the 
development of  novel anti-cancer treatment strategies. The general approach is to use or 
stimulate the patient’s immune system in order to fight the cancer. Several approaches have 
been approved by the American Food and Drug Administration (FDA) and are currently 
implemented as part of  standard anti-cancer treatment regimens for specific types of  
cancer. Different types of  cancer immunotherapy exist, which can be divided into passive 
and active approaches as well as specific and non-specific mechanisms of  action. One 
approach of  cellular immunotherapy are dendritic cell (DC)-based vaccines. The use of  DC 
as therapeutic vaccine is based on their primary role in detecting invading pathogens in our 
body. The principle of  this approach is to isolate white blood cells of  the patient and isolate a 
precursor of  these cells (monocytes) and manipulate them ex vivo. This includes instructing 
them to recognize specific pattern expressed only by the cancer cells and boosting their 
capacity by adding specific triggers to maximize their potency, the so-called maturation 
stimuli. DC-based vaccines are already tested in clinical trials and have been proven to 
be safe and non-toxic, however overall clinical outcome is still limited. The first vaccine 
against advanced prostate cancer, Provenge®, has been approved by the FDA in 2010 7, 8. 
This vaccine is prolonging the patient’s life-time for several months without eradicating the 
tumour. Moreover, several clinical trials are currently ongoing testing various DC-based 
vaccination strategies illustrating the potential role of  DC-based vaccines in future standard 
anti-cancer treatments. Nonetheless, the limited overall positive clinical outcome monitored 
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thus far is indicative for the need of  further optimizations. 
This thesis aimed to improve these therapeutic anti-cancer DC-based vaccines. We focused 
on analysing the potency of  different maturation stimuli on the capacity of  DC to interact 
with helper cells of  the immune system (T helper cells and natural killer cells) which is 
important to eliminate cancer cells. 
We revealed that, at least in vitro, the potency of  a dendritic cell to interact with natural 
killer cells and T cells is dependent on their capacity to produce one soluble factor: the 
cytokine IL-12. In the human system, this factor dose-dependently determines the outcome 
of  the immune response and thus the potential anti-cancer response. These findings 
are strengthened by recent clinical trials indicating a positive correlation between high 
IL-12-producing DC and time to disease progression 9, 10. Moreover, older studies tested 
the systemic application of  IL-12 and revealed a positive anti-cancer effect. However, this 
implementation of  systemic IL-12 administration in cancer treatment approaches was 
hindered by its dose-limiting toxicities 11-17. Altogether, these findings emphasize on the use 
of  IL-12-producing DC to ensure local production and delivery of  this cytokine in order to 
come one step closer to successful vaccination strategies. This knowledge is very important 
to set new release criteria for DC maturation stimuli.
We showed that stimuli which have been used thus far by other groups did not lead to 
high IL-12-producing DC. However, we also revealed a huge donor-to-donor variation 
in the capacity of  DC to produce IL-12 upon the same stimulation. Further research 
should investigate whether e.g. polymorphisms in the IL-12 gene are responsible for this 
in order to select only responding patients for clinical trials. Alternatively, DC-derived from 
low-responders could be engineered to constitutively produce high levels of  IL-12. With 
introducing this new release criterion there is a possibility to increase the currently moderate 
clinical responses of  anti-cancer DC-based vaccination. 
In this line, we identified a maturation cocktail which is able to generate high IL-12-producing 
DC. This combination of  maturation stimuli has been filed as patent in May 2012 18. 
Consequently, in March 2015, a spin-off  company, CiMaas, has been founded by Prof. 
dr. GMJ Bos (CEO) and Dr. WTV Germeraad (CSO) being two of  the inventors of  
the intellectual property. This biotech company focuses on the development of  cellular 
immunotherapy against cancer. The target group for DC-based vaccines in initial clinical 
trials will be patients with lung cancer (5-year survival in NL: 17%) and patients with 
multiple myeloma (5-year survival in NL: 40%) 19. During the upcoming two years the 
knowledge acquired in this project as well as preceding research by our group will be 
translated into the start of  a clinical trial. Currently, the findings are validated and tested, 
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which also includes regulatory affairs. All products need be available in good manufacturing 
practice (GMP) and standard operating procedures need to be set up. After the writing of  
the investigational medicinal product dossier and the permission of  central committee on 
research involving human subjects, two phase I/II clinical trials are scheduled to start in the 
first quarter of  2017. DC made according to the procedure described in chapter 4 will be 
electroporated with mRNA coding for the Wilms-tumour I antigen, an important tumour 
antigen expressed in cancer cells and being essential for their survival. A collaboration with 
Prof. dr. K. Thielemans (University of  Brussels, Belgium) has been set up from whom the 
mRNA will be supplied. The design of  the trial is similar to the design of  trials by Dr. V.F.I. 
van Tendeloo (University of  Antwerp, Belgium) to allow some comparison of  the different 
DC in a clinical context.
Even though the introduction of  Provenge® to the market shows the potential of  personalized 
cell therapy as new anti-cancer treatment, several aspects and patient inclusion criteria may 
be considered before starting the clinical trials with the optimized method to generate DC 
as described above. To prove the potential superiority of  our new DC generation method, in 
initial trials only patients of  which the DC have high IL-12-producing capacities determined 
on beforehand in vitro should be included. Once the success of  this treatment has been 
proven, alternatives to also treat low-responders should be developed. 
Another crucial hurdle for the effectiveness of  cellular immunotherapy in general is the 
suppressive tumour environment. The tumour is embedded in a complex microenvironment 
formed by lymphoid myeloid cells, stromal cells, vasculature, lymphatic vessel, cytokines 
and chemokines. The tumour itself  can interfere by the expression of  inhibitory ligands, 
creation of  a tolerogenic environment, and recruitment of  regulatory cells 20,21. Tumours 
are able to co-opt immune inhibitory pathways which are under physiological circumstances 
responsible to regulate immune responses and control self-tolerance, duration, and 
magnitude of  the induced responses. As such tumours increase their immune resistance. 
To increase the efficacy of  DC-based vaccination, combination therapies should be applied, 
targeting the tumours on multiple levels by using e.g. checkpoint inhibitors.
Besides the implementation of  improved DC-based vaccines, CiMaas is also focussing on 
NK cell therapy. NK cells are important in killing virally infected cells of  the human body 
and also play a crucial role in killing tumour cells. This adoptive cell therapeutic approach 
is based on the use of  donor NK cells, selected according to specific criteria, to attack the 
cancer cells. In humanized mouse models for breast cancer and multiple myeloma, NK cells 
eliminated the tumours. CiMaas is currently focusing on methods to generate high numbers 
of  NK cells in GMP complying conditions which are needed for translation of  this therapy 
to cancer patients. Optimizations aim to enhance the cytotoxic capacity of  NK cells by 
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addition of  various cytokines during expansion and the selection of  appropriate allogeneic 
donors having KIR-ligand mismatched NK cells favouring their cytotoxic capacities. Even 
though studies described in this thesis where not primarily focusing on improving NK cell 
therapy, we did show that direct incubation of  NK cells with pathogen-derived products 
(PAMPs) positively influenced the activation of  NK cells and subsequent interaction with 
DC. Moreover, increasing evidence in literature describes enhanced cytolytic capacities of  
NK cells after PAMP-activation 22, 23. Incorporation of  PAMPs to activate NK cells before 
injection could enhance the NK cell-mediated effects in vivo and may reduce the number of  
NK cells needed to treat a patient. Arguably, NK cells could also be injected with adjuvants 
in order to boost their activity in vivo. Further research is needed to evaluate the effect of  
these pathogen-derived products on NK cell function.
To sum up, the findings described in this dissertation mainly contribute to the progress of  
therapeutic DC-based anti-cancer vaccines. The obtained data of  this thesis and previous 
research efforts of  our laboratory are currently translated into clinical products and will be 
soon applied in clinical trials. Possibly, this form of  personalized treatments will in the near 
future not only achieve prolongation of  the patient’s life-time but also attack the tumour 
itself  more efficiently in non-toxic manner and be incorporated more and more in future 
standard anti-cancer treatment regimens. 
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IL  interleukin
ILC  innate lymphoid cells
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LPS  lipopolysaccharide 
mAb  monoclonal antibody
MAP  mitogen-activated protein
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mDC  mature DC
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MFI  mean fluorescence intensity
MHC  major histocompatibility complex
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NFkB  nuclear factor kappa B
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